<!DOCTYPE html>
<html class="no-js">
  <head>
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "https://www.googletagmanager.com/gtm.js?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-PG2NN3W");
    </script>
    <!-- End Google Tag Manager -->

    <title>ASCVD Risk Estimator +</title>
    <meta
      name="viewport"
      content="width=device-width, initial-scale = 1.0, maximum-scale=1.0, user-scalable=no"
    />
    <meta charset="utf-8" />
    <script type="text/javascript">
      let fullURL = document.URL;
      var baseURL = '';
      if(fullURL.indexOf("?") !== -1){
        baseURL = fullURL.substring(0,fullURL.indexOf('?'));
      }
      else if(fullURL.indexOf("#") !== -1){
        baseURL = fullURL.substring(0,fullURL.indexOf('#'));
      }
      else
        baseURL = '';
      
      let style = document.createElement("link");
        style.setAttribute("rel", "shortcut icon");
        style.setAttribute("href", 'favicon.ico');
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/styledown.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/normalize.min.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/jquery-ui.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/jquery-uistructure.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/foundation.min.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/foundation-sites.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/font-awesome.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/index.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/ascvd-riskplus.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
      style = document.createElement("link");
        style.setAttribute("href", baseURL+"assets/css/print-css.css");
        style.setAttribute("rel", "stylesheet");
        document.head.appendChild(style);
    </script>
  </head>

  <body onbeforeunload="window.scrollTo(0,0);">
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-PG2NN3W"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->
    <div
      data-bind="page: {id:'calculate', role: 'start', beforeShow:remakeSticky()}"
      class="page with-group-sections"
    >
      <div class="row">
        <div class="data-display" id="scorebar">
          <div class="sticky-holder">
            <header class="header page">
              <span class="logo">
                <a href="#!/calculate/estimate"
                  ><img
                    src="assets/img/header_image.png"
                    alt="ASCVD Risk Estimator Plus"
                /></a>
              </span>
              <ul class="nav tabs tabs-primary">
                <li id="estimate-Tab" class="selected">
                  <a
                    href="#!/calculate/estimate/"
                    class="condensable small btn-ga4"
                    >Estimate Risk</a
                  >
                </li>
                <li
                  id="therapy-Tab"
                  class=""
                  data-bind="css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : (($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                  custom-tooltip-parent
                >
                  <a
                    href="#!/calculate/therapy/"
                    data-bind="click:$root.NavigateToForecastPage.bind('event', 'Clicked tab')"
                    class="condensable small ti-ce-ga4"
                    >Therapy Impact</a
                  >
                </li>
                <div class="custom-tooltip bottom">
                  Potential risk reduction impact of different therapies can
                  only be calculated for patients 40-79 years of age at an
                  initial visit.
                </div>
                <li
                  id="advice-Tab"
                  class=""
                  data-bind="css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : (($root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                  custom-tooltip-parent
                >
                  <a
                    href="#!/calculate/advice/riskgraph/"
                    data-bind="click:$root.NavigateToSummaryPage.bind('event', 'Clicked tab')"
                    class="condensable small va-ce-ga4"
                    >Advice</a
                  >
                </li>
                <div class="custom-tooltip bottom">
                  Advice section is accessible when required characteristics for
                  patients 40-79 years of age are entered.
                </div>
              </ul>
            </header>
            <div class="score-bar-holder">
              <div class="score-bar row">
                <div
                  class="text-center text-bold small-fs-4x large-fs-6x current-risk columns"
                  data-bind="css: {hide: ($root.Form().invalidLdlMessage() || $root.invalidAgeValue() || $root.Form().TenYearRisk()!='~%' || $root.Form().VisitTypeUI()!=undefined)}"
                >
                  ....
                </div>
                <div
                  class="medium-6 columns current-risk"
                  data-bind="css: {'small-12': $root.Form().VisitType()==false,'small-6': $root.Form().VisitType()==true, 'medium-offset-3': $root.Form().VisitType()==false}, visible: ($root.invalidAgeValue() || $root.Form().invalidLdlMessage()) ||  ($root.Form().VisitTypeUI()!=undefined || $root.Form().TenYearRisk()!='~%')"
                >
                  <div class="small-6 columns">
                    <div
                      class="text-right text-bold small-fs-3x large-fs-5x"
                      data-bind="text: $root.Form().TenYearRisk, visible: !$root.Form().invalidLdlMessage() && !$root.invalidAgeValue()"
                    >
                      ~%
                    </div>
                    <div
                      class="text-right text-bold"
                      data-bind="text: $root.Form().riskRange, visible: $root.Form().TenYearRisk() != '~%' && !$root.Form().invalidLdlMessage()"
                    >
                      Intermediate
                    </div>
                  </div>
                  <div
                    class="text-right small-6 columns text-bold small-fs-3x large-fs-6x"
                    data-bind="visible:  ($root.invalidAgeValue())"
                    style="font-size: 1em; line-height: 1.2"
                  >
                    This calculator only provides 10-year risk estimates for
                    individuals 40-79 years of age.&nbsp;<a
                      data-open="young-recommendation-modal"
                      id="modalLaucher"
                      class="link"
                      >Click here</a
                    >
                    to view brief suggestions for younger patients.
                  </div>
                  <div
                    class="text-right small-6 columns text-bold small-fs-3x large-fs-6x"
                    data-bind="text:  ($root.Form().invalidLdlMessage()), visible: Boolean($root.invalidAgeValue() === false && Form().invalidLdlMessage())"
                    style="font-size: 1em; line-height: 1.2"
                  ></div>
                  <div
                    class="reveal large"
                    id="young-recommendation-modal"
                    data-reveal
                  >
                    <div
                      data-bind="template: {name: 'young-patient-recommendation'}"
                      style="overflow: auto"
                    ></div>
                    <button
                      class="close-button"
                      data-close=""
                      aria-label="Close reveal"
                      type="button"
                    >
                      <span aria-hidden="true">×</span>
                    </button>
                  </div>
                  <div
                    class="text-left small-6 columns text-bold data-header small-fs-2x large-fs-3x"
                  >
                    Current 10-Year
                    <br />ASCVD Risk<sup>**</sup>
                  </div>
                </div>
                <div
                  id="followup-score-bar"
                  class="column medium-6 small-6 previous-risk"
                  data-bind="css: {hide: $root.Form().VisitType()===undefined || $root.Form().VisitType()===false}"
                >
                  <div
                    class="small-6 medium-3 large-5 columns text-right text-bold"
                  >
                    <div
                      class="small-fs-3x large-fs-5x"
                      data-bind="text:$root.Form().TenYearRiskInitial"
                    >
                      ~%
                    </div>
                    <div data-bind="text: $root.Form().previousRiskRange"></div>
                  </div>
                  <div
                    class="text-left small-6 medium-9 large-7 columns text-bold data-header small-fs-2x large-fs-3x"
                  >
                    Previous 10-Year
                    <br />ASCVD Risk
                  </div>
                </div>
              </div>
              <div
                class="lifetime-risk row score-bar"
                data-bind="visible: ($root.invalidAgeValue() || $root.Form().invalidLdlMessage()) ||  ($root.Form().VisitTypeUI()!=undefined || $root.Form().TenYearRisk()!='~%')"
              >
                <div
                  class="small-6 columns medium-6 text-right"
                  data-bind="css:{ hide: $root.Form().VisitTypeUI()==true}"
                >
                  <span
                    class="small-fs-2x large-fs-3x"
                    data-bind="visible: $root.ageValidation().id!=3"
                  >
                    Lifetime ASCVD Risk: &nbsp;&nbsp;
                    <span
                      class="text-bold"
                      data-bind="text: $root.Form().yourLifeTimeRisk"
                    ></span>
                  </span>
                  <span
                    class="small-fs-1x large-fs-2x"
                    data-bind="visible: $root.ageValidation().id == 3"
                    >Lifetime Risk Calculator only provides lifetime risk
                    estimates for individuals 20 to 59 years of age.</span
                  >
                </div>
                <div
                  class="medium-6 columns end"
                  data-bind="css: {'medium-offset-3': $root.Form().VisitType()==true, 'small-6': $root.Form().VisitType()==false, 'text-center': $root.Form().VisitType()==true}"
                >
                  <span
                    class="small-fs-2x large-fs-3x"
                    data-bind="visible: !$root.invalidAgeValue()"
                  >
                    Optimal ASCVD Risk: &nbsp;&nbsp;
                    <span
                      class="text-bold"
                      data-bind="text: $root.Form().validOptimalRiskValue"
                    ></span>
                  </span>
                  <span
                    data-bind="visible: $root.invalidAgeValue()"
                    class="small-fs-1x large-fs-2x"
                    >Optimal ASCVD Risk Calculator only provides optimal risk
                    estimates for individuals 40 to 79 years of age.</span
                  >
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div
        data-bind="page: {id: 'estimate', name: 'estimate', afterShow:tabchange, beforeShow:pageScrollTop}"
        class="page-wrapper fullscreen-spacer"
        id="estimate-page"
      >
        <div
          class="page-wrapper not-highlighted"
          style="margin-top: 10px; padding-bottom: 0"
        >
          <!--Main Content starts here -->
          <div class="row collapse">
            <div class="small-12 columns">
              <div class="question right reset">
                <div
                  class="switch-input-space column small-8 medium-10 large-10 text-right"
                >
                  <label class="switch-value text-left">Unit of Measure</label>
                  <div class="small switch value-switch switch-2x">
                    <input
                      tabindex="1"
                      class="switch-input"
                      id="checkbox-value-switch-radius"
                      type="checkbox"
                      data-bind="checked:Form().UnitOfMeasure, click:Form().UOMAction"
                    />
                    <label
                      class="switch-paddle"
                      for="checkbox-value-switch-radius"
                    >
                      <span class="switch-active btn-ga4" aria-hidden="true"
                        >US</span
                      >
                      <span class="switch-inactive btn-ga4" aria-hidden="true"
                        >SI</span
                      >
                    </label>
                  </div>
                </div>
                <div
                  class="switch-input-space column small-4 medium-2 large-2 text-right"
                  style="padding-top: 0.5em"
                >
                  <a
                    class="right bold reset-all"
                    data-bind="click:$root.resetAll"
                  >
                    <i class="fa fa-repeat"></i>Reset All
                  </a>
                </div>
              </div>
            </div>
          </div>
          <!--Warning box above the VISIT TYPE card starts-->
          <div
            class="row"
            id="ToS"
            data-bind="visible: !isFollowUp()"
            style="margin-bottom: 12px"
          >
            <div class="medium-12">
              <div
                id="estimate-callout"
                class="callout warning alert-box caution-box-style"
                data-closable=""
                data-bind="visible: $root.doNotShowAgainVisible"
              >
                <b>Welcome to the ASCVD Risk Estimator Plus</b>
                <br />
                <br />
                <b>Terms of Service</b>
                <br />
                <p>
                  Click the Terms tab at the bottom of the app before using the
                  ASCVD Risk Estimator Plus (“the Product”) to read the full
                  Terms of Service and License Agreement (the “Agreement”) which
                  governs the use of the Product. The Agreement includes, among
                  other detailed terms and conditions, certain disclaimers of
                  warranties by the American College of Cardiology Foundation
                  (“ACCF”) and requires the user to agree to release ACCF from
                  any and all liability arising in connection with your use of
                  the Product. By using the Product, you accept and agree to be
                  bound by all of the terms and conditions set forth in the
                  Agreement, including such disclaimers and releases. If you do
                  not accept the terms and conditions of the Agreement, you may
                  not proceed to use the Product. The Agreement is subject to
                  change from time to time, and your continued use of the
                  Product constitutes your acceptance of and agreement to be
                  bound by any revised terms of the Agreement.
                </p>
                <b>For Optimal Use:</b>
                <ul>
                  <li>
                    Estimate patient’s 10-year ASCVD risk at an initial visit to
                    establish a reference point.
                  </li>
                  <li>
                    Forecast the potential impact of different interventions on
                    patient risk.
                  </li>
                  <li>
                    Reassess ASCVD risk at follow-up visits. Follow up risk
                    incorporates change in risk factor levels over time and
                    requires both initial and follow up values.
                  </li>
                  <li>
                    Use the information above to help with clinician-patient
                    discussions on risk and risk-lowering interventions.
                  </li>
                </ul>
                <p class="swappable medium">
                  See the<span class="short-text"> “About”</span
                  ><span class="long-text"> "About the App"</span> screen in
                  this app for a definition of terms and additional
                  instructions.
                </p>
                <b
                  ><a class="close" id="appNotificationClose" data-close=""
                    >x</a
                  ></b
                >
                <p class="text-right bold not-show-again">
                  <a onclick="notShowAgain()">Do not show me this again</a>
                </p>
              </div>
            </div>
          </div>
          <div class="row">
            <div class="callout warning medium-12 columns">
              <h5>
                App should be used for primary prevention patients (those
                without ASCVD) only.
              </h5>
            </div>
          </div>
          <div class="row group-section shrink-waypoint">
            <div class="small-12 medium-6 large-3 column">
              <div
                class="question required"
                data-bind="css: $root.ageValidation().status"
              >
                <div class="label-holder">
                  <label for="">
                    <span
                      class="text"
                      data-bind="with: $root.FormData.formToolTips.ageToolTip"
                      >Current Age
                      <i
                        class="fa fa-info-circle tip-top"
                        data-bind="attr: { title: tooltipTitle }"
                        data-tooltip
                      ></i
                    ></span>
                    <span class="required-holder">
                      <i class="fa fa-holder-dynamic"></i>
                    </span>
                  </label>
                </div>
                <div class="input-holder">
                  <div class="input-space">
                    <input
                      type="number"
                      data-bind="value:Form().Age, valueUpdate: 'blur', attr: {min: 20, max: 79, step: 1 }"
                    />
                  </div>
                </div>
                <div class="message-holder">
                  <span data-bind="css: $root.ageValidation().status">
                    <i class="fa fa-holder"></i>
                    <span
                      class="text"
                      data-bind="text: $root.ageValidation().message"
                    ></span>
                  </span>
                </div>
                <div class="hint">Age must be between 20-79</div>
              </div>
            </div>
            <div
              class="question small-12 medium-6 large-4 column required"
              data-bind="css: $root.sexValidation().status"
            >
              <div class="label-holder">
                <label for="inputSex">
                  <span class="text">Sex</span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable expanded"
                    data-bind="foreach:$root.FormData.sex"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Sex(label)},css:{'selected':$root.Form().Sex() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.sexValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.sexValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint"></div>
            </div>
            <div
              class="question small-12 medium-12 large-5 end column required"
              data-bind="css: $root.raceValidation().status "
            >
              <div class="label-holder">
                <label for="inputRace">
                  <span class="text">Race</span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable small race--group-button"
                    data-bind="foreach:$root.FormData.race"
                  >
                    <a
                      href=""
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Race(label)},css:{'selected':$root.Form().Race() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="hint"></div>
              <div class="message-holder">
                <span data-bind="css: $root.raceValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.raceValidation().message"
                  ></span>
                </span>
              </div>
            </div>
            <div class="column small-12" data-bind="visible:isRaceOther">
              <div class="callout highlighted">
                <span class="bold">Note:</span> These estimates may
                <i>underestimate</i> the 10-year and lifetime risk for persons
                from some race/ethnic groups, especially American Indians, some
                Asian Americans (e.g., of south Asian ancestry), and some
                Hispanics (e.g., Puerto Ricans), and may <i>overestimate</i> the
                risk for others, including some Asian Americans (e.g., of east
                Asian ancestry) and some Hispanics (e.g., Mexican Americans).
                Because the primary use of these risk estimates is to facilitate
                the very important discussion regarding risk reduction through
                lifestyle change, the imprecision introduced is small enough to
                justify proceeding with lifestyle change counseling informed by
                these results.
              </div>
            </div>
            <div class="clearfix"></div>
            <!----------------------- BLOOD PRESSURE ROW ----------------------->
            <div
              class="question small-12 medium-6 large-4 column required"
              data-bind="css: $root.bloodPresureValidation().status "
            >
              <div class="label-holder">
                <label for="">
                  <span class="text">
                    Systolic Blood Pressure
                    <small class="pre">(mm Hg)</small>
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <input
                    type="number"
                    data-bind="value:Form().BloodPressure, valueUpdate: 'blur', attr: { min: 90, max: 200, step: 1}"
                  />
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.bloodPresureValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.bloodPresureValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint">Value must be between 90-200</div>
            </div>
            <div
              class="question required small-12 medium-6 large-4 column end"
              data-bind="css: $root.DBloodPressureValidation().status "
            >
              <div class="label-holder">
                <label for="">
                  <span class="text">
                    Diastolic Blood Pressure
                    <small class="pre">(mm Hg)</small>
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <input
                    type="number"
                    data-bind="value:Form().DBloodPressure, valueUpdate: 'blur', attr: { min: 60, max: 130, step: 1}"
                  />
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.DBloodPressureValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.DBloodPressureValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint">Value must be between 60-130</div>
            </div>
            <div class="clearfix"></div>
            <!----------------------- CHOLESTEROL ROW -------------------------->
            <div
              class="question large-4 medium-6 small-12 column required"
              data-bind="css: $root.totalCholesterolValidation().status "
            >
              <div class="label-holder">
                <label for="">
                  <span class="text">
                    Total Cholesterol
                    <small data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >(mg/dL)</small
                    >
                    <small data-bind="visible: $root.Form().UnitOfMeasure()"
                      >(mmol/L)</small
                    >
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <input
                    type="number"
                    data-bind="value:Form().TotalCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 3.367 : 130, max: $root.Form().UnitOfMeasure() ? 8.288 : 320, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                  />
                </div>
              </div>
              <div class="message-holder">
                <span
                  data-bind="css: $root.totalCholesterolValidation().status"
                  class=""
                >
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.totalCholesterolValidation().message"
                  ></span>
                </span>
              </div>
              <div
                class="hint"
                data-bind="visible: !$root.Form().UnitOfMeasure() "
              >
                Value must be between 130 - 320
              </div>
              <div
                class="hint"
                data-bind="visible: $root.Form().UnitOfMeasure()"
              >
                Value must be between 3.367 - 8.288
              </div>
            </div>
            <div
              class="question large-4 medium-6 small-12 column required"
              data-bind="css: $root.hdlValidation().status "
            >
              <div class="label-holder">
                <label for="">
                  <span class="text">
                    HDL Cholesterol
                    <small data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >(mg/dL)</small
                    >
                    <small data-bind="visible: $root.Form().UnitOfMeasure() "
                      >(mmol/L)</small
                    >
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <input
                    type="number"
                    data-bind="value:Form().HDLCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 0.518 : 20, max: $root.Form().UnitOfMeasure() ? 2.590 : 100, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                  />
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.hdlValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.hdlValidation().message"
                  ></span>
                </span>
              </div>
              <div
                class="hint"
                data-bind="visible: !$root.Form().UnitOfMeasure() "
              >
                Value must be between 20 - 100
              </div>
              <div
                class="hint"
                data-bind="visible: $root.Form().UnitOfMeasure() "
              >
                Value must be between 0.518 - 2.59
              </div>
            </div>
            <div
              class="question required large-4 medium-6 small-12 column end"
              data-bind="css: $root.ldlValidation().status, addCSS: {'required-advice': $root.Form().VisitType()==false}"
            >
              <div class="label-holder">
                <label for="">
                  <span
                    class="text"
                    data-bind="with: $root.FormData.formToolTips.ldlToolTip"
                  >
                    LDL Cholesterol
                    <small
                      class="pre"
                      data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >(mg/dL)</small
                    >
                    <small
                      class="pre"
                      data-bind="visible: $root.Form().UnitOfMeasure() "
                      >(mmol/L)</small
                    >
                    <i
                      class="fa fa-info-circle tip-top"
                      data-bind="attr: { title: tooltipTitle }"
                      data-tooltip
                    ></i>
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <input
                    type="number"
                    data-bind="value:Form().LDLCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 0.777 : 30, max: $root.Form().UnitOfMeasure() ? 7.770 : 300, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                  />
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.ldlValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.ldlValidation().message"
                  ></span>
                </span>
              </div>
              <div
                class="hint"
                data-bind="visible: !$root.Form().UnitOfMeasure() "
              >
                Value must be between 30-300
              </div>
              <div
                class="hint"
                data-bind="visible: $root.Form().UnitOfMeasure() "
              >
                Value must be between 0.777-7.770
              </div>
            </div>
            <div class="clearfix"></div>
            <!----------------------- CHOLESTEROL ROW ENDS --------------------->
            <!------------------------ PERSONAL HISTORY ROW --------------------->
            <div
              class="question required small-12 medium-6 large-4 column"
              data-bind="css: $root.diabeticValidation().status"
            >
              <div class="label-holder">
                <label for="check-diabetic">
                  <span class="text">History of Diabetes?</span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable expanded"
                    data-bind="foreach:$root.FormData.diabetic"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Diabetic(label)},css:{'selected':$root.Form().Diabetic() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.diabeticValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.diabeticValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint"></div>
            </div>
            <div
              class="question required small-12 medium-12 column"
              data-bind="css: $root.smokerValidation().status, addCSS: {'large-8': $root.Form().Smoker()!='Former', 'large-4': $root.Form().Smoker()=='Former'}"
            >
              <div class="label-holder">
                <label for="check-smoker">
                  <span
                    class="text"
                    data-bind="with: $root.FormData.formToolTips.smokerToolTip"
                    >Smoker?
                    <i
                      class="fa fa-info-circle tip-top"
                      data-bind="attr: { title: tooltipTitle }"
                      data-tooltip
                    ></i
                  ></span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group expanded selectable is-smoker-button"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Smoker('Current')},css:{'selected':$root.Form().Smoker() == 'Current'}"
                      ><i class="fa fa-check"></i><span>Current</span> &nbsp;<i
                        class="fa fa-info-circle tip-bottom custom-size"
                        style="display: inline-block"
                        title="Smokes every day or on some days. "
                        data-tooltip
                      ></i
                    ></a>
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Smoker('Former')},css:{'selected':$root.Form().Smoker() == 'Former'}"
                      ><i class="fa fa-check"></i><span>Former</span>&nbsp;<i
                        style="display: inline-block"
                        class="fa fa-info-circle tip-bottom custom-size"
                        title="Does not currently smoke and has been abstinent for at least 7 days in a row."
                        data-tooltip
                      ></i
                    ></a>
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Smoker('Never')},css:{'selected':$root.Form().Smoker() == 'Never'}"
                      ><i class="fa fa-check"></i><span>Never</span>&nbsp;<i
                        style="display: inline-block"
                        class="fa fa-info-circle tip-bottom custom-size"
                        title="Has not smoked regularly and doesn't currently smoke."
                        data-tooltip
                      ></i
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.smokerValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.smokerValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint"></div>
            </div>
            <div
              class="question required small-12 large-4 column"
              data-bind="visible:quiteSmoking, css: $root.smokingSelectValidation().status"
            >
              <div class="label-holder">
                <label for="">
                  <span class="text bold"
                    >How long ago did patient quit smoking?
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder row collapse">
                <div class="input-space">
                  <select
                    name="quitSelect"
                    id="quitSelect"
                    data-bind="
                                                  options: $root.FormData.quiteSmoking,
                                                  optionsText: 'label',
                                                  optionsValue: $data,
                                                  selectedOption: $root.Form().QuiteSmokingMonths,
                                                  optionsCaption: 'Select',
                                                  value:$root.Form().QuiteSmokingMonths"
                  ></select>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.smokingSelectValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.smokingSelectValidation().message"
                  ></span>
                </span>
              </div>
            </div>
            <div class="clearfix"></div>
            <div
              class="question required small-12 medium-6 large-4 column"
              data-bind="css: $root.hypertensionValidation().status"
            >
              <div class="label-holder">
                <label for="check-hypertension">
                  <span class="text" style="white-space: normal">
                    On Hypertension Treatment?
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable expanded small"
                    data-bind="foreach:$root.FormData.hypertension"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().Hypertension(label)},css:{'selected':$root.Form().Hypertension() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.hypertensionValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.hypertensionValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint"></div>
            </div>
            <div
              class="question required small-12 medium-6 large-4 column"
              data-bind="css: $root.statinValidation().status, addCSS: {'required-advice': $root.Form().VisitType()==false}"
            >
              <div class="label-holder">
                <label for="check-statin">
                  <span
                    class="text"
                    data-bind="with: $root.FormData.formToolTips.statinToolTip"
                    >On a Statin?
                    <i
                      class="fa fa-info-circle tip-top"
                      data-bind="attr: { title: tooltipTitle }"
                      data-tooltip
                    ></i
                  ></span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>

              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable expanded small"
                    data-bind="foreach:$root.FormData.onStatin"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().OnStatin(label)},css:{'selected':$root.Form().OnStatin() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.statinValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.statinValidation().message"
                  ></span>
                </span>
              </div>
              <div class="hint"></div>
            </div>
            <div
              class="question required small-12 medium-6 large-4 column end"
              data-bind="css: $root.aspirinValidation().status, addCSS: {'required-advice': $root.Form().VisitType()==false}"
            >
              <div class="label-holder">
                <label for="check-aspirin">
                  <span
                    class="text"
                    data-bind="with: $root.FormData.formToolTips.aspirinToolTip"
                    >On Aspirin Therapy?
                    <i
                      class="fa fa-info-circle tip-top"
                      data-bind="attr: { title: tooltipTitle }"
                      data-tooltip
                    ></i>
                  </span>
                  <span class="required-holder">
                    <i class="fa fa-holder-dynamic"></i>
                  </span>
                </label>
              </div>
              <div class="input-holder">
                <div class="input-space">
                  <div
                    class="button-group selectable expanded small"
                    data-bind="foreach:$root.FormData.onAspirin"
                  >
                    <a
                      href=""
                      style="white-space: nowrap"
                      class="button small"
                      data-bind="click:function(){appmodel.Form().OnAspirin(label)},css:{'selected':$root.Form().OnAspirin() == label}"
                      ><i class="fa fa-check"></i
                      ><span data-bind="text:label"></span
                    ></a>
                  </div>
                </div>
              </div>
              <div class="message-holder">
                <span data-bind="css: $root.aspirinValidation().status">
                  <i class="fa fa-holder"></i>
                  <span
                    class="text"
                    data-bind="text: $root.aspirinValidation().message"
                  ></span>
                </span>
              </div>
            </div>
            <!------------------------ PERSONAL HISTORY ROW ENDS ----------------->
          </div>
          <!-- "Do you have previous value" section starts -->
          <div
            class="row group-section"
            data-bind="css: {disabled: $root.invalidAgeValue() || $root.Form().invalidLdlMessage(), 'no-pointer-events': $root.invalidAgeValue() || $root.Form().invalidLdlMessage()}"
          >
            <div class="row column" id="compareQuestion">
              <div
                class="question required required-advice small-12 medium-6 column"
                data-bind="css: $root.visitTypeValidation().status"
              >
                <div class="label-holder">
                  <label for="compare-previous-visit">
                    <span
                      class="text"
                      data-bind="with: $root.FormData.formToolTips.previousvisitToolTip"
                      >Do you want to refine current risk estimation using data
                      from a previous visit?
                      <i
                        style="color: #333333"
                        class="fa fa-info-circle tip-top"
                        data-bind="attr: { title: tooltipTitle }"
                        data-tooltip
                      ></i>
                    </span>
                    <span class="required-holder">
                      <i class="fa fa-holder-dynamic"></i>
                    </span>
                  </label>
                </div>
                <div class="input-holder">
                  <div class="input-space">
                    <div
                      class="button-group selectable expanded"
                      data-bind="foreach:$root.FormData.visitType"
                    >
                      <a
                        href=""
                        style="white-space: nowrap"
                        class="button"
                        data-bind="click:function(){appmodel.Form().VisitTypeUI(value);gotoCompare();},css:{'selected':$root.Form().VisitTypeUI() == value, disabled: $root.invalidAgeValue() || $root.Form().invalidLdlMessage(), 'no-pointer-events': $root.invalidAgeValue() || $root.Form().invalidLdlMessage()}, attr: {'tabindex': $root.invalidAgeValue() || $root.Form().invalidLdlMessage() ? '-1' : undefined}"
                        ><i class="fa fa-check"></i
                        ><span data-bind="text:label"></span
                      ></a>
                    </div>
                  </div>
                </div>
                <div class="message-holder">
                  <span data-bind="css: $root.visitTypeValidation().status">
                    <i class="fa fa-holder"></i>
                    <span
                      class="text"
                      data-bind="text: $root.visitTypeValidation().message"
                    ></span>
                  </span>
                </div>
                <div class="hint"></div>
              </div>
            </div>
          </div>
          <!-- "Do you have previous value" section ends -->
        </div>
        <div id="follow-up-card" data-bind="visible: $root.isFollowUp">
          <div class="page paper-page highlighted">
            <div class="page-wrapper">
              <section class="section card">
                <div class="row shrink-waypoint">
                  <div class="colored-paper clearfix">
                    <div class="small-8 medium-8 large-8 columns">
                      <h3>Values at Previous Visit</h3>
                    </div>
                    <div
                      class="switch-input-space column small-4 medium-4 large-4 text-right"
                      style="padding-top: 1.5em"
                    >
                      <a
                        class="right bold reset-all-inverted show-for-medium"
                        data-bind="click:$root.resetBaselineValues"
                      >
                        <i class="fa fa-repeat"></i>Reset
                      </a>
                      <a
                        class="right bold reset-all-inverted show-for-small-only"
                        data-bind="click:$root.resetBaselineValues"
                      >
                        <i class="fa fa-repeat"></i>Reset
                      </a>
                    </div>
                  </div>
                  <div class="row columns">
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineAgeValidation().status"
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text">Age at Previous Visit</span>
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <input
                            id="baselineage"
                            type="number"
                            data-bind="value:Form().BaselineAge, valueUpdate: 'blur', attr: { min: 40, max: 79, step: 1}"
                          />
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineAgeValidation().status"
                          class="warning"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineAgeValidation().message"
                            >Age is Missing</span
                          >
                        </span>
                      </div>
                      <div class="hint">Age must be between 40-79</div>
                    </div>
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineTotalCholesterolValidation().status "
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text">
                            Total Cholesterol at Previous Visit
                            <!-- ko if: (viewportWidth() >= 658 && viewportWidth() <= 713) || (viewportWidth() >= 1024 && viewportWidth() <= 1042) || (viewportWidth() <= 363)-->
                            <br />
                            <!-- /ko -->
                            <small
                              class="pre"
                              data-bind="visible: !$root.Form().UnitOfMeasure() "
                              >(mg/dL)</small
                            >
                            <small
                              class="pre"
                              data-bind="visible: $root.Form().UnitOfMeasure() "
                              >(mmol/L)</small
                            >
                          </span>
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <input
                            type="number"
                            data-bind="value:Form().BaselineTotalCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 3.367 : 130, max: $root.Form().UnitOfMeasure() ? 8.288 : 320, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                          />
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineTotalCholesterolValidation().status"
                          class="warning"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineTotalCholesterolValidation().message"
                            >Total Cholesterol is Missing</span
                          >
                        </span>
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >
                        Value must be between 130 - 320
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: $root.Form().UnitOfMeasure() "
                      >
                        Value must be between 3.367 - 8.288
                      </div>
                    </div>
                    <!--ko if: viewportWidth() < 1024 && viewportWidth() >= 640 -->
                    <div style="clear: both"></div>
                    <!-- /ko -->
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineHdlValidation().status "
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text">
                            HDL Cholesterol at Previous Visit
                            <!-- ko if: (viewportWidth() >= 647 && viewportWidth() <= 702) || (viewportWidth() >= 1024 && viewportWidth() <= 1026)  -->
                            <br />
                            <!-- /ko -->
                            <small
                              class="pre"
                              data-bind="visible: !$root.Form().UnitOfMeasure() "
                              >(mg/dL)</small
                            >
                            <small
                              class="pre"
                              data-bind="visible: $root.Form().UnitOfMeasure() "
                              >(mmol/L)</small
                            >
                          </span>
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <input
                            type="number"
                            data-bind="value:Form().BaselineHDLCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 0.518 : 20, max: $root.Form().UnitOfMeasure() ? 2.590 : 100, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                          />
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineHdlValidation().status"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineHdlValidation().message"
                          ></span>
                        </span>
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >
                        Value must be between 20 - 100
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: $root.Form().UnitOfMeasure() "
                      >
                        Value must be between 0.518 - 2.59
                      </div>
                    </div>
                    <!--ko if: viewportWidth() >= 1024 -->
                    <div style="clear: both"></div>
                    <!-- /ko -->
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineLdlValidation().status "
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text">
                            LDL Cholesterol at Previous Visit
                            <!-- ko if: (viewportWidth() >= 658 && viewportWidth() <= 728) || (viewportWidth() >= 1071 && viewportWidth() <= 1081) || (viewportWidth() <= 363)-->
                            <br />
                            <!-- /ko -->
                            <small
                              class="pre"
                              data-bind="visible: !$root.Form().UnitOfMeasure() "
                              >(mg/dL)</small
                            >
                            <small
                              class="pre"
                              data-bind="visible: $root.Form().UnitOfMeasure() "
                              >(mmol/L)</small
                            >
                            <i
                              class="fa fa-info-circle tip-top"
                              data-bind="attr: { title: $root.FormData.formToolTips.ldlToolTip.tooltipTitle }"
                              data-tooltip
                            ></i>
                          </span>
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <input
                            type="number"
                            data-bind="value:Form().BaselineLDLCholesterolValue, valueUpdate: 'blur', attr: { min: $root.Form().UnitOfMeasure() ? 0.777 : 30, max: $root.Form().UnitOfMeasure() ? 7.770 : 300, step: $root.Form().UnitOfMeasure() ? 0.001 : 1}"
                          />
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineLdlValidation().status"
                          class="warning"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineLdlValidation().message"
                            >LDL Cholesterol at Initial Visit is Missing</span
                          >
                        </span>
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: !$root.Form().UnitOfMeasure() "
                      >
                        Value must be between 30-300
                      </div>
                      <div
                        class="hint"
                        data-bind="visible: $root.Form().UnitOfMeasure() "
                      >
                        Value must be between 0.777-7.770
                      </div>
                    </div>
                    <!--ko if: viewportWidth() < 1024 && viewportWidth() >= 640 -->
                    <div style="clear: both"></div>
                    <!-- /ko -->
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineBloodPresureValidation().status "
                    >
                      <div class="label-holder">
                        <label for=""
                          ><span class="text pre"
                            >Systolic Blood Pressure at Previous Visit
                            <small class="">(mm Hg)</small></span
                          >
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <input
                            type="number"
                            data-bind="value:Form().BaselineBloodPressure, valueUpdate: 'blur', attr: { min: 90, max: 200, step: 1}"
                          />
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineBloodPresureValidation().status"
                          class="warning"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineBloodPresureValidation().message"
                            >Systolic Blood Pressure is Missing</span
                          >
                        </span>
                      </div>
                      <div class="hint">Value must be between 90-200</div>
                    </div>
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineHypertensionValidation().status"
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text pre"
                            >On Hypertension Treatment at Previous Visit?</span
                          >
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <div
                            class="button-group selectable expanded small"
                            data-bind="foreach:$root.FormData.hypertension"
                          >
                            <a
                              href=""
                              style="white-space: nowrap"
                              class="button small"
                              data-bind="click:function(){appmodel.Form().BaselineHypertension(label)},css:{'selected':$root.Form().BaselineHypertension() == label}"
                              ><i class="fa fa-check"></i
                              ><span data-bind="text:label"></span
                            ></a>
                          </div>
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineHypertensionValidation().status"
                          class="warning"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineHypertensionValidation().message"
                            >Treatment Hypertension is Missing</span
                          >
                        </span>
                        <div class="hint"></div>
                      </div>
                    </div>
                    <div style="clear: both"></div>
                    <div
                      class="question required small-12 medium-6 large-4 column"
                      data-bind="css: $root.baselineDiabeticValidation().status ,visible:(Form().Diabetic() != 'No')"
                    >
                      <div class="label-holder">
                        <label for="">
                          <span class="text"
                            >History of Diabetes at Previous Visit?</span
                          >
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <div
                            class="button-group selectable expanded small"
                            data-bind="foreach:$root.FormData.diabetic"
                          >
                            <a
                              href=""
                              style="white-space: nowrap"
                              class="button small"
                              data-bind="click:function(){appmodel.Form().BaselineDiabetic(label)},css:{'selected':$root.Form().BaselineDiabetic() == label}"
                              ><i class="fa fa-check"></i
                              ><span data-bind="text:label"></span
                            ></a>
                          </div>
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineDiabeticValidation().status"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineDiabeticValidation().message"
                          ></span>
                        </span>
                        <div class="hint"></div>
                      </div>
                    </div>
                    <div
                      class="question required small-12 medium-6 large-4 column end"
                      data-bind="css: $root.baselineSmokerValidation().status ,visible:$root.Form().isSmoker() || !Form().Smoker() || quiteSmoking()"
                    >
                      <div class="label-holder">
                        <label for="check-smoker">
                          <span
                            class="text pre"
                            data-bind="with: $root.FormData.formToolTips.smokerToolTip"
                            >Was a Smoker at Previous Visit (or within a year
                            before the visit)?
                            <i
                              class="fa fa-info-circle tip-top"
                              data-bind="attr: { title: tooltipTitle }"
                              data-tooltip
                            ></i
                          ></span>
                          <span class="required-holder">
                            <i class="fa fa-holder-dynamic"></i>
                          </span>
                        </label>
                      </div>
                      <div class="input-holder">
                        <div class="input-space">
                          <div
                            class="button-group selectable expanded"
                            data-bind="foreach:$root.FormData.YesNoQuestion"
                          >
                            <a
                              href=""
                              style="white-space: nowrap"
                              class="button small"
                              data-bind="click:function(){appmodel.Form().BaselineSmoker(label)},css:{'selected':$root.Form().BaselineSmoker() == label}"
                              ><i class="fa fa-check"></i
                              ><span data-bind="html:label"></span
                            ></a>
                          </div>
                        </div>
                      </div>
                      <div class="message-holder">
                        <span
                          data-bind="css: $root.baselineSmokerValidation().status"
                        >
                          <i class="fa fa-holder"></i>
                          <span
                            class="text"
                            data-bind="text: $root.baselineSmokerValidation().message"
                          ></span>
                        </span>
                      </div>
                      <div class="hint"></div>
                    </div>
                  </div>
                </div>
              </section>
            </div>
          </div>
        </div>
        <div class="page-wrapper" style="padding-top: 0">
          <div class="row hide-for-small-only">
            <div class="small-12 column text-right">
              <a
                href="#!/calculate/therapy/"
                class="button right"
                data-bind="click:$root.NavigateToForecastPage.bind('event', 'Clicked button'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : ($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock()} "
                custom-tooltip-parent
                ><span class="ti-ce-ga4">Determine Therapy Impact</span
                >&nbsp;&nbsp;<i class="fa fa-arrow-circle-right fa-6"></i
              ></a>
              <div class="custom-tooltip top">
                Potential risk reduction impact of different therapies can only
                be calculated for patients 40-79 years of age at an initial
                visit.
              </div>
            </div>
            <div class="small-12 column text-right">
              <a
                href="#!/calculate/advice/riskgraph"
                class="button right left10 va-ce-ga4"
                data-bind="click:$root.NavigateToSummaryPage.bind('event', 'Clicked button'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : (($root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                custom-tooltip-parent
                >View Advice&nbsp;&nbsp;<i
                  class="fa fa-arrow-circle-right fa-6"
                ></i
              ></a>
              <div class="custom-tooltip bottom">
                Advice section is accessible when required characteristics for
                patients 40-79 years of age are entered.
              </div>
            </div>
          </div>
          <div class="row show-for-small-only text-right">
            <div class="small-12 column">
              <a
                href="#!/calculate/therapy/"
                class="button right"
                data-bind="click:$root.NavigateToForecastPage.bind('event', 'Clicked button'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : ($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock()}"
                custom-tooltip-parent
                ><span class="ti-ce-ga4">Determine Therapy Impact</span
                >&nbsp;&nbsp;<i class="fa fa-arrow-circle-right fa-6"></i
              ></a>
              <div class="custom-tooltip top">
                Potential risk reduction impact of different therapies can only
                be calculated for patients 40-79 years of age at an initial
                visit.
              </div>
            </div>
            <div class="small-12 column text-right">
              <a
                href="#!/calculate/advice/riskgraph"
                class="button right left10 va-ce-ga4"
                data-bind="click:$root.NavigateToSummaryPage.bind('event', 'Clicked button'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage()) ? false : (($root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                custom-tooltip-parent
                >View Advice&nbsp;&nbsp;<i
                  class="fa fa-arrow-circle-right fa-6"
                ></i
              ></a>
              <div class="custom-tooltip bottom">
                Advice section is accessible when required characteristics for
                patients 40-79 years of age are entered.
              </div>
            </div>
          </div>
          <h4 class="row">
            <span class="sub-line">
              <b
                >For more information about the inputs and calculations used in
                this app, see “Terms and Concepts” in the Resources tab
                below.</b
              ><br />
              <sup>**</sup>10-year risk for ASCVD is categorized as:<br />Low-risk
              (&lt;5%)<br />Borderline risk (5% to 7.4%)<br />Intermediate risk
              (7.5% to 19.9%)<br />High risk (≥20%)<br />
              <i class="fa fa-asterisk" aria-hidden="true"></i>&nbsp;Indicates a
              field required to calculate current 10-year ASCVD risk for
              patients age 40-79 or Lifetime risk for patients age 20-59. Risk
              will automatically calculate once these fields are populated.
              <br />
              <i class="fa fa-circle-o" aria-hidden="true"></i>&nbsp;Indicates
              additional questions required to determine individualized patient
              advice for patients age 40-79. Answering these questions in
              addition to the indicated risk fields will activate the Therapy
              Impact and Advice tabs.
            </span>
          </h4>
        </div>
      </div>
      <div
        data-bind="page: {id: 'therapy', name: 'therapy', afterShow:tabchange, beforeShow:pageScrollTop}"
        class="page-wrapper fullscreen-spacer"
      >
        <div class="row collapse">
          <div class="large-11 small-10 columns">
            <h1>Project Risk Reduction by Therapy</h1>
          </div>
          <div class="large-1 small-2 columns text-right">
            <div class="question float-right">
              <div
                class="switch-input-space column large-12 small-4 medium-5"
                style="padding-top: 2.5em"
              >
                <a
                  class="right bold reset-all"
                  data-bind="click:$root.resetForcast"
                >
                  <i class="fa fa-repeat"></i>Reset
                </a>
              </div>
            </div>
          </div>
        </div>

        <div class="row group-section shrink-waypoint">
          <div class="accordion">
            <div class="consideration">
              <h4
                class="toggle no-extra-lineheight"
                onclick="panelVisibleToggle('.consideration')"
              >
                <i class="fa fa-holder"></i
                ><span class="text no-extra-lineheight"
                  >View Advice Summary for this Patient</span
                >
              </h4>
              <div
                id="advice-card"
                class="collapsable-panel"
                style="display: none"
              >
                <div class="row">
                  <div class="column small-12">
                    <span>
                      <p data-bind="text:recommendationType().advice">
                        Continue usual care at MD’s discretion.
                      </p>
                    </span>
                    <ul>
                      <li
                        data-bind="visible: ($root.recommendationType().bpControl)"
                      >
                        <span class="bold">BP:</span>
                        <span
                          data-bind="htmlMarkup: $root.recommendationType().bpControl.adviceTherapyImpact"
                        ></span>
                      </li>
                      <li
                        data-bind="visible:($root.recommendationType().ldlControl)"
                      >
                        <span class="bold">LDL-C:</span>
                        <span
                          data-bind="htmlMarkup: $root.recommendationType().ldlControl.adviceTherapyImpact"
                        ></span>
                      </li>
                      <li
                        data-bind="visible:($root.recommendationType().diabetesControl)"
                      >
                        <span class="bold">Diabetes:</span>
                        <span
                          data-bind="htmlMarkup: $root.recommendationType().diabetesControl.adviceTherapyImpact"
                        ></span>
                      </li>
                      <li
                        data-bind="visible:($root.recommendationType().smokingControl)"
                      >
                        <span class="bold">Smoking:</span>
                        <span
                          data-bind="text: $root.recommendationType().smokingControl.adviceTherapyImpact"
                        ></span>
                      </li>
                      <li
                        data-bind="visible:($root.recommendationType().aspirinControl)"
                      >
                        <span class="bold">Aspirin:</span>
                        <span
                          data-bind="text: $root.recommendationType().aspirinControl.adviceTherapyImpact"
                        ></span>
                      </li>
                    </ul>
                  </div>
                </div>
                <div class="">
                  <p class="">
                    <span class="bold">Lifestyle: </span>The most important way
                    to prevent ASCVD is to promote a healthy lifestyle
                    throughout life. Medications to reduce ASCVD risk should
                    only be considered part of a shared decision-making process
                    for optimal treatment when a patient's risk is sufficiently
                    high. Decisions around the therapies listed above are
                    assumed to be made in the context of ACC/AHA
                    guideline-recommended lifestyle interventions.
                  </p>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div
          class="forecast-score-bar-holder"
          data-bind="template: {name: 'small-forecast-template', data: $root}"
        ></div>
        <div class="page paper-page">
          <div class="page-wrapper">
            <section
              class="section card no-vertical-margin"
              data-bind="css:{ghost:!$root.Form().isTreatmentOne()}"
            >
              <div id="treatment1" class="row">
                <div
                  id="t1-score"
                  class="colored-paper"
                  data-bind="css:{info:Form().isTreatmentOne() && Form().TreatmentOneScore() == '~%', warning:Form().TreatmentOneScore()=='NA'}"
                >
                  <span data-bind="visible:$root.Form().isTreatmentOne()">
                    <h5>
                      <span class="sub-line"
                        >Projected 10-Year ASCVD Risk
                      </span>
                    </h5>
                    <h3>
                      <span
                        data-bind="text:Form().TreatmentOneScore() == 'NA' ?'NA*' :Form().TreatmentOneScore() "
                        >T1 15.3 %</span
                      >&nbsp;
                      <span data-bind="text:Form().TratmentOneCaption"
                        >Stop Smoking, Add Statin Treatments</span
                      >
                    </h3>
                  </span>
                  <a
                    data-bind="click:Form().AddTreatmentOne, visible: !$root.Form().isTreatmentOne()"
                  >
                    <h4
                      class="text-center no-vertical-margin"
                      data-bind="visible:!$root.Form().isTreatmentOne()"
                    >
                      <i class="fa fa-plus-circle" aria-hidden="true"></i
                      >&nbsp;&nbsp;Add New Treatment Scenario
                    </h4>
                  </a>
                </div>
                <div
                  data-bind="visible:$root.Form().isTreatmentOne()"
                  class="shrink-waypoint-f1"
                >
                  <br />
                  <div
                    data-bind="foreach:$root.FormData.treatmentOne"
                    class="showafterthis1"
                  >
                    <div
                      class="input-holder columns question"
                      data-bind="css: responsiveClass"
                    >
                      <div class="switch-input-space">
                        <div class="switch radius">
                          <input
                            class="switch-input"
                            type="checkbox"
                            data-bind="attr: {'id': htmlID}, checkedValue: $data, checked: $root.Form().TratmentOne_selected, enable: enable()"
                          />
                          <label
                            class="switch-paddle switch-btn"
                            data-bind="attr: {'for': htmlID}, click:function(){$root.Form().AddTreatmentTwo();return true;}"
                          >
                            <span
                              class="show-for-sr"
                              data-bind="text:$data.text"
                            ></span>
                            <span class="switch-active" aria-hidden="true">
                              <i class="fa fa-check-circle-o"></i>
                            </span>
                            <span class="switch-inactive" aria-hidden="true">
                              <i class="fa fa-times-circle"></i>
                            </span>
                          </label>
                        </div>
                        <label class="switch-value">
                          <span class="bold" data-bind="text:text"></span>
                          <i
                            class="fa fa-info-circle tip-top"
                            data-bind="visible: showInfo, attr: { title: tooltipTitle }"
                            data-tooltip
                          ></i>
                        </label>
                      </div>
                    </div>
                  </div>
                  <div
                    class="row column large-12 text-center clearfixed invisible"
                  >
                    <a
                      class="button small secondary invisible"
                      data-bind="click:Form().RemoveTreatmentOne"
                      >Remove this scenario</a
                    >
                  </div>
                  <div class="row column">
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                      >*Guidelines do not recommend statin therapy for patients
                      with 10-year risk &lt; 5%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                      >*Guidelines do not typically recommend aspirin therapy
                      for patients with 10-year risk &lt; 10%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isBPGuidelineVisible"
                      >*ACC/AHA Guidelines do not specify antihypertensive drug
                      therapy for SBP&lt;120 mmHg (&lt;130 mmHg
                      w/diabetes)</small
                    >
                  </div>
                </div>
              </div>
            </section>
          </div>
        </div>
        <div class="page paper-page">
          <div class="page-wrapper">
            <section
              class="section card no-vertical-margin"
              data-bind="css:{ghost:!$root.Form().isTreatmentTwo()}"
            >
              <div id="treatment2" class="row">
                <div
                  id="t2-score"
                  class="colored-paper"
                  data-bind="css:{info:Form().isTreatmentTwo() && Form().TreatmentTwoScore() == '~%', warning:Form().TreatmentTwoScore()=='NA'}"
                >
                  <span data-bind="visible:$root.Form().isTreatmentTwo()">
                    <h5>
                      <span class="sub-line">Projected 10-Year ASCVD Risk</span>
                    </h5>
                    <h3>
                      <span
                        data-bind="text:Form().TreatmentTwoScore() == 'NA' ?'NA*' :Form().TreatmentTwoScore() "
                        >T2 15.3 %</span
                      >&nbsp;
                      <span data-bind="text:Form().TratmentTwoCaption"
                        >Stop Smoking, Add Statin Treatments</span
                      >
                    </h3>
                  </span>
                  <a
                    data-bind="click:Form().AddTreatmentTwo, visible: !$root.Form().isTreatmentTwo()"
                  >
                    <h4
                      class="text-center no-vertical-margin"
                      data-bind="visible:!$root.Form().isTreatmentTwo()"
                    >
                      <i class="fa fa-plus-circle" aria-hidden="true"></i
                      >&nbsp;&nbsp;<span class="btn-ga4"
                        >Project a Different Therapy Combination</span
                      >
                    </h4>
                  </a>
                </div>
                <div
                  data-bind="visible:$root.Form().isTreatmentTwo()"
                  class="showafterthis2"
                >
                  <br />
                  <div data-bind="foreach:$root.FormData.treatmentTwo">
                    <div
                      class="input-holder columns question"
                      data-bind="css: responsiveClass"
                    >
                      <div class="switch-input-space">
                        <div class="switch radius">
                          <input
                            class="switch-input"
                            type="checkbox"
                            data-bind="attr: {'id': htmlID}, checkedValue: $data, checked: $root.Form().TratmentTwo_selected, enable: enable()"
                          />
                          <label
                            class="switch-paddle switch-btn"
                            data-bind="attr: {'for': htmlID}"
                          >
                            <span
                              class="show-for-sr"
                              data-bind="text:$data.text"
                            ></span>
                            <span class="switch-active" aria-hidden="true">
                              <i class="fa fa-check-circle-o"></i>
                            </span>
                            <span class="switch-inactive" aria-hidden="true">
                              <i class="fa fa-times-circle"></i>
                            </span>
                          </label>
                        </div>
                        <label class="switch-value">
                          <span class="bold" data-bind="text:text"></span>
                          <i
                            class="fa fa-info-circle tip-top"
                            data-bind="visible: showInfo, attr: { title: tooltipTitle }"
                            data-tooltip
                          ></i>
                        </label>
                      </div>
                    </div>
                  </div>
                  <div
                    class="row column large-12 text-center clearfixed invisible"
                  >
                    <a
                      class="button small secondary invisible"
                      data-bind="click:Form().RemoveTreatmentTwo"
                      >Remove this scenario</a
                    >
                  </div>
                  <div class="row column">
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                      >*Guidelines do not recommend statin therapy for patients
                      with 10-year risk &lt; 5%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                      >*Guidelines do not typically recommend aspirin therapy
                      for patients with 10-year risk &lt; 10%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isBPGuidelineVisible"
                      >*ACC/AHA Guidelines do not specify antihypertensive drug
                      therapy for SBP&lt;120 mmHg (&lt;130 mmHg
                      w/diabetes)</small
                    >
                  </div>
                </div>
              </div>
            </section>
          </div>
        </div>
        <div
          class="page paper-page"
          data-bind="visible:$root.Form().isTreatmentTwo()"
        >
          <div class="page-wrapper">
            <section
              class="section card no-vertical-margin"
              data-bind="css:{ghost:!$root.Form().isTreatmentThree()}"
            >
              <div id="treatment3" class="row">
                <div
                  id="t3-score"
                  class="colored-paper"
                  data-bind="css:{info:Form().isTreatmentThree() && Form().TreatmentThreeScore() == '~%', warning:Form().TreatmentThreeScore()=='NA'}"
                >
                  <span data-bind="visible:$root.Form().isTreatmentThree()">
                    <h5>
                      <span class="sub-line">Projected 10-Year ASCVD Risk</span>
                    </h5>
                    <h3>
                      <span
                        data-bind="text:Form().TreatmentThreeScore() == 'NA' ?'NA*' :Form().TreatmentThreeScore() "
                        >T3 15.3 %</span
                      >&nbsp;
                      <span data-bind="text:Form().TratmentThreeCaption"
                        >Stop Smoking, Add Statin Treatments</span
                      >
                    </h3>
                  </span>
                  <a
                    data-bind="click:Form().AddTreatmentThree, visible: !$root.Form().isTreatmentThree()"
                  >
                    <h4
                      class="text-center no-vertical-margin"
                      data-bind="visible:!$root.Form().isTreatmentThree()"
                    >
                      <i class="fa fa-plus-circle" aria-hidden="true"></i
                      >&nbsp;&nbsp;<span class="btn-ga4"
                        >Project a Different Therapy Combination</span
                      >
                    </h4>
                  </a>
                </div>
                <div data-bind="visible:$root.Form().isTreatmentThree()">
                  <br />
                  <div
                    data-bind="foreach:$root.FormData.treatmentThree"
                    class="showafterthis3"
                  >
                    <div
                      class="input-holder columns question"
                      data-bind="css: responsiveClass"
                    >
                      <div class="switch-input-space">
                        <div class="switch radius">
                          <input
                            class="switch-input"
                            type="checkbox"
                            data-bind="attr: {'id': htmlID}, checkedValue: $data, checked: $root.Form().TratmentThree_selected, enable: enable()"
                          />
                          <label
                            class="switch-paddle switch-btn"
                            data-bind="attr: {'for': htmlID}"
                          >
                            <span
                              class="show-for-sr"
                              data-bind="text:$data.text"
                            ></span>
                            <span class="switch-active" aria-hidden="true">
                              <i class="fa fa-check-circle-o"></i>
                            </span>
                            <span class="switch-inactive" aria-hidden="true">
                              <i class="fa fa-times-circle"></i>
                            </span>
                          </label>
                        </div>
                        <label class="switch-value">
                          <span class="bold" data-bind="text:text"></span>
                          <i
                            class="fa fa-info-circle tip-top"
                            data-bind="visible: showInfo, attr: { title: tooltipTitle }"
                            data-tooltip
                          ></i>
                        </label>
                      </div>
                    </div>
                  </div>
                  <div
                    class="row column large-12 text-center clearfixed invisible"
                  >
                    <a
                      class="button small secondary"
                      data-bind="click:Form().RemoveTreatmentThree"
                      >Remove this scenario</a
                    >
                  </div>
                  <div class="row column">
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                      >*Guidelines do not recommend statin therapy for patients
                      with 10-year risk &lt; 5%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isStatinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                      >*Guidelines do not typically recommend aspirin therapy
                      for patients with 10-year risk &lt; 10%</small
                    >
                    <br
                      data-bind="visible: $root.Form().TratmentGuidelineData.isAspirinGuidelineVisible"
                    />
                    <small
                      data-bind="visible: $root.Form().TratmentGuidelineData.isBPGuidelineVisible"
                      >*ACC/AHA Guidelines do not specify antihypertensive drug
                      therapy for SBP&lt;120 mmHg (&lt;130 mmHg
                      w/diabetes)</small
                    >
                  </div>
                </div>
              </div>
            </section>
          </div>
        </div>
        <div class="reveal" id="exampleModal1" data-reveal>
          <div
            class="large-12 medium-12 small-12 large-centered medium-centered columns"
            id="summary-table"
          >
            <table class="table banded">
              <thead>
                <tr>
                  <th style="text-align: right">Therapy(s)</th>
                  <th
                    class="text-right td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    Projected ASCVD Risk for this patient if Therapy Initiated
                  </th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td style="text-align: right">Statin*</td>
                  <td
                    class="td-right-border"
                    style="width: 50%; border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskStatin())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="text-align: right">BP drug(s)**</td>
                  <td
                    class="td-right-border"
                    style="width: 50%; border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskBP())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="text-align: right">Stop smoking†</td>
                  <td
                    class="td-right-border"
                    style="width: 50%; border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">Aspirinǂ</td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirin())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinStatin())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    BP drug(s) + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinBP())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + BP drug(s)
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskStatinBP())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + Stop smoking
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskStatinSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Stop smoking + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    BP drug(s) + Stop smoking
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskBPSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + BP drug(s) + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinStatinBP())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    BP drug(s) + Stop smoking + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinBPSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + BP drug(s) + Stop smoking
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskStatinBPSmoking())"
                    ></span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + Stop smoking + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskAspirinStatinSmoking())"
                    >
                    </span>
                  </td>
                </tr>
                <tr class="">
                  <td style="width: 50%; text-align: right">
                    Statin + BP drug(s) + Stop smoking + Aspirin
                  </td>
                  <td
                    class="td-right-border"
                    style="border-left: solid 1px #333333"
                  >
                    <span
                      data-bind="htmlMarkup:percentageFormat(Form().RiskFormula.ForecastRiskSartAll4())"
                    ></span>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
          <div class="row">
            <small
              >*Start moderate intensity statin, or intensify statin from a
              moderate to a high intensity dose.</small
            >
            <br />
            <small
              >**Start blood-pressure lowering medication if not currently
              taking, or add BP-lowering med (s) to patient’s existing
              regime.</small
            >
            <br />
            <small>†Stop smoking for two years</small> <br />
            <small>ǂStart or continue taking aspirin.</small> <br />
            <small
              >¶ NA = Not Applicable. Risk is not shown for therapy(s) that are
              not recommended. Guidelines do not recommend statin therapy for
              patients with 10-year ASCVD risk &#60;5%. Guidelines do not
              typically recommend aspirin therapy for patients with 10-year risk
              &#60;10%. ACC/AHA Guidelines do not specify antihypertensive drug
              therapy for SBP&#60;120 mmHg (&#60;130 mmHg w/diabetes)</small
            >
          </div>
          <button
            class="close-button"
            data-close
            aria-label="Close reveal"
            type="button"
          >
            <span aria-hidden="true">&times;</span>
          </button>
        </div>
        <div class="row">
          <div class="small-12 text-center columns hide-for-small-only">
            <a
              class="button btn-ga4"
              onclick=""
              data-open="exampleModal1"
              data-bind="click: function() {if($root.Form().Smoker()=='Former'){$root.Form().Smoker.prototype.months=$root.Form().QuiteSmokingMonths();$root.Form().Smoker('Never');$root.Form().Smoker.prototype.changed='yes';}}"
              >View All Risk Reduction Scenarios</a
            >
          </div>
          <div class="small-12 text-center columns show-for-small-only">
            <a
              class="button small btn-ga4"
              onclick=""
              data-open="exampleModal1"
              data-bind="click: function() {if(Form().Smoker()=='Former'){Form().Smoker.prototype.months=Form().QuiteSmokingMonths();Form().Smoker('Never');Form().Smoker.prototype.changed='yes';}}"
              >View All Risk Reduction Scenarios</a
            >
          </div>
        </div>

        <div class="row hide-for-small-only">
          <div class="small-6 large-6 column">
            <a href="#!/calculate/estimate/" class="button right" onclick=""
              ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                class="btn-ga4"
                >Estimate Risk</span
              ></a
            >
          </div>
          <div class="small-6 large-6 column text-right">
            <a
              href="#!/calculate/advice/riskgraph/"
              class="button right left10 va-ce-ga4"
              data-bind="css: {disabled:  !$root.recommendationUnlock()}"
              custom-tooltip-parent
              >View Advice&nbsp;&nbsp;<i
                class="fa fa-arrow-circle-right fa-6"
              ></i
            ></a>
            <div class="custom-tooltip bottom">
              Advice section is accessible when required characteristics for
              patients 40-79 years of age are entered.
            </div>
          </div>
        </div>
        <div class="row show-for-small-only">
          <div class="small-6 large-6 column">
            <a
              href="#!/calculate/estimate/"
              class="button small right"
              onclick=""
              ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                class="btn-ga4"
                >Estimate Risk</span
              ></a
            >
          </div>
          <div class="small-6 large-6 column text-right">
            <a
              href="#!/calculate/advice/riskgraph/"
              class="button small right left10 va-ce-ga4"
              data-bind="css: {disabled:  !$root.recommendationUnlock()}"
              custom-tooltip-parent
              >View Advice&nbsp;&nbsp;<i
                class="fa fa-arrow-circle-right fa-6"
              ></i
            ></a>
            <div class="custom-tooltip bottom">
              Advice section is accessible when required characteristics for
              patients 40-79 years of age are entered.
            </div>
          </div>
        </div>
        <h4 class="row">
          <span class="sub-line">
            <sup>**</sup>10-year risk for ASCVD is categorized as:<br />Low-risk
            (&lt;5%)<br />Borderline risk (5% to 7.4%)<br />Intermediate risk
            (7.5% to 19.9%)<br />High risk (≥20%)
          </span>
        </h4>
      </div>
      <div
        data-bind="page: {id: 'advice', name: 'advice', afterShow:tabchange, beforeShow:pageScrollTop}"
        class="page-wrapper fullscreen-spacer"
      >
        <div class="page-wrapper">
          <div class="row collapse">
            <h1 id="visit-summary-header">
              <span>Visit Summary</span>
              <span class="sub-line"
                >Below is a summary of patient’s risk, treatment options, and
                treatment advice based on the data provided.</span
              >
            </h1>
            <div class="column large-6">
              <a
                class="button btn-ga4"
                id="email"
                data-rel="external"
                onclick="sendEmail()"
                >Email Advice</a
              >
            </div>
             <div class="column small-4">
              <a class="button btn-ga4" id="print" onclick="printApp();"
                >Print with Complete Treatment Advice</a
              >
            </div>
            <div class="column small-2 text-right">
              <a class="button btn-ga4" id="print" onclick="printApp();"
                >Print</a
              >
            </div>
          </div>

          <div class="row collapse">
            <h2 class="column large-6 medium-6 small-6">
              Treatment Advice<sup>*</sup>
            </h2>
            <div
              class="column large-6 medium-6 small-6 text-right"
              style="line-height: 28px; margin-top: 25px"
            >
              <a
                id="optimize_action"
                data-action="expand"
                onclick="OptimizeToggle(this)"
                data-accr="optimize"
                class="underline"
                >Expand All</a
              >
            </div>
            <div class="page-wrapper column small-12">
              <section id="optimize" class="group-section">
                <div id="treatment_advice" class="accordion 2C selected" data-bind="">
                  <div class="abcs">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.abcs');"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >LDL-C Management (for this Patient)</span
                      >
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div class="column small-12">
                          <p
                            data-bind="htmlMarkup: $root.recommendationType().ldlControl.adviceLDLSection"
                          >
                            Consider whether BP-lowering or LDL-C lowering, or
                            both, is best approach.
                          </p>
                          <div
                            class="reveal large"
                            id="statin-intensity-modal"
                            data-reveal
                          >
                            <div
                              data-bind="template: {name: 'statin-intensity-table-modified'}"
                              style="overflow: auto"
                            ></div>
                            <button
                              class="close-button"
                              data-close=""
                              aria-label="Close reveal"
                              type="button"
                            >
                              <span aria-hidden="true">×</span>
                            </button>
                          </div>
                          <p
                            data-bind="htmlMarkup: $root.recommendationType().ldlControl.adviceLDLSGR"
                          ></p>
                          <p>
                            <a
                              target="_blank"
                              href="https://www.acc.org/guidelines/hubs/blood-cholesterol"
                              class="link"
                              >Link to Full ACC/AHA Cholesterol Guideline</a
                            >
                            <br /><a
                              target="_blank"
                              href="http://www.onlinejacc.org/content/63/25_part_b/2935?_ga=2.145115380.1960733943.1500303927-237461518.1450120708"
                              class="link"
                              >Link to Full ACC/AHA CV Risk Guideline</a
                            >
                          </p>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div class="abcs_blood">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.abcs_blood');"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Blood Pressure Management (for this Patient)</span
                      >
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div
                          class="column small-12"
                          style="overflow: auto"
                          data-bind="htmlMarkup: $root.recommendationType().bpControl.adviceBPSection"
                        ></div>
                      </div>
                    </div>
                  </div>
                  <div class="tobacco_cessation">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.tobacco_cessation')"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Tobacco Cessation (for this Patient)
                      </span>
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div class="column small-12">
                          <p
                            data-bind="htmlMarkup: $root.recommendationType().smokingControl.adviceSmokingSection"
                          ></p>
                          <p
                            data-bind="htmlMarkup: $root.recommendationType().smokingControl.adviceSmokingSGR"
                          ></p>
                        </div>
                      </div>
                    </div>
                  </div>

                  <div class="diabetes_advice">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.diabetes_advice');"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Diabetes Mellitus Management (General)</span
                      >
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div
                          class="column small-12"
                          style="overflow: auto"
                          data-bind="htmlMarkup: $root.recommendationType().diabetesControl.adviceDiabetesSection"
                        ></div>
                      </div>
                    </div>
                  </div>
                  <div class="lifestyle">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.lifestyle');"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Lifestyle Recommendations (General)</span
                      >
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div class="column small-12">
                          <h5>Nutrition and Diet</h5>
                          <ul>
                            <li>
                              To reduce ASCVD risk in all patients:
                              <ul class="list-type-none">
                                <li>
                                  - A diet emphasizing intake of vegetables,
                                  fruits, legumes, nuts, whole grains, and fish
                                  is recommended (I, B-R). A diet containing
                                  reduced amounts of cholesterol and sodium can
                                  be beneficial (IIa, B-NR).
                                </li>
                                <li>
                                  - Replacement of saturated fat with dietary
                                  mono- and poly-unsaturated fats can be
                                  beneficial (IIa, B-NR).
                                </li>
                                <li>
                                  - Minimizing the intake of trans fats,
                                  processed meats, refined carbohydrates, and
                                  sweetened beverages as part of a heart healthy
                                  diet is reasonable (IIa, B-NR).
                                </li>
                              </ul>
                            </li>
                            <li>
                              For adults with type 2 diabetes mellitus:
                              <ul class="list-type-none">
                                <li>
                                  - A tailored nutrition plan focusing on a
                                  heart-healthy dietary pattern is recommended
                                  to improve glycemic control, achieve weight
                                  loss (if needed), and improve other ASCVD risk
                                  factors (I, A).
                                </li>
                              </ul>
                            </li>
                          </ul>
                          <h5>Exercise and Physical Activity</h5>
                          <ul>
                            <li>
                              To reduce ASCVD risk, adults should:
                              <ul class="list-type-none">
                                <li>
                                  - Be routinely counseled to optimize a
                                  physically active lifestyle (I, B-R).
                                </li>
                                <li>
                                  - Engage in at least 150 minutes per week of
                                  accumulated moderate intensity or 75 minutes
                                  per week of vigorous intensity aerobic
                                  physical activity (or an equivalent
                                  combination of moderate and vigorous activity)
                                  (I, B-NR). This includes adults with type 2
                                  diabetes mellitus (I, A).
                                </li>
                                <li>
                                  - Decrease sedentary behavior (IIb, C-LD).
                                </li>
                              </ul>
                            </li>
                            <li>
                              For adults unable to meet the minimum physical
                              activity recommendations:
                              <ul class="list-type-none">
                                <li style="overflow: auto">
                                  - Engaging in some moderate or vigorous
                                  intensity physical activity, even if less than
                                  this recommended amount, can be beneficial to
                                  reduce ASCVD risk (IIa, B-NR).
                                  <table class="table top-aligned-table">
                                    <thead>
                                      <tr>
                                        <th>Intensity</th>
                                        <th>METS</th>
                                        <th>Examples</th>
                                      </tr>
                                    </thead>
                                    <tbody>
                                      <tr>
                                        <td>Sedentary Behavior<sup>*</sup></td>
                                        <td>1-1.5</td>
                                        <td>
                                          Sitting, reclining, or lying; watching
                                          TV
                                        </td>
                                      </tr>
                                      <tr>
                                        <td>Light</td>
                                        <td>1.6-2.9</td>
                                        <td>
                                          Walking slowly, cooking, light house
                                          work
                                        </td>
                                      </tr>
                                      <tr>
                                        <td>Moderate</td>
                                        <td>3.0-5.9</td>
                                        <td>
                                          Brisk walking (2.4-4mph), biking
                                          5-9mph, ballroom dancing, active yoga,
                                          recreational swimming
                                        </td>
                                      </tr>
                                      <tr>
                                        <td>Vigorous</td>
                                        <td>&ge;6</td>
                                        <td>
                                          Jogging/running, biking ≥10mph,
                                          singles tennis, swimming laps
                                        </td>
                                      </tr>
                                    </tbody>
                                  </table>
                                  <sup>*</sup>Sedentary behavior is defined as
                                  any waking behavior characterized by an energy
                                  expenditure &le;1.5 metabolic equivalents
                                  (METs), while in a sitting, reclining, or
                                  lying posture. Standing is a sedentary
                                  activity in that it involves &le;1.5 METs, but
                                  is not considered a component of sedentary
                                  behavior; mph indicates miles per hour
                                </li>
                              </ul>
                            </li>
                          </ul>
                          <h5>Obesity and Being Overweight</h5>
                          <ul>
                            <li>
                              In overweight and obese adults:
                              <ul class="list-type-none">
                                <li>
                                  - Weight loss is recommended to improve the
                                  ASCVD risk-factor profile (I, B-R).
                                </li>
                                <li>
                                  - Counseling and comprehensive lifestyle
                                  interventions, including calorie restriction,
                                  are recommended for achieving and maintaining
                                  weight loss (I, B-R).
                                </li>
                                <li>
                                  - Calculating body mass index is recommended
                                  annually or more frequently to identify
                                  overweight and obese adults for weight loss
                                  considerations (I, C-EO).
                                </li>
                                <li>
                                  - It is reasonable to measure waist
                                  circumference to identify those at higher
                                  cardiometabolic risk (IIa, B-NR).
                                </li>
                              </ul>
                            </li>
                          </ul>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div class="general_asprin">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.general_asprin')"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Aspirin Use Recommendations (for this Patient)
                      </span>
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div
                          class="column small-12"
                          style="overflow: auto"
                          data-bind="htmlMarkup: $root.recommendationType().aspirinControl.adviceAspirinSection"
                        ></div>
                      </div>
                    </div>
                  </div>
                  <div class="absc_info">
                    <h4
                      class="toggle with-underline"
                      onclick="panelVisibleToggle('.absc_info');"
                    >
                      <i class="fa fa-holder"></i
                      ><span class="text"
                        >Therapy Safety Information (General)</span
                      >
                    </h4>
                    <div class="collapsable-panel" style="display: none">
                      <div class="row">
                        <div class="column small-12">
                          <p>
                            See Resource Section of this app for full
                            prescribing information.
                          </p>
                          <ul>
                            <li>
                              <span class="bold">Statins:</span> There is
                              moderate quality evidence that statins do not
                              increase the overall risk of adverse events, but
                              that they may increase the risk of diagnosis of
                              type 2 diabetes in certain individuals.
                            </li>
                            <li>
                              <span class="bold"
                                >Blood Pressure-Lowering Therapies:</span
                              >
                              Adverse effects of blood-pressure-lowering
                              therapies are generally poorly reported, and vary
                              by drug class.
                            </li>
                            <li>
                              <span class="bold">Tobacco Cessation:</span>
                              Adverse effects of tobacco cessation therapies are
                              generally poorly reported, and vary by drug.
                            </li>
                            <li>
                              <span class="bold">Aspirin:</span> There is
                              high-quality evidence indicating that aspirin may
                              increase the risk of major bleeding. A calculator
                              for considering major bleeding risks and potential
                              benefits of aspirin therapy for MI and stroke
                              prevention is available
                              <a
                                style="text-decoration: underline"
                                target="_blank"
                                href="http://annals.org/aim/article/2513179/aspirin-use-primary-prevention-cardiovascular-disease-colorectal-cancer-u-s"
                                >here</a
                              >.
                            </li>
                          </ul>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </section>
            </div>

            <div class="clear-both"></div>
          </div>
          <section class="section card" id="graph-card">
            <div class="colored-paper">
              <h5 class="text-center">ASCVD Risk Profile</h5>
            </div>
            <div class="tabs-content">
              <div
                data-bind="page: {id: 'riskgraph', name: 'riskgraph',beforeShow:listchange }"
                class="page-wrapper"
                style="position: relative"
              >
                <div id="container" class="row columns small-6"></div>
                <div class="highcharts-riskrange">
                  <small>10-yr risk for first ASCVD event is:</small><br />
                  <h5
                    class="no-margin"
                    data-bind="text: $root.Form().riskRange"
                  ></h5>
                </div>
              </div>
              <div
                data-bind="page: {id: 'riskresult', name: 'riskresult',beforeShow:listchange }"
                class="page-wrapper"
              ></div>
            </div>
            <br />
            <div
              class="row"
              data-bind="visible: ($root.Form().VisitType()==false) && ($root.Form().TreatmentOneScore() != '~%' || $root.Form().TreatmentTwoScore() != '~%' || $root.Form().TreatmentThreeScore() != '~%')"
            >
              <ul class="list-type-none">
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text bullet square-bullet">Actual Risk</span>
                </li>
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text bullet circle-bullet">Projected Risk</span>
                </li>
              </ul>
            </div>
            <p
              class="text-center hide-for-print"
              data-bind="visible: ($root.Form().VisitType()==false) && ($root.Form().TreatmentOneScore() == '~%' && $root.Form().TreatmentTwoScore() == '~%' && $root.Form().TreatmentThreeScore() == '~%')"
            >
              Enter potential treatment scenarios on the "Therapy Impact" tab to
              plot them on the graph above as well.
            </p>
            <br />
            <div
              class="row columns"
              data-bind="visible: ($root.Form().VisitType()==false) && ($root.Form().TreatmentOneScore() != '~%' || $root.Form().TreatmentTwoScore() != '~%' || $root.Form().TreatmentThreeScore() != '~%')"
            >
              <span class="text"
                >*Projected Risk with the following therapies:</span
              >
            </div>
            <div
              class="row"
              data-bind="visible: ($root.Form().VisitType()==false) && ($root.Form().TreatmentOneScore() != '~%' || $root.Form().TreatmentTwoScore() != '~%' || $root.Form().TreatmentThreeScore() != '~%')"
            >
              <ul class="no-bullet">
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text"
                    >ASA = Start or continue taking aspirin</span
                  >
                </li>
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text"
                    >BP = Start, add, or intensify blood pressure
                    medication</span
                  >
                </li>
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text"
                    >Ch = Manage cholesterol by starting or intensifying
                    statin</span
                  >
                </li>
                <li class="small-12 medium-6 large-6 columns">
                  <span class="text"
                    >Sm = Stop smoking for at least 2 years</span
                  >
                </li>
              </ul>
            </div>
          </section>
          <div class="row group-section card">
            <div class="colored-paper summary-head">
              <h2>Inputs</h2>
            </div>
            <div
              class="row column large-5 medium-5 small-12"
              style="margin: auto"
              id="summary-inputs"
            >
              <br />
              <div class="callout secondary">
                <h4>Inputs</h4>
                <ul class="no-bullet">
                  <li class="group-divide">
                    Sex:
                    <span class="strong" data-bind="text:Form().Sex()"
                      >Female</span
                    >
                  </li>
                  <li>
                    Race:
                    <span class="strong" data-bind="text:Form().Race()"
                      >White</span
                    >
                  </li>
                  <table class="table summary-table">
                    <thead class="summarytable-head">
                      <tr>
                        <th>Values</th>
                        <th data-bind="visible: isFollowUp()">Previous</th>
                        <th data-bind="visible: !isFollowUp()">Current</th>
                        <th data-bind="visible: isFollowUp()">
                          Current
                          <!--<small>(Follow-Up)</small> -->
                        </th>
                      </tr>
                    </thead>
                    <tbody class="table-body">
                      <tr>
                        <td>Age:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().Age() : Form().BaselineAge()"
                          ></span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().Age()"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>
                          Total Cholesterol
                          <small
                            data-bind="visible: !$root.Form().UnitOfMeasure() "
                            >(mg/dL)</small
                          >
                          <small
                            data-bind="visible: $root.Form().UnitOfMeasure() "
                            >(mmol/L)</small
                          >
                        </td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().TotalCholesterolValue(): Form().BaselineTotalCholesterolValue()"
                          ></span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().TotalCholesterolValue()"
                            >240</span
                          >
                        </td>
                      </tr>
                      <tr>
                        <td>
                          HDL Cholesterol
                          <small
                            data-bind="visible: !$root.Form().UnitOfMeasure() "
                            >(mg/dL)</small
                          >
                          <small
                            data-bind="visible: $root.Form().UnitOfMeasure() "
                            >(mmol/L)</small
                          >
                        </td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().HDLCholesterolValue(): Form().BaselineHDLCholesterolValue()"
                          ></span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().HDLCholesterolValue()"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>
                          LDL Cholesterol
                          <small
                            data-bind="visible: !$root.Form().UnitOfMeasure() "
                            >(mg/dL)</small
                          >
                          <small
                            data-bind="visible: $root.Form().UnitOfMeasure() "
                            >(mmol/L)</small
                          >
                        </td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().LDLCholesterolValue(): Form().BaselineLDLCholesterolValue()"
                          ></span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().LDLCholesterolValue()"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>Systolic Blood Pressure<small> (mm Hg)</small></td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().BloodPressure(): Form().BaselineBloodPressure()"
                            >98</span
                          >
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().BloodPressure()"
                            >140</span
                          >
                        </td>
                      </tr>
                      <tr>
                        <td>Diastolic Blood Pressure<small> (mm Hg)</small></td>
                        <td>
                          <span
                            class="strong"
                            data-bind="text:!isFollowUp() ?Form().DBloodPressure(): ' '"
                            >98</span
                          >
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text:Form().DBloodPressure()"
                            >140</span
                          >
                        </td>
                      </tr>
                      <tr>
                        <td>Diabetes:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="visible: !isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().isDiabetic()?'Yes':'No'"
                            ></span>
                          </span>
                          <span
                            class="strong"
                            data-bind="visible: isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().isBaseLineDiabetic()?'Yes':'No'"
                            ></span>
                          </span>
                        </td>
                        <td data-bind="visible: isFollowUp() ">
                          <span
                            class="strong"
                            data-bind="text: Form().isDiabetic() ? 'Yes':'No'"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>Smoker:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="visible: !isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().Smoker"
                            ></span>
                          </span>
                          <span
                            class="strong"
                            data-bind="visible: isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().isBaseLineSmoker()  ? 'Yes':'No'"
                            ></span>
                          </span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text: Form().Smoker()"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>Treatment for Hypertension:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="visible: !isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().isHypertension()  ? 'Yes':'No'"
                            ></span>
                          </span>
                          <span
                            class="strong"
                            data-bind="visible: isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().isBaseLineHypertension()  ? 'Yes':'No'"
                            ></span>
                          </span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text: Form().isHypertension()  ? 'Yes':'No'"
                            >Yes</span
                          >
                        </td>
                      </tr>
                      <tr>
                        <td>Aspirin Therapy:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="visible: !isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().OnAspirin()"
                            ></span>
                          </span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text: Form().OnAspirin()"
                          ></span>
                        </td>
                      </tr>
                      <tr>
                        <td>Statin:</td>
                        <td>
                          <span
                            class="strong"
                            data-bind="visible: !isFollowUp()"
                          >
                            <span
                              class="strong"
                              data-bind="text: Form().OnStatin()"
                            ></span>
                          </span>
                        </td>
                        <td data-bind="visible: isFollowUp()">
                          <span
                            class="strong"
                            data-bind="text: Form().OnStatin()"
                          ></span>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </ul>
              </div>
              <div class="callout highlighted" data-bind=" visible:isRaceOther">
                <span class="bold">Note:</span> These estimates may
                <i>underestimate</i> the 10-year and lifetime risk for persons
                from some race/ethnic groups, especially American Indians, some
                Asian Americans (e.g., of south Asian ancestry), and some
                Hispanics (e.g., Puerto Ricans), and may <i>overestimate</i> the
                risk for others, including some Asian Americans (e.g., of east
                Asian ancestry) and some Hispanics (e.g., Mexican Americans).
                <br />
                Because the primary use of these risk estimates is to facilitate
                the very important discussion regarding risk reduction through
                lifestyle change, the imprecision introduced is small enough to
                justify proceeding with lifestyle change counseling informed by
                these results.
              </div>
            </div>
          </div>

          <div class="column small-12 row">
            <!--                        <h4 class="italic">Disclaimer</h4>-->

            <p class="italic disclaimer-print" id="disclaimer-print">
              <sup>*</sup>Disclaimer: The results and recommendations provided
              by this application are intended to inform but do not replace
              clinical judgment. Therapeutic options should be individualized
              and determined after discussion between the patient and their care
              provider.
            </p>
            <p class="italic disclaimer-print" id="disclaimer-print-2">
              Recommendations are designated with both a class of recommendation
              (COR) and a level of evidence (LOE). The class of recommendation
              indicates the strength of recommendation, encompassing the
              estimated magnitude and certainty of benefit in proportion to
              risk. The level of evidence rates the quality of scientific
              evidence supporting the intervention on the basis of the type,
              quantity, and consistency of data from clinical trials and other
              sources.
            </p>
          </div>

          <div class="row hide-for-small-only collapse">
            <div class="small-12 column">
              <a
                href="#!/calculate/estimate/"
                class="button right left10"
                data-bind=""
                ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                  class="btn-ga4"
                  >Estimate Risk</span
                ></a
              >
            </div>
            <div class="small-12 column">
              <a
                href="#!/calculate/therapy/"
                class="button right"
                onclick=""
                data-bind="click:$root.NavigateToForecastPage.bind('event', 'null'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage()) ? false : ($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock()}"
                custom-tooltip-parent
                ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                  class="ti-ce-ga4"
                  >Determine Therapy Impact</span
                ></a
              >
              <div class="custom-tooltip top">
                Potential risk reduction impact of different therapies can only
                be calculated for patients 40-79 years of age at an initial
                visit.
              </div>
            </div>
          </div>
          <div class="row show-for-small-only collapse">
            <div class="small-12 column">
              <a href="#!/calculate/estimate/" class="button right" data-bind=""
                ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                  class="btn-ga4"
                  >Estimate Risk</span
                ></a
              >
            </div>
            <div class="small-12 column">
              <a
                href="#!/calculate/therapy/"
                class="button left"
                onclick=""
                data-bind="click:$root.NavigateToForecastPage.bind('event', 'null'), css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage()) ? false : ($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock()}"
                custom-tooltip-parent
                ><i class="fa fa-arrow-circle-left fa-6"></i>&nbsp;&nbsp;<span
                  class="ti-ce-ga4"
                  >Determine Therapy Impact</span
                ></a
              >
              <div class="custom-tooltip top">
                Potential risk reduction impact of different therapies can only
                be calculated for patients 40-79 years of age at an initial
                visit.
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div
      data-bind="page: {id:'content', role: 'start', beforeShow:remakeSticky()}"
      class="page with-group-sections"
    >
      <div class="row">
        <div class="data-display" id="scorebar">
          <div class="sticky-holder">
            <header class="header page">
              <span class="logo">
                <a href="#!/calculate/estimate/"
                  ><img
                    id="logoimg"
                    src="assets/img/header_image.png"
                    alt="ASCVD Risk Estimator +"
                /></a>
              </span>
              <ul class="nav tabs tabs-primary">
                <li id="estimate-Tab" class="selected">
                  <a
                    href="#!/calculate/estimate/"
                    class="condensable small btn-ga4"
                    >Estimate Risk</a
                  >
                </li>
                <li
                  id="therapy-Tab"
                  class=""
                  data-bind="css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : (($root.Form().VisitTypeUI()==true || $root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                  custom-tooltip-parent
                >
                  <a
                    href="#!/calculate/therapy/"
                    data-bind="click:$root.NavigateToForecastPage.bind('event', 'Clicked tab')"
                    class="condensable small ti-ce-ga4"
                    >Therapy Impact</a
                  >
                </li>
                <div class="custom-tooltip bottom">
                  Potential risk reduction impact of different therapies can
                  only be calculated for patients 40-79 years of age at an
                  initial visit.
                </div>
                <li
                  id="advice-Tab"
                  class=""
                  data-bind="css: {disabled: ($root.Form().VisitType() == false && $root.Form().invalidLdlMessage() && $root.recommendationUnlock()) ? false : (($root.Form().VisitTypeUI()==undefined) ? true : !$root.recommendationUnlock())}"
                  custom-tooltip-parent
                >
                  <a
                    href="#!/calculate/advice/riskgraph/"
                    data-bind="click:$root.NavigateToSummaryPage.bind('event', 'Clicked tab')"
                    class="condensable small va-ce-ga4"
                    >Advice</a
                  >
                </li>
                <div class="custom-tooltip bottom">
                  Advice section is accessible when required characteristics for
                  patients 40-79 years of age are entered.
                </div>
              </ul>
            </header>
          </div>
        </div>
      </div>
      <!--Resources Page Starts here-->
      <div
        class="page with-group-sections fullscreen-spacer page-wrapper"
        data-bind="page: {id:'resources',  afterShow:footertabchange, beforeShow:pageScrollTop}"
      >
        <div class="page-wrapper">
          <div class="row">
            <div class="medium-12 row collapse">
              <h1>Resources</h1>
            </div>
          </div>
          <section class="section group-section">
            <div class="row">
              <div class="column medium-6 medium-push-6">
                <h3>Patient Resources</h3>
                <nav class="nav-list small">
                  <ul>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_risk">
                        <span class="text">
                          Understanding My Cardiovascular Risk
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/patient-split-layout/patient_lifestyle"
                      >
                        <span class="text"> Diet and Physical Activity </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/patient-split-layout/patient_obesity">
                        <span class="text">
                          Weight Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/patient-split-layout/patient_cholesterol"
                      >
                        <span class="text">
                          Blood Cholesterol Management Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/patient-split-layout/statin_infographic"
                      >
                        <span class="text">
                          Groups that Benefit from Statin Therapy Infographic
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/patient-split-layout/patient_reference_definition"
                      >
                        <span class="text"> Common Cardiovascular Terms </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/patient-split-layout/outside_resources_links"
                      >
                        <span class="text"> Links to Outside Resources </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
              </div>
              <div class="column medium-6 medium-pull-6">
                <h3>Clinician Resources</h3>
                <nav class="nav-list small">
                  <ul>
                    <h3>
                      <span class="sub-line">Using This App</span>
                    </h3>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_patient_scenario"
                      >
                        <span class="text">
                          Patient Scenario for Using the App
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_understanding"
                      >
                        <span class="text">
                          Understanding Cardiovascular Risk
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/terms_conditions"
                      >
                        <span class="text"> App Terms and Concepts </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/recommendation_class_and_evidence_level"
                      >
                        <span class="text">
                          Class of Recommendation and Level of Evidence Table
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <h3>
                      <span class="sub-line">Cholesterol</span>
                    </h3>
                    <li>
                      <a href="#!/content/clinician-split-layout/key_points">
                        <span class="text">
                          Key Points from 2018 Cholesterol Guideline
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/risk_enhancing_factors"
                      >
                        <span class="text"> ASCVD Risk-enhancing Factors </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/ethnicity_issues"
                      >
                        <span class="text">
                          Ethnicity Issues in Risk Evaluation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/general_population"
                      >
                        <span class="text">
                          General Populations Recommendation Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/guideline_flowchart"
                      >
                        <span class="text">
                          Primary Prevention of ASCVD - Summary
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/secondary_prevention"
                      >
                        <span class="text">
                          Secondary Prevention - Patients with Clinical ASCVD
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients"
                      >
                        <span class="text">
                          LDL-C Treatment Suggestions for Younger Patients
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a href="#!/content/clinician-split-layout/statin_dose">
                        <span class="text">
                          Intensities of Statin Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/monitor_flowchart"
                      >
                        <span class="text">
                          Recommendations to Monitor Response to LDL-C Lowering
                          Therapy
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations"
                      >
                        <span class="text">
                          Statin Safety Recommendations
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/discussion_checklist"
                      >
                        <span class="text">
                          Discussion Checklist for Therapy Initiation
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/cac_score_inform_decisions"
                      >
                        <span class="text">
                          Using CAC Score to Inform Decisions
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <h3>
                      <span class="sub-line">Blood Pressure</span>
                    </h3>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/bp_categories_and_treatement_strategies"
                      >
                        <span class="text">
                          BP Categories and Treatment Strategies
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/accurate_bp_measurement"
                      >
                        <span class="text"> Accurate BP Measurement </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/oral_hypertensive_drug_dosing"
                      >
                        <span class="text">
                          Oral Antihypertensive Drug Dosing and Usage
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/nonpharmacologic_blood_pressure_interventions"
                      >
                        <span class="text">
                          Nonpharmacologic Hypertension Interventions
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/substances_that_can_elevate_bp"
                      >
                        <span class="text">
                          Substances that Can Elevate BP
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <h3>
                      <span class="sub-line">Other Therapy Information</span>
                    </h3>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_lifestyle"
                      >
                        <span class="text"> Lifestyle Recommendations </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_diabetes"
                      >
                        <span class="text"> Diabetes Management </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/clinical_tobacco"
                      >
                        <span class="text"> Tobacco Cessation </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/prescribing_information"
                      >
                        <span class="text"> Prescribing Information </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                    <h3>
                      <span class="sub-line">External Resource Links</span>
                    </h3>
                    <li>
                      <a
                        href="#!/content/clinician-split-layout/reference_external_links"
                      >
                        <span class="text">
                          External Link to More Resources
                        </span>
                        <i class="fa fa-holder-dynamic"> </i>
                      </a>
                    </li>
                  </ul>
                </nav>
              </div>
            </div>
            <div class="row">
              <div class="small-12 column">
                <h3 class="">References</h3>
                <ul class="patient-scenario">
                  <li>
                    Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi Jr JL,
                    Kalyani RR, Kosiborod M, Magwire ML, Neumiller JJ, Morris
                    PB, Sperling LS.
                  </li>
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/full/10.1016/j.jacc.2020.05.037?_ga=2.126037572.898130258.1596396742-1539357681.1595960991"
                      >2020 Expert consensus decision pathway on novel therapies
                      for cardiovascular risk reduction in patients with type 2
                      diabetes: a report of the American College of Cardiology
                      Solution Set Oversight Committee.</a
                    >
                    J Am Coll Cardiol 2020; DOI:10.1016/j.jacc.2020.05.037
                  </li>
                  <br />
                  <li>
                    Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger
                    ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy
                    JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS,
                    Williams KA Sr, Yeboah J, Ziaeian B.<a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.03.010?_ga=2.121261505.898130258.1596396742-1539357681.1595960991"
                    >
                      2019 ACC/AHA Guideline on the Primary Prevention of
                      Cardiovascular Disease: A Report of the American College
                      of Cardiology/American Heart Association Task Force on
                      Clinical Practice Guidelines.</a
                    >
                    J Am Coll Cardiol 2019;74:e177–232.
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2018.11.003?__cf_chl_jschl_tk__=46926462146be1333201d7bd137cf82d0517f41c-1596483626-0-AQO7kpJK07g7wMS8qNWpM1sYGZXq4PuubkDr6w-7oYrDEhQJEWK60kUs-1xM_dbIjpLHt7tOI5_Og06N4ta8ABuJ02J9NCGFwV1wIngfFC9XUlrZe_OeUFLZ7nX_80SgIDhC0IWxY9f_w3X7CIj20jI_uXfTRuJqzq7VZucNIZzWFIfdMPKoK4A8AhUWx64CjqvVg15gyY5ugtEoG1TQWnzSxM8xeewQaF7JRFFj0TsoDTbsI67yOVlul6r1ouKz8pZo70OFGd4d1lkUR1s53Nv2u0FDhkrS-2jmy-OuQXugCqT6FA3vsH1NJ-lw-PKKoeiCgqCds3dQ5KMIgQDQuHK92p1XQ1m_ppBK4hShkBnk5HJJywYYuAbbB5OLrnU4TA&_ga=2.250216911.898130258.1596396742-1539357681.1595960991"
                      >Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK,
                      Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino
                      J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones
                      DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer
                      CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani
                      SS, Yeboah J. 2018
                      ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                      guideline on the management of blood cholesterol: a report
                      of the American College of Cardiology Foundation/American
                      Heart Association Task Force on Clinical Practice
                      Guidelines. J Am Coll Cardiol. 2018; xx:xxxx-xxxx.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://circ.ahajournals.org/content/circulationaha/129/25_suppl_2/S49.full.pdf"
                      >Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S,
                      D’Agostino RB Sr, Gibbons R, Greenland P, Lackland DT,
                      Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST,
                      Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA
                      guideline on the assessment of cardiovascular risk: a
                      report of the American College of Cardiology/American
                      Heart Association Task Force on Practice Guidelines. J Am
                      Coll Cardiol 2014;63:2935–59.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://www.onlinejacc.org/content/early/2016/11/23/j.jacc.2016.10.018?_ga=1.167237245.237461518.1450120708"
                      >Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM,
                      Wright JS, Pelser C, Gulati M, Masoudi FA, Goff Jr. DC,
                      Estimating Longitudinal Risks and Benefits From
                      Cardiovascular Preventive Therapies Among Medicare
                      Patients: The Million Hearts Longitudinal ASCVD Risk
                      Assessment Tool, Journal of the American College of
                      Cardiology (2016), doi: 10.1016/ j.jacc.2016.10.018.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2017.11.006?_ga=2.16395007.898130258.1596396742-1539357681.1595960991"
                      >Whelton PK, Carey RM, Aronow WS, et al. 2017
                      ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
                      for the Prevention, Detection, Evaluation, and Management
                      of High Blood Pressure in Adults. J Am Coll Cardiol. 2017;
                      DOI:10.1016/j.jacc.2017.11.006</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.ahajournals.org/doi/full/10.1161/circulationaha.105.548206"
                      >Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. (2006)
                      Prediction of lifetime risk for cardiovascular disease by
                      risk factor burden at 50 years of age. Circulation
                      113:791–798</a
                    >
                  </li>
                </ul>
              </div>
            </div>
          </section>
        </div>
      </div>

      <div data-bind="page: {id:'clinician-split-layout'}">
        <div class="medium split-layout fill-page-height">
          <div class="split-sidebar">
            <div class="content-padding" style="padding-top: 1em">
              <h4 class="">Clinician Resources</h4>
            </div>
            <nav class="nav-list small">
              <ul>
                <h4 class="content-padding">
                  <span class="sub-line">Using This App</span>
                </h4>
                <li class="">
                  <a
                    href="#!/content/clinician-split-layout/clinical_patient_scenario"
                  >
                    <span class="text">
                      Patient Scenario for Using the App
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_understanding"
                  >
                    <span class="text">
                      Understanding Cardiovascular Risk
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/terms_conditions">
                    <span class="text"> App Terms and Concepts </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/recommendation_class_and_evidence_level"
                  >
                    <span class="text">
                      Class of Recommendation and Level of Evidence Table
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <h4 class="content-padding">
                  <span class="sub-line">Cholesterol</span>
                </h4>
                <li>
                  <a href="#!/content/clinician-split-layout/key_points">
                    <span class="text">
                      Key Points from 2018 Cholesterol Guideline
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/risk_enhancing_factors"
                  >
                    <span class="text"> ASCVD Risk-enhancing Factors </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/ethnicity_issues">
                    <span class="text">
                      Ethnicity Issues in Risk Evaluation
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/general_population"
                  >
                    <span class="text">
                      General Populations Recommendation Summary
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/guideline_flowchart"
                  >
                    <span class="text">
                      Primary Prevention of ASCVD - Summary
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/secondary_prevention"
                  >
                    <span class="text">
                      Secondary Prevention - Patients with Clinical ASCVD
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients"
                  >
                    <span class="text">
                      LDL-C Treatment Suggestions for Younger Patients
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/statin_dose">
                    <span class="text"> Intensities of Statin Therapy </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/monitor_flowchart">
                    <span class="text">
                      Recommendations to Monitor Response to LDL-C Lowering
                      Therapy
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations"
                  >
                    <span class="text"> Statin Safety Recommendations </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/discussion_checklist"
                  >
                    <span class="text">
                      Discussion Checklist for Therapy Initiation
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/cac_score_inform_decisions"
                  >
                    <span class="text">
                      Using CAC Score to Inform Decisions
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>

                <h4 class="content-padding">
                  <span class="sub-line">Blood Pressure</span>
                </h4>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/bp_categories_and_treatement_strategies"
                  >
                    <span class="text">
                      BP Categories and Treatment Strategies
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/accurate_bp_measurement"
                  >
                    <span class="text"> Accurate BP Measurement </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/oral_hypertensive_drug_dosing"
                  >
                    <span class="text">
                      Oral Antihypertensive Drug Dosing and Usage
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/nonpharmacologic_blood_pressure_interventions"
                  >
                    <span class="text">
                      Nonpharmacologic Hypertension Interventions
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/substances_that_can_elevate_bp"
                  >
                    <span class="text"> Substances that Can Elevate BP </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>

                <h4 class="content-padding">
                  <span class="sub-line">Other Therapy Information</span>
                </h4>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_lifestyle"
                  >
                    <span class="text"> Lifestyle Recommendations </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/clinical_diabetes">
                    <span class="text"> Diabetes Management </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/clinical_tobacco">
                    <span class="text"> Tobacco Cessation </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/prescribing_information"
                  >
                    <span class="text"> Prescribing Information </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <h4 class="content-padding">
                  <span class="sub-line">External Resources</span>
                </h4>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/reference_external_links"
                  >
                    <span class="text"> External Link to More Resources </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
              </ul>
            </nav>
            <div class="content-padding" style="padding-top: 1em">
              <h4 class="">Patient Resources</h4>
            </div>
            <nav class="nav-list small">
              <ul>
                <li>
                  <a href="#!/content/patient-split-layout/patient_risk">
                    <span class="text">
                      Understanding My Cardiovascular Risk
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_lifestyle">
                    <span class="text"> Diet and Physical Activity </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_obesity">
                    <span class="text">
                      Weight Management Recommendations
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_cholesterol">
                    <span class="text">
                      Blood Cholesterol Management Recommendations
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/statin_infographic">
                    <span class="text">
                      Groups that Benefit from Statin Therapy Infographic
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/patient-split-layout/patient_reference_definition"
                  >
                    <span class="text"> Common Cardiovascular Terms </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/patient-split-layout/outside_resources_links"
                  >
                    <span class="text"> Links to Outside Resources </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
              </ul>
            </nav>
            <div class="row">
              <div class="small-12 column">
                <h3 class="">References</h3>
                <ul class="patient-scenario">
                  <li>
                    Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi Jr JL,
                    Kalyani RR, Kosiborod M, Magwire ML, Neumiller JJ, Morris
                    PB, Sperling LS.
                  </li>
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/full/10.1016/j.jacc.2020.05.037?_ga=2.126037572.898130258.1596396742-1539357681.1595960991"
                      >2020 Expert consensus decision pathway on novel therapies
                      for cardiovascular risk reduction in patients with type 2
                      diabetes: a report of the American College of Cardiology
                      Solution Set Oversight Committee.</a
                    >
                    J Am Coll Cardiol 2020; DOI:10.1016/j.jacc.2020.05.037
                  </li>
                  <br />
                  <li>
                    Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger
                    ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy
                    JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS,
                    Williams KA Sr, Yeboah J, Ziaeian B.<a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.03.010?_ga=2.121261505.898130258.1596396742-1539357681.1595960991"
                    >
                      2019 ACC/AHA Guideline on the Primary Prevention of
                      Cardiovascular Disease: A Report of the American College
                      of Cardiology/American Heart Association Task Force on
                      Clinical Practice Guidelines.</a
                    >
                    J Am Coll Cardiol 2019;74:e177–232.
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2018.11.003?__cf_chl_jschl_tk__=46926462146be1333201d7bd137cf82d0517f41c-1596483626-0-AQO7kpJK07g7wMS8qNWpM1sYGZXq4PuubkDr6w-7oYrDEhQJEWK60kUs-1xM_dbIjpLHt7tOI5_Og06N4ta8ABuJ02J9NCGFwV1wIngfFC9XUlrZe_OeUFLZ7nX_80SgIDhC0IWxY9f_w3X7CIj20jI_uXfTRuJqzq7VZucNIZzWFIfdMPKoK4A8AhUWx64CjqvVg15gyY5ugtEoG1TQWnzSxM8xeewQaF7JRFFj0TsoDTbsI67yOVlul6r1ouKz8pZo70OFGd4d1lkUR1s53Nv2u0FDhkrS-2jmy-OuQXugCqT6FA3vsH1NJ-lw-PKKoeiCgqCds3dQ5KMIgQDQuHK92p1XQ1m_ppBK4hShkBnk5HJJywYYuAbbB5OLrnU4TA&_ga=2.250216911.898130258.1596396742-1539357681.1595960991"
                      >Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK,
                      Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino
                      J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones
                      DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer
                      CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani
                      SS, Yeboah J. 2018
                      ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                      guideline on the management of blood cholesterol: a report
                      of the American College of Cardiology Foundation/American
                      Heart Association Task Force on Clinical Practice
                      Guidelines. J Am Coll Cardiol. 2018; xx:xxxx-xxxx.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://circ.ahajournals.org/content/circulationaha/129/25_suppl_2/S49.full.pdf"
                      >Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S,
                      D’Agostino RB Sr, Gibbons R, Greenland P, Lackland DT,
                      Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST,
                      Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA
                      guideline on the assessment of cardiovascular risk: a
                      report of the American College of Cardiology/American
                      Heart Association Task Force on Practice Guidelines. J Am
                      Coll Cardiol 2014;63:2935–59.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://www.onlinejacc.org/content/early/2016/11/23/j.jacc.2016.10.018?_ga=1.167237245.237461518.1450120708"
                      >Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM,
                      Wright JS, Pelser C, Gulati M, Masoudi FA, Goff Jr. DC,
                      Estimating Longitudinal Risks and Benefits From
                      Cardiovascular Preventive Therapies Among Medicare
                      Patients: The Million Hearts Longitudinal ASCVD Risk
                      Assessment Tool, Journal of the American College of
                      Cardiology (2016), doi: 10.1016/ j.jacc.2016.10.018.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/abs/10.1016/j.jacc.2017.11.006?_ga=2.16395007.898130258.1596396742-1539357681.1595960991"
                      >Whelton PK, Carey RM, Aronow WS, et al. 2017
                      ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
                      for the Prevention, Detection, Evaluation, and Management
                      of High Blood Pressure in Adults. J Am Coll Cardiol. 2017;
                      DOI:10.1016/j.jacc.2017.11.006</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.ahajournals.org/doi/full/10.1161/circulationaha.105.548206"
                      >Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. (2006)
                      Prediction of lifetime risk for cardiovascular disease by
                      risk factor burden at 50 years of age. Circulation
                      113:791–798</a
                    >
                  </li>
                </ul>
              </div>
            </div>
          </div>
          <div class="split-content page with-group-sections page-wrapper">
            <div class="section-nav back hide-for-medium">
              <a href="#!/content/resources/">
                <div class="circle"><i class="fa fa-holder-dynamic"> </i></div>
                <div class="text">Back to Resources</div>
              </a>
            </div>
            <div class="page-wrapper">
              <div
                data-bind="template: { name: 'clinician_resources_expand'}"
              ></div>
            </div>
          </div>
        </div>
      </div>
      <div data-bind="page: {id:'patient-split-layout'}">
        <div class="medium split-layout fill-page-height">
          <div class="split-sidebar">
            <h4 class="content-padding">Clinician Resources</h4>
            <nav class="nav-list small">
              <ul>
                <h4 class="content-padding">
                  <span class="sub-line">Using This App</span>
                </h4>
                <li class="">
                  <a
                    href="#!/content/clinician-split-layout/clinical_patient_scenario"
                  >
                    <span class="text">
                      Patient Scenario for Using the App
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_understanding"
                  >
                    <span class="text">
                      Understanding Cardiovascular Risk
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/terms_conditions">
                    <span class="text"> App Terms and Concepts </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/recommendation_class_and_evidence_level"
                  >
                    <span class="text">
                      Class of Recommendation and Level of Evidence Table
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <h4 class="content-padding">
                  <span class="sub-line">Cholesterol</span>
                </h4>
                <li>
                  <a href="#!/content/clinician-split-layout/key_points">
                    <span class="text">
                      Key Points from 2018 Cholesterol Guideline
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/risk_enhancing_factors"
                  >
                    <span class="text"> ASCVD Risk-enhancing Factors </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/ethnicity_issues">
                    <span class="text">
                      Ethnicity Issues in Risk Evaluation
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/general_population"
                  >
                    <span class="text">
                      General Populations Recommendation Summary
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/guideline_flowchart"
                  >
                    <span class="text">
                      Primary Prevention of ASCVD - Summary
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/secondary_prevention"
                  >
                    <span class="text">
                      Secondary Prevention - Patients with Clinical ASCVD
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/ldlc_treatment_younger_patients"
                  >
                    <span class="text">
                      LDL-C Treatment Suggestions for Younger Patients
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/statin_dose">
                    <span class="text"> Intensities of Statin Therapy </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/monitor_flowchart">
                    <span class="text">
                      Recommendations to Monitor Response to LDL-C Lowering
                      Therapy
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations"
                  >
                    <span class="text"> Statin Safety Recommendations </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/discussion_checklist"
                  >
                    <span class="text">
                      Discussion Checklist for Therapy Initiation
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/cac_score_inform_decisions"
                  >
                    <span class="text">
                      Using CAC Score to Inform Decisions
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>

                <h4 class="content-padding">
                  <span class="sub-line">Blood Pressure</span>
                </h4>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/bp_categories_and_treatement_strategies"
                  >
                    <span class="text">
                      BP Categories and Treatment Strategies
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/accurate_bp_measurement"
                  >
                    <span class="text"> Accurate BP Measurement </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/oral_hypertensive_drug_dosing"
                  >
                    <span class="text">
                      Oral Antihypertensive Drug Dosing and Usage
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/nonpharmacologic_blood_pressure_interventions"
                  >
                    <span class="text">
                      Nonpharmacologic Hypertension Interventions
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/substances_that_can_elevate_bp"
                  >
                    <span class="text"> Substances that Can Elevate BP </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>

                <h4 class="content-padding">
                  <span class="sub-line">Other Therapy Information</span>
                </h4>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/clinical_lifestyle"
                  >
                    <span class="text"> Lifestyle Recommendations </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/clinical_diabetes">
                    <span class="text"> Diabetes Management </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/clinician-split-layout/clinical_tobacco">
                    <span class="text"> Tobacco Cessation </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/clinician-split-layout/prescribing_information"
                  >
                    <span class="text"> Prescribing Information </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                  <h4 class="content-padding">
                    <span class="sub-line">External Resources</span>
                  </h4>
                </li>

                <li>
                  <a
                    href="#!/content/clinician-split-layout/reference_external_links"
                  >
                    <span class="text"> External Link to More Resources </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
              </ul>
            </nav>
            <h4 class="content-padding">Patient Resources</h4>
            <nav class="nav-list small">
              <ul>
                <li>
                  <a href="#!/content/patient-split-layout/patient_risk">
                    <span class="text">
                      Understanding My Cardiovascular Risk
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_lifestyle">
                    <span class="text"> Diet and Physical Activity </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_obesity">
                    <span class="text">
                      Weight Management Recommendations
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/patient_cholesterol">
                    <span class="text">
                      Blood Cholesterol Management Recommendations
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a href="#!/content/patient-split-layout/statin_infographic">
                    <span class="text">
                      Groups that Benefit from Statin Therapy Infographic
                    </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/patient-split-layout/patient_reference_definition"
                  >
                    <span class="text"> Common Cardiovascular Terms </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
                <li>
                  <a
                    href="#!/content/patient-split-layout/outside_resources_links"
                  >
                    <span class="text"> Links to Outside Resources </span>
                    <i class="fa fa-holder-dynamic"> </i>
                  </a>
                </li>
              </ul>
            </nav>
            <div class="row">
              <div class="small-12 column">
                <h3 class="">References</h3>
                <ul class="patient-scenario">
                  <li>
                    Albert MA, Buroker AB, Dennison-Himmelfarb C, Goldberger ZD,
                    Hahn EJ, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED,
                    Miedema MD, Munoz D, Smith SC, Virani SS, Williams KA,
                    Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the
                    Prevention of Cardiovascular Disease: A Report of the
                    American College of Cardiology and American Heart
                    Association Task Force on Clinical Practice Guidelines. J Am
                    Coll Cardiol. In Press.
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.acc.org/guidelines#doctype=Guidelines"
                      >Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK,
                      Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino
                      J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones
                      DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer
                      CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani
                      SS, Yeboah J. 2018
                      ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
                      guideline on the management of blood cholesterol: a report
                      of the American College of Cardiology Foundation/American
                      Heart Association Task Force on Clinical Practice
                      Guidelines. J Am Coll Cardiol. 2018; xx:xxxx-xxxx.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://circ.ahajournals.org/content/circulationaha/129/25_suppl_2/S49.full.pdf"
                      >Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S,
                      D’Agostino RB Sr, Gibbons R, Greenland P, Lackland DT,
                      Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST,
                      Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA
                      guideline on the assessment of cardiovascular risk: a
                      report of the American College of Cardiology/American
                      Heart Association Task Force on Practice Guidelines. J Am
                      Coll Cardiol 2014;63:2935–59.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="http://www.onlinejacc.org/content/early/2016/11/23/j.jacc.2016.10.018?_ga=1.167237245.237461518.1450120708"
                      >Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM,
                      Wright JS, Pelser C, Gulati M, Masoudi FA, Goff Jr. DC,
                      Estimating Longitudinal Risks and Benefits From
                      Cardiovascular Preventive Therapies Among Medicare
                      Patients: The Million Hearts Longitudinal ASCVD Risk
                      Assessment Tool, Journal of the American College of
                      Cardiology (2016), doi: 10.1016/ j.jacc.2016.10.018.</a
                    >
                  </li>
                  <br />
                  <li>
                    <a
                      target="_blank"
                      href="https://www.jacc.org/doi/10.1016/j.jacc.2017.11.006"
                      >Whelton PK, Carey RM, Aronow WS, et al. 2017
                      ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
                      for the Prevention, Detection, Evaluation, and Management
                      of High Blood Pressure in Adults. J Am Coll Cardiol. 2017;
                      DOI:10.1016/j.jacc.2017.11.006</a
                    >
                  </li>
                </ul>
              </div>
            </div>
          </div>
          <div class="split-content page with-group-sections page-wrapper">
            <div class="section-nav back hide-for-medium">
              <a href="#!/content/resources/">
                <div class="circle"><i class="fa fa-holder-dynamic"> </i></div>
                <div class="text">Back to Resources</div>
              </a>
            </div>
            <div class="page-wrapper">
              <div
                data-bind="page: {id:'patient_risk',afterShow: listchange}"
                class="group-section"
              >
                <h1 class="with-underline">
                  Understanding My Cardiovascular Risk
                </h1>
                <p>
                  The "2013 ACC/AHA Guideline on the Assessment of
                  Cardiovascular Risk" provides clear recommendations for
                  estimating cardiovascular disease risk. Risk assessments are
                  extremely useful when it comes to reducing risk for
                  cardiovascular disease because they help determine whether a
                  patient is at high risk for cardiovascular disease, and if so,
                  what can be done to address any cardiovascular risk factors a
                  patient may have. Here are the highlights of the guideline:
                </p>
                <ul>
                  <li>
                    <p>
                      Risk assessments are used to determine the likelihood of a
                      patient developing cardiovascular disease, heart attack or
                      stroke in the future. In general, patients at higher risk
                      for cardiovascular disease require more intensive
                      treatment to help prevent the development of
                      cardiovascular disease.
                    </p>
                  </li>
                  <li>
                    <p>
                      Risk assessments are calculated using a number of factors
                      including age, gender, race, cholesterol and blood
                      pressure levels, diabetes and smoking status, and the use
                      of blood pressure-lowering medications. Typically, these
                      factors are used to estimate a patient's risk of
                      developing cardiovascular disease in the next 10 years.
                      For example, someone who is young with no risk factors for
                      cardiovascular disease would have a very low 10-year risk
                      for developing cardiovascular disease. However, someone
                      who is older with risk factors like diabetes and high
                      blood pressure will have a much higher risk of developing
                      cardiovascular disease in the next 10 years.
                    </p>
                  </li>
                  <li>
                    <p>
                      If a preventive treatment plan is unclear based on the
                      calculation of risk outlined above, care providers should
                      take into account other factors such as family history and
                      level of C-reactive protein. Taking this additional
                      information into account should help inform a treatment
                      plan to reduce a patient's 10-year risk of developing
                      cardiovascular disease.
                    </p>
                  </li>
                  <li>
                    <p>
                      Calculating the 10-year risk for cardiovascular disease
                      using traditional risk factors is recommended every 4-6
                      years in patients 20-79 years old who are free from
                      cardiovascular disease. However, conducting a more
                      detailed 10-year risk assessment every 4-6 years is
                      reasonable in adults ages 40-79 who are free of
                      cardiovascular disease. Assessing a patient's 30-year risk
                      of developing cardiovascular disease can also be useful
                      for patients 20-59 years of age who are free of
                      cardiovascular disease and are not at high short-term risk
                      for cardiovascular disease.
                    </p>
                  </li>
                  <li>
                    <p>
                      Risk estimations vary drastically by gender and race.
                      Patients with the same traditional risk factors for
                      cardiovascular disease such as high blood pressure can
                      have a different 10-year risk for cardiovascular disease
                      as a result of their sex and race.
                    </p>
                  </li>
                  <li>
                    <p>
                      After care providers and patients work together to conduct
                      a risk assessment, it's important that they discuss the
                      implications of their findings. Together, patients and
                      their care providers should weigh the risks and benefits
                      of various treatments and lifestyle changes to help reduce
                      the risk of developing cardiovascular disease.
                    </p>
                  </li>
                </ul>
                <p class="quiet">
                  Source:
                  <a
                    class="link"
                    target="_blank"
                    href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Risk-Assessment"
                  >
                    www.cardiosmart.org
                  </a>
                </p>
              </div>
              <div
                data-bind="page: {id:'patient_lifestyle',afterShow: listchange}"
                class="group-section"
              >
                <h1 class="with-underline">
                  Diet and Physical Activity Recommendations
                </h1>
                <p>
                  The "2013 AHA/ACC Guideline on Lifestyle Management to Reduce
                  Cardiovascular Risk" provides recommendations for
                  heart-healthy lifestyle choices based on the latest research
                  and evidence. The guidelines focus on two important lifestyle
                  choices--diet and physical activity--which can have a drastic
                  impact on cardiovascular health. Here's what every patient
                  should know about the latest recommendations for reducing
                  cardiovascular disease risk through diet and exercise.
                </p>
                <h3>Diet</h3>
                <ul>
                  <li>
                    Diet is a vital tool for lowering cholesterol and blood
                    pressure levels, which are two major risk factors for
                    cardiovascular disease.
                  </li>
                  <li>
                    Patients with high cholesterol and high blood pressure
                    levels should eat plenty of vegetables, fruits and whole
                    grains and incorporate low-fat dairy products, poultry,
                    fish, legumes, non-tropical vegetable oils and nuts into
                    their diet. They should also limit intake of sweets,
                    sugar-sweetened beverages and red meats.
                  </li>
                  <li>
                    There are many helpful strategies for heart-healthy eating,
                    including the DASH diet and the USDA's Choose My Plate.
                  </li>
                  <li>
                    Patients who need to lower their cholesterol should reduce
                    saturated and trans fat intake. Ideally, only 5-6% of daily
                    caloric intake should come from saturated fat.
                  </li>
                  <li>
                    Patients with high blood pressure should consume no more
                    than 2,400 mg of sodium a day, ideally reducing sodium
                    intake to 1,500 mg a day. However, even reducing sodium
                    intake in one's current diet by 1,000 mg each day can help
                    lower blood pressure.
                  </li>
                  <li>
                    It's important to adapt the recommendations above, keeping
                    in mind calorie requirements, as well as, personal and
                    cultural food preferences. Nutrition therapy for other
                    conditions like diabetes should also be considered. Doing so
                    helps create healthy eating patterns that are realistic and
                    sustainable.
                  </li>
                </ul>
                <h3>Physical Activity</h3>
                <ul>
                  <li>
                    Regular physical activity helps lower cholesterol and blood
                    pressure, reducing the risk for cardiovascular disease.
                  </li>
                  <li>
                    In general, adults should engage in aerobic physical
                    activity 3-4 times a week with each session lasting an
                    average of 40 minutes.
                  </li>
                  <li>
                    Moderate (brisk walking or jogging) to vigorous (running or
                    biking) physical activity is recommended to reduce
                    cholesterol levels.
                  </li>
                </ul>
                <p class="quiet">
                  Source:
                  <a
                    class="link"
                    target="_blank"
                    href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Lifestyle"
                  >
                    www.cardiosmart.org
                  </a>
                </p>
              </div>
              <div
                data-bind="page: {id:'patient_obesity',afterShow: listchange}"
                class="group-section"
              >
                <h1 class="with-underline">
                  Weight Management Recommendations
                </h1>
                <p>
                  The "2013 AHA/ACC/TOS Guideline for the Management of
                  Overweight and Obesity in Adults" was created to reflect the
                  latest research to outline best practices when it comes to
                  treating obesity--a condition that affects more than one-third
                  of American adults. These guidelines help address questions
                  like "What's the best way to lose weight?" and "When is
                  bariatric surgery appropriate?". Here is what every patient
                  should know about the treatment of overweight and obesity:
                </p>
                <ul>
                  <li>
                    <p>
                      <strong> Definition of obesity: </strong> Obesity is a
                      medical condition in which excess body fat has accumulated
                      to the extent that it can have an adverse effect on one's
                      health. Obesity can be diagnosed using body mass index
                      (BMI), a measurement of height and weight, as well as
                      waist circumference. Obesity is categorized as having a
                      BMI of 30 or greater. Abdominal obesity is defined as
                      having a waist circumference greater than 40 inches for a
                      man or 35 inches for a woman.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Benefits of weight loss: </strong> Obesity
                      increases the risk for serious conditions such as
                      cardiovascular disease, diabetes and death, but losing
                      just a little bit of weight can result in significant
                      health benefits. For an adult who is obese, losing just
                      3-5% of body weight can improve blood pressure and
                      cholesterol levels and reduce the risk for cardiovascular
                      disease and diabetes. Ideally, care providers recommend
                      5-10% weight loss for obese adults, which can produce even
                      greater health benefits.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Weight loss strategies: </strong> There is no
                      single diet or weight loss program that works best for all
                      patients. In general, reduced caloric intake and a
                      comprehensive lifestyle intervention involving physical
                      activity and behavior modification tailored according to a
                      patient's preferences and health status is most successful
                      for sustained weight loss. Further, weight loss
                      interventions should include frequent visits with health
                      care providers and last more than one year for sustained
                      weight loss.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Bariatric Surgery: </strong> Bariatric surgery
                      may be a good option for severely obese patients to reduce
                      their risk of health complications and improve overall
                      health. However, bariatric surgery should be reserved for
                      only the highest risk patients until more evidence is
                      available on this issue. Present guidelines advise that
                      weight loss surgery is only recommended for patients with
                      extreme obesity (BMI &ge;40) or in patients that have a
                      BMI &ge;35 in addition to a chronic health condition.
                    </p>
                  </li>
                </ul>
                <p class="quiet">
                  Source:
                  <a
                    class="link"
                    target="_blank"
                    href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Obesity"
                  >
                    www.cardiosmart.org
                  </a>
                </p>
              </div>
              <div
                data-bind="page: {id:'patient_cholesterol',afterShow: listchange}"
                class="group-section"
              >
                <h1 class="with-underline">
                  Blood Cholesterol Management Recommendations
                </h1>
                <p>
                  The American College of Cardiology (ACC) and the American
                  Heart Association (AHA) recently developed new standards for
                  treating blood cholesterol. These recommendations are based on
                  a thorough and careful review of the very latest, highest
                  quality clinical trial research. They help care providers
                  deliver the best care possible. This page provides some of the
                  highlights from the new practice guidelines. The ultimate goal
                  of the new cholesterol practice guidelines is to reduce a
                  person's risk of heart attack, stroke and death. For this
                  reason, the focus is not just on measuring and treating
                  cholesterol, but identifying whether someone already has or is
                  at risk for atherosclerotic cardiovascular disease (ASCVD) and
                  could benefit from treatment.
                </p>
                <h3>What is ASCVD?</h3>
                <p>
                  Heart attack and stroke are usually caused by atherosclerotic
                  cardiovascular disease (ASCVD). ASCVD develops because of a
                  build-up of sticky cholesterol-rich plaque. Over time, this
                  plaque can harden and narrow the arteries.
                </p>
                <p>
                  These practice guidelines outline the most effective
                  treatments that lower blood cholesterol in those individuals
                  most likely to benefit. Most importantly, they were selected
                  as the best strategies to lower cholesterol to help reduce
                  future heart attack or stroke risk. Share this information
                  with your health care provider so that you can ask questions
                  and work together to decide what is right for you.
                </p>
                <h3>Key Points</h3>
                <p>
                  Based on the most up-to-date and complete look at available
                  clinical trial results:
                </p>
                <ul>
                  <li>
                    <p>
                      Health care providers should focus on identifying those
                      people who are most likely to have a heart attack or
                      stroke and make sure they are given effective treatment to
                      reduce their risk.
                    </p>
                  </li>
                  <li>
                    <p>
                      Cholesterol should be considered along with other factors
                      known to make a heart attack or stroke more likely.
                    </p>
                  </li>
                  <li>
                    <p>
                      Knowing your risk of heart attack and stroke can help you
                      and your health care provider decide whether you may need
                      to take a medication&mdash;most likely a statin&mdash;to
                      lower that risk.
                    </p>
                  </li>
                  <li>
                    <p>
                      If a medication is needed, statins are recommended as the
                      first choice to lower heart attack and stroke risk among
                      certain higher-risk patients based on an overwhelming
                      amount of evidence. For those unable to take a statin,
                      there are other cholesterol-lowering drugs; however, there
                      is less research to support their use.
                    </p>
                  </li>
                </ul>
                <h3>Evaluating Your Risk</h3>
                <p>
                  Your health care provider will first want to assess your risk
                  of ASCVD (assuming you don't already have it). This
                  information will help determine if you are at high enough risk
                  of a heart attack or stroke to need treatment.
                </p>
                <p>
                  To do this, your care provider will 1) review your medical
                  history and 2) gauge your overall risk for heart attack or
                  stroke. He/she will likely want to know:
                </p>
                <ul>
                  <li>
                    <p>
                      whether you have had a heart attack, stroke or blockages
                      in the arteries of your heart, neck, or legs.
                    </p>
                  </li>
                  <li>
                    <p>
                      your risk factors. In addition to your total cholesterol,
                      LDL cholesterol, and HDL (so-called "good") cholesterol,
                      your health care provider will consider your age, if you
                      have diabetes, and whether you smoke and/or have high
                      blood pressure.
                    </p>
                  </li>
                  <li>
                    <p>
                      about your lifestyle habits, other medical conditions, any
                      previous drug treatments, and if anyone in your family has
                      high cholesterol or suffered a heart attack or stroke at
                      an early age.
                    </p>
                  </li>
                </ul>
                <p>
                  A lipid or blood cholesterol panel will be needed as part of
                  this evaluation. This blood test measures the amount of fatty
                  substances (called lipids) in your blood. You may have to fast
                  (not eat for a period of time) before having your blood drawn.
                </p>
                <p>
                  If there is any question about your risk of ASCVD, or whether
                  you might benefit from drug therapy, your care provider may
                  make additional assessments or order additional tests. The
                  results of these tests can help you and your health care team
                  decide what might be the best treatment for you. These tests
                  may include:
                </p>
                <ul>
                  <li>
                    <p>
                      <strong> Lifetime risk estimates </strong> &mdash;how
                      likely you are to have a heart attack and stroke during
                      your lifetime
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Coronary artery calcium (CAC) score </strong>
                      &mdash;a test that shows the presence of plaque or fatty
                      build-up in the heart artery walls
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong>
                        High-sensitivity C-Reactive Protein (CRP)
                      </strong>
                      &mdash;a blood test that measures the amount of CRP, a
                      marker of inflammation or irritation in the body; higher
                      levels have been associated with heart attack and stroke
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Ankle-brachial index (ABI) </strong> &mdash;the
                      ratio of the blood pressure in the ankle compared to blood
                      pressure in the arm, which can predict peripheral artery
                      disease (PAD)
                    </p>
                  </li>
                </ul>
                <p>
                  If you have very high levels of low-density lipoprotein (LDL
                  or "bad") cholesterol, your care provider may want to find out
                  if you have a genetic or familial form of
                  hypercholesterolemia. This condition can be passed on in
                  families.
                </p>
                <h3>Your Treatment Plan</h3>
                <p>
                  Before coming up with a specific treatment plan, your care
                  provider will talk with you about options for lowering your
                  blood cholesterol and reducing your personal risk of
                  atherosclerotic disease. This will likely include a discussion
                  about heart-healthy living and whether you might benefit from
                  a cholesterol-lowering medication.
                </p>
                <h3>Heart-Healthy Lifestyle</h3>
                <p>
                  Adopting a heart-healthy lifestyle continues to be the first
                  and best way to lower your risk of problems. Doing so can also
                  help control or prevent other risk factors (for example: high
                  blood pressure or diabetes). Experts suggest:
                </p>
                <ul>
                  <li>
                    <p>
                      <strong>
                        Eating a diet rich in vegetables, fruits, and whole
                        grains
                      </strong>
                      ; this also includes low-fat dairy products, poultry,
                      fish, legumes, and nuts; it limits intake of sweets,
                      sugar-sweetened beverages and red meats.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Getting regular exercise </strong> ; check with
                      your health care provider about how often and how much is
                      right for you.
                    </p>
                  </li>
                  <li>
                    <p><strong> Maintaining a healthy weight </strong> .</p>
                  </li>
                  <li>
                    <p>
                      <strong> Not smoking or getting help quitting </strong> .
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Staying on top of your health </strong> , risk
                      factors and medical appointments. For some people,
                      lifestyle changes alone may not be enough to prevent a
                      heart attack or stroke. In these cases, taking a statin at
                      the right dose will most likely be necessary.
                    </p>
                  </li>
                </ul>
                <h3>Medications</h3>
                <p>
                  There are two types of cholesterol-lowering medications:
                  statins and non-statins.
                </p>
                <h3>Statin Therapy</h3>
                <p>
                  There is a large body of evidence that shows the use of a
                  statin provides the greatest benefit and fewest safety issues.
                  In particular, specific groups of patients appear to benefit
                  most from taking moderate or high-intensity statin therapy.
                  Based on this information, your care provider will likely
                  recommend a statin if you have:
                </p>
                <ul>
                  <li>
                    <p>ASCVD</p>
                  </li>
                  <li>
                    <p>Very high LDL cholesterol (190 mg/dL or higher)</p>
                  </li>
                  <li>
                    <p>
                      Type 2 diabetes and are between 40 and 75 years of age
                    </p>
                  </li>
                  <li>
                    <p>
                      Above a certain likelihood of having a heart attack or
                      stroke in the next 10 years (7.5% or higher) and are
                      between 40 and 75 years of age
                    </p>
                  </li>
                </ul>
                <p>
                  In certain cases, your care provider may still recommend a
                  statin even if you don't fit into one of the groups above.
                  He/she will consider your overall health and other factors to
                  help decide if you are at enough risk to benefit from a
                  statin. Based on the guidelines, these may include:
                </p>
                <ul>
                  <li>
                    <p>Family history of premature heart attack or stroke</p>
                  </li>
                  <li>
                    <p>Your lifetime risk of ASCVD</p>
                  </li>
                  <li>
                    <p>LDL-cholesterol &ge;160 mg/dL</p>
                  </li>
                  <li>
                    <p>hs-CRP &ge;2 mg/L</p>
                  </li>
                  <li>
                    <p>Results from other special testing (CAC scoring, ABI)</p>
                  </li>
                </ul>
                <h3>
                  If you are on a statin, your care provider will need to find
                  the dose that is right for you.
                </h3>
                <ul>
                  <li>
                    <p>
                      People who have had a heart attack, stroke or other types
                      of ASCVD tend to benefit the most from taking the highest
                      amount (dose) of statin therapy if they tolerate it. This
                      may be more appropriate than taking multiple drugs to
                      lower cholesterol.
                    </p>
                  </li>
                  <li>
                    <p>
                      A more moderate dose of statin may be appropriate for some
                      people with ASCVD, such as those over 75 years or those
                      that might have problems taking the highest dose of a
                      statin (i.e., those with prior organ transplantation).
                    </p>
                  </li>
                </ul>
                <p>
                  Sometimes more than one statin needs to be tried before
                  finding the one that works best.
                </p>
                <p>
                  If you are 75 years or older and have not already had a heart
                  attack, stroke or other types of ASCVD, your care provider
                  will discuss whether a statin is right for you.
                </p>
                <h3>Other cholesterol-lowering medications</h3>
                <p>
                  Not all patients will be able to take the optimum dose of
                  statin. After attention to lifestyle changes and statin
                  therapy, non-statin drugs may be considered if you have
                  high-risk with known ASCVD, diabetes, or very high LDL
                  cholesterol values (&ge;190 mg/dL) and:
                </p>
                <ul>
                  <li>
                    <p>
                      Have side effects from statins that prevent you from
                      getting to the optimal dose or are not able to take a
                      statin at all.
                    </p>
                  </li>
                  <li>
                    <p>
                      Are limited from taking an optimal dose due to other drugs
                      that you are taking, including:
                    </p>
                    <ul>
                      <li>
                        <p>Transplant drug regimens to prevent rejection</p>
                      </li>
                      <li>
                        <p>Multiple drugs to treat HIV</p>
                      </li>
                      <li>
                        <p>
                          Some antibiotics like erythromycin and clarithromycin
                          or certain oral anti-fungal drugs
                        </p>
                      </li>
                    </ul>
                  </li>
                </ul>
                <p>
                  As always, it's important to talk with your health care
                  provider about which medication is right for you.
                </p>
                <h3>What About Having Goals of Treatment?</h3>
                <p>
                  Although keeping LDL-cholesterol lower with an optimal dose of
                  statin is supported strongly by clinical trials, getting to a
                  specific goal level is not.
                </p>
                <h3>Staying on Top of Your Risk</h3>
                <ul>
                  <li>
                    <p>
                      <strong>
                        Take steps to lower your risk factors for heart attack,
                        stroke and other problems
                      </strong>
                      &mdash;Make healthy choices (eating a healthy diet,
                      getting exercise, maintaining a healthy weight and not
                      smoking). Drug therapy, if needed, can help control risk
                      factors.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Report side effects </strong> &mdash;Muscle aches
                      are commonly reported and may or may not be due to the
                      statin. If you are having problems, your care provider
                      needs to know to help manage any side effects and possibly
                      switch you to a different statin.
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Take your medications as directed </strong> .
                    </p>
                  </li>
                  <li>
                    <p>
                      <strong> Get blood cholesterol and other tests </strong>
                      that are recommended by your health care team. These can
                      help assess whether statin therapy&mdash;and the
                      dose&mdash;is working for you.
                    </p>
                  </li>
                </ul>
                <h3>Questions to Ask</h3>
                <ul>
                  <li>
                    <p>
                      What are my risk factors for heart attack and stroke? Am I
                      on the best prevention program to minimize this risk?
                    </p>
                  </li>
                  <li>
                    <p>
                      Is my cholesterol high enough that it might be due to a
                      genetic condition?
                    </p>
                  </li>
                  <li>
                    <p>
                      What lifestyle changes can I make to stay healthy and
                      prevent problems?
                    </p>
                  </li>
                  <li>
                    <p>Do I need to be on a statin?</p>
                  </li>
                  <li>
                    <p>How do I monitor how I am doing?</p>
                  </li>
                  <li>
                    <p>
                      What should I do if I develop muscle aches or weakness
                      after starting the statin?
                    </p>
                  </li>
                  <li>
                    <p>
                      What do I do if I have other symptoms after starting the
                      statin?
                    </p>
                  </li>
                </ul>
                <p class="quiet">
                  Source:
                  <a
                    class="link"
                    target="_blank"
                    href="https://www.cardiosmart.org/Heart-Conditions/Guidelines/Cholesterol"
                  >
                    www.cardiosmart.org
                  </a>
                </p>
              </div>
              <div
                data-bind="page: {id:'bp_infographic',afterShow: listchange}"
                class="group-section"
              ></div>
              <div
                data-bind="page: {id:'statin_infographic',afterShow: listchange}"
                class="group-section"
              >
                <div class="row">
                  <h1>Groups that Benefit from Statin Therapy Infographic</h1>
                </div>
                <div
                  class="holder patient-statin-infographic-panzoom"
                  style="position: relative"
                >
                  <div class="parent panzoom" style="margin: 0">
                    <div class="panzoom-element">
                      <img
                        src="assets/img/squared_metal_@2X.png"
                        data-src="assets/graphics/Benifit-Group-Infographic.svg"
                        alt="Groups that benifit from Statins"
                      />
                    </div>
                  </div>
                </div>
              </div>
              <div
                data-bind="page: {id:'patient_reference_definition',afterShow: listchange}"
                class="group-section"
              >
                <div class="content-padding">
                  <h1 class="with-underline">
                    Common Cardiovascular Terms
                    <span class="sub-line">Alphabetical Glossary</span>
                  </h1>
                  <input
                    placeholder="Search"
                    type="search"
                    data-bind="value: glossaryQuery, valueUpdate: 'keyup'"
                  />
                  <ul
                    class="no-bullet"
                    data-bind="template: {name:'glossaryItem', foreach:$root.glossaryItems}"
                  ></ul>
                  <script type="text/html" id="glossaryItem">
                    <li class="group-divide-auto">
                      <h4 data-bind="html: label"></h4>
                      <p data-bind="html: definition"></p>
                    </li>
                  </script>
                  <p class="quiet">
                    <a
                      class="link"
                      target="_blank"
                      href="https://www.cardiosmart.org/AZ-Topics"
                      >For additional cardiovascular terms visit
                      www.cardiosmart.org</a
                    >
                  </p>
                </div>
              </div>
              <div
                data-bind="page: {id:'outside_resources_links',afterShow: listchange}"
                class="group-section"
              >
                <h1>Links to Outside Resources</h1>
                <nav class="nav nav-list small">
                  <ul>
                    <li>
                      <a
                        target="_blank"
                        href="https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol"
                      >
                        <span class="text"
                          >High Cholesterol Condition Center</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li>
                    <!-- <li>
                      <a
                        target="_blank"
                        href="http://www.cardiosmartguide.com/cholesterol/#/1/"
                      >
                        <span class="text">Managing Your Cholesterol ebook</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li> -->
                    <li>
                      <a
                        target="_blank"
                        href="https://www.cardiosmart.org/healthwise/aa44/406/aa44406"
                      >
                        <span class="text">“Should I take statins?” tool</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li>
                    <li>
                      <a
                        target="_blank"
                        href="https://www.cardiosmart.org/Healthy-Living/Stop-Smoking"
                      >
                        <span class="text"
                          >High Blood Pressure condition center</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li>
                    <li>
                      <a
                        target="_blank"
                        href="https://www.cardiosmart.org/assets/fact-sheet/aspirin-and-heart-disease-fact-sheet"
                      >
                        <span class="text"
                          >Aspirin and Heart Disease fact sheet</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li>
                    <li>
                      <a
                        target="_blank"
                        href="https://www.cardiosmart.org/Healthy-Living/Stop-Smoking"
                      >
                        <span class="text"
                          >Stopping Smoking condition center</span
                        ><i class="fa fa-holder-dynamic"></i>
                      </a>
                    </li>
                  </ul>
                </nav>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--Resources Page Ends here-->
      <!--Terms Page Starts here-->
      <div
        data-bind="page: {id: 'terms', name: 'terms', afterShow:footertabchange, beforeShow:pageScrollTop}"
        class="page-wrapper fullscreen-spacer footer-tabs"
      >
        <div class="page-wrapper">
          <div class="row">
            <div class="medium-12 row collapse">
              <h1>Terms</h1>
            </div>
          </div>
          <div class="row group-section">
            <h3 class="highlighted">
              ASCVD Risk Estimator Plus Terms of Service and License Agreement
            </h3>
            <p>
              This Terms of Service and License Agreement constitutes a legal
              agreement (collectively, the "Agreement") between the American
              College of Cardiology Foundation ("ACCF") and You and your agents
              ("You") for the use of ASCVD Risk Estimator Plus (the "Product"),
              whether You use the mobile application version of the Product or
              the web version of the Product. The Product allows You to access
              certain content included in the Product ("Content") relating to
              calculation of ASCVD Risk and corresponding guideline advice.
            </p>
            <p>
              By using the Product, You accept and agree to be bound by all of
              the terms and conditions set forth in this Agreement. If You do
              not wish to accept the terms and conditions of this Agreement, You
              may not proceed to use the Product.
            </p>
            <p>
              ACCF may change the terms of this Agreement from time to time
              without further notice directly to You. When the terms are
              changed, ACCF will post a general conspicuous notice. If You do
              not agree with the revised terms, please discontinue use of the
              Product immediately. Your continued use of the Product following
              such notice constitutes your acceptance of and agreement to be
              bound by any revised terms of the Agreement. This Agreement
              expressly incorporates by reference and includes rules or
              disclaimers that may be posted and updated within the Product or
              communicated to You from time to time.
            </p>
            <br />
            <h3 class="highlighted">Term and Termination</h3>
            <p>
              ACCF may terminate your access and/or the Product at any time. You
              agree that any termination of your access to the Product shall not
              result in any liability or other obligation of ACCF to You, or any
              third party in connection with such termination.
            </p>
            <br />
            <h3 class="highlighted">Intellectual Property Rights</h3>
            <p>
              This Product, including the information, text, graphics, images,
              audio and video files, trademarks and other materials that may be
              contained therein (collectively "Content"), is owned by ACCF
              and/or its suppliers and is protected by patents, copyrights,
              trademarks, and other proprietary rights. Except as specifically
              provided in this Agreement, your use of the Product shall be
              governed and constrained by applicable patent, copyright,
              trademark and other intellectual property laws. ACCF grants You a
              limited, nonexclusive, nontransferable, revocable license to
              utilize and access the Product for your noncommercial, personal
              use according to the terms and conditions in this Agreement. You
              may not modify, publish, transmit, participate in the transfer or
              sale of, reproduce, create derivative works from, distribute,
              perform, display, incorporate into another website, or in any
              other way exploit the Service and/or any of the Content, in whole
              or in part. Except as expressly granted by this Agreement, You
              acquire no right, title or interest in the Product or the Content
              or other data or materials incorporated in the Product. ACCF, ACC
              or affiliates or licensors thereof shall retain all right, title
              and interest in the Product and Content.
            </p>
            <br />
            <h3 class="highlighted">Limitation of Liability</h3>
            <p>
              TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW, ACCF HEREBY
              DISCLAIMS, AND IN NO EVENT SHALL ACCF OR ANY PARTY INVOLVED IN
              CREATING OR PRODUCING THE PRODUCT BE LIABLE FOR, ANY DIRECT,
              INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY
              DAMAGES, INCLUDING WITHOUT LIMITATION, DAMAGES FOR LOSS OF
              PROFITS, GOODWILL, USE, DATA LOSS, OR OTHER LOSSES, WHETHER IN AN
              ACTION OF CONTRACT, NEGLIGENCE OR OTHER TORTIOUS ACTION, EVEN IF
              ACCF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES,
              RESULTING FROM: (i) THE USE OR INABILITY TO USE THE PRODUCT, (ii)
              THE COST OF ANY SUBSTITUTE PRODUCTS AND/OR SERVICES RESULTING FROM
              ANY PRODUCTS, DATA, INFORMATION OR SERVICES OBTAINED OR WHICH YOU
              WERE UNABLE TO OBTAIN OR TRANSACTIONS EFFECTED OR FAILED TO BE
              EFFECTED, (iii) THE USE OR INABILITY TO USE ANY THIRD PARTY
              APPLICATIONS CONTAINED WITHIN THE PRODUCT, OR (iv) ANY MATTER
              OTHERWISE RELATED TO YOUR USE OF THE PRODUCT.
            </p>
            <br />
            <h3 class="highlighted">Release of Liability</h3>
            <p>
              You assume all risks associated with use of the Product including,
              but not limited to any harm, injury or damages resulting directly
              or indirectly from the use of the Product, all such risks being
              known and understood by You. In consideration of your use of the
              Product, You, for yourself and anyone entitled to act on your
              behalf, waive and forever release ACCF, its officers, trustees,
              employees, representatives and successors from all claims and
              liabilities of any kind arising out of your use or misuse of the
              Product.
            </p>
            <br />
            <h3 class="highlighted">Indemnification</h3>
            <p>
              You hereby agree to indemnify, save and hold ACCF, its directors,
              officers, shareholders, parents, subsidiaries, affiliates, agents
              and licensors harmless from and against any and all claims,
              liability, losses, damages and costs, including, without
              limitation, reasonable attorneys' fees and costs, arising out of
              your use or misuse of the Product or Content, or any violation of
              this Agreement. ACCF assumes the right, at your expense, to assume
              the exclusive defense and control of any matter for which you are
              required to indemnify ACCF, and you agree to cooperate with ACCF’s
              defense of these claims. ACCF will use reasonable efforts to
              notify you of any such claim, action, or proceeding upon becoming
              aware of it.
            </p>
            <br />
            <h3 class="highlighted">Disclaimer of Warranties</h3>
            <p>
              THE PRODUCT AND CONTENT ARE PROVIDED ON AN "AS IS" AND "AS
              AVAILABLE" BASIS. ACCF AND ITS SUPPLIERS EXPRESSLY DISCLAIM ALL
              WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT OR CONTENT,
              WHETHER EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF
              MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND
              NON-INFRINGEMENT. ACCF MAKES NO WARRANTY THAT THE PRODUCT AND/OR
              ANY CONTENT THEREIN WILL MEET YOUR REQUIREMENTS, OR WILL BE
              UNINTERRUPTED, TIMELY, SECURE, CURRENT, ACCURATE, COMPLETE OR
              ERROR-FREE OR THE RESULTS THAT MAY BE OBTAINED BY USE OF THE
              PRODUCT OR ANY CONTENT THEREIN WILL BE ACCURATE OR RELIABLE. YOU
              UNDERSTAND AND ACKNOWLEDGE THAT YOUR SOLE AND EXCLUSIVE REMEDY
              WITH RESPECT TO ANY DEFECT IN OR DISSATISFACTION WITH THE PRODUCT
              IS TO CEASE ITS USE.
            </p>
            <p>
              The Content on the Product is presented as an educational service
              intended for licensed healthcare professionals. While the Content
              in the Product is about specific medical and healthcare issues,
              the Content is not a substitute for or replacement of personalized
              medical advice and is not intended to be used as the sole basis
              for making individualized medical or health-related decisions.
            </p>
            <p>
              The views and opinions expressed are those of the contributing
              authors and editors and do not necessarily represent the views of
              the ACCF. The material is not intended to present the only, or
              necessarily best, methods or procedures for the medical situations
              addressed, but rather is intended to represent an approach, view,
              statement or opinion.
            </p>
            <p>
              Any reference to a specific therapy or commercial product in this
              Product does not constitute a guarantee or endorsement by ACCF of
              the quality or value of such therapy or product or any claims made
              by the manufacturer of such therapy or commercial product.
            </p>
            <p>
              In addition, any statements about such therapy or commercial
              products are solely based on published clinical prediction rules
              and estimates of drug treatment effects from published clinical
              studies and do not represent an ACCF endorsement or evaluation of
              these products.
            </p>
            <br />
            <h3 class="highlighted">Force Majeure</h3>
            <p>
              ACCF will be excused from performance under this Agreement and
              will not be liable or considered in default under this Agreement
              in the event that the Product is unavailable for any period of
              time, or if ACCF is otherwise unable to perform its obligations
              hereunder, in whole or in part, as a result of a Force Majeure
              Event. For purposes of this Section, "Force Majeure Event" means
              an event or series of events caused by or resulting from any of
              the following: (1) weather conditions or other elements of nature
              or acts of God; (2) government regulation; (3) quarantines or
              embargoes; (4) telecommunications, network, computer, server or
              Internet downtime; (5) unauthorized access to ACCF's information
              technology systems by third parties; or (6) any other causes
              beyond the reasonable control of ACCF.
            </p>
            <br />
            <h3 class="highlighted">No Assignment</h3>
            <p>
              This Agreement is personal to You, and You may not assign your
              rights or obligations to anyone.
            </p>
            <br />
            <h3 class="highlighted">No Waiver</h3>
            <p>
              Neither failure nor delay on the part of any party to exercise any
              right, remedy, power or privilege hereunder nor course of dealing
              between the parties shall operate as a waiver thereof, or of the
              exercise of any other right, remedy, power or privilege. No term
              of this Agreement shall be deemed waived, and no breach consented
              to, unless such waiver or consent shall be in writing and signed
              by the party claimed to have waived or consented. No waiver of any
              rights or consent to any breaches shall constitute a waiver of any
              other rights or consent to any other breach.
            </p>
            <br />
            <h3 class="highlighted">Severability</h3>
            <p>
              If any provision in this Agreement is held invalid or
              unenforceable under applicable law, the remaining provisions shall
              continue in full force and effect.
            </p>
            <br />
            <h3 class="highlighted">Governing Law</h3>
            <p>
              This Agreement will be governed by and construed exclusively in
              accordance with the laws of the District of Columbia, USA, without
              regard to its conflicts of law principles and, to the extent
              applicable, the federal laws of the United States. If a dispute
              arises between ACCF and You, You hereby agree to submit such
              dispute to non-binding mediation, followed by binding arbitration,
              if necessary. Both the mediation and arbitration will be conducted
              by JAMS applying the laws of the District of Columbia without
              regard to its conflicts of laws principles and in the District of
              Columbia as venue.
            </p>
            <br />
            <h3 class="highlighted">Certification</h3>
            <p>
              I hereby certify that I understand and agree to the terms stated
              in this Agreement and that this Agreement applies to my initial
              use of the Product and all other subsequent uses of the Product.
              BY USING THIS PRODUCT, I HEREBY AFFIRM THAT I HAVE READ, FULLY
              UNDERSTAND, AND AGREE TO THE ABOVE STATEMENTS.
            </p>
          </div>
        </div>
      </div>
      <!--terms Page Ends here-->
      <!--About App page starts here-->
      <div
        data-bind="page: {id: 'about', name: 'about', afterShow:footertabchange}"
        class="page-wrapper fullscreen-spacer footer-tabs"
      >
        <div class="page-wrapper">
          <div class="row">
            <div class="medium-12 row collapse">
              <h1>About the App</h1>
            </div>
          </div>
          <div class="row group-section no-box-shadow">
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">This app was last updated:</h3>
            </div>
            <div class="medium-12 small-12 columns">
              <p>July 2023</p>
            </div>
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">Provide feedback:</h3>
            </div>
            <div class="medium-12 small-12 columns">
              <p>
                <a
                  target="_blank"
                  href="https://www.surveymonkey.com/r/ASCVDPlus"
                  class="link"
                  >Click here to fill out our feedback survey</a
                >
              </p>
            </div>
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">Target patient population:</h3>
            </div>
            <div class="medium-12 small-12 columns">
              <p>
                The Risk Estimator is intended for use in patients at risk for
                atherosclerotic coronary artery disease (ASCVD) and
                ASCVD-related events, especially due to dyslipidemia and
                hypertension.
              </p>
            </div>
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">
                The why and how of risk assessment<sup>*</sup>
              </h3>
            </div>

            <div class="medium-12 small-12 columns">
              <p>
                When considering drug therapy for primary prevention of ASCVD,
                clinicians and patients should begin by calculating the 10-year
                and lifetime ASCVD risk estimates to identify patients in
                higher-risk groups who are likely to have greater net benefit
                and lower number needed to treat for both statins and
                antihypertensive therapy. Current U.S. prevention guidelines for
                blood pressure and cholesterol management recommend use of the
                pooled cohort equations (PCE) to assess 10-year ASCVD risk and
                start a process of shared decision-making between clinicians and
                patients. Lifetime risk assessment appears to be particularly
                useful for describing and communicating ASCVD risk in younger
                individuals. The Million Hearts Longitudinal ASCVD Risk
                Assessment equation can also be used to update a patient’s risk
                by comparing change in risk factors from a previous to the
                current visit. (See “Terms and Concepts” in the Resources
                section for more information about each of these calculations
                and where they are utilized in the app.)
              </p>
              <p>
                The guidelines recommend the use of the PCE as an important
                starting point, but not as the final arbiter, for
                decision-making in primary prevention of ASCVD. The initial risk
                estimate should form the basis for a discussion that includes:
              </p>
              <ul class="list-type-none">
                <li>
                  - Burden and severity of CVD risk factors and control of these
                  risk factors.
                </li>
                <li>
                  - Presence of risk-enhancing conditions (See “ASCVD Risk
                  Enhancing Factors” in the Resources section at the bottom of
                  this app). It is difficult to determine how much a
                  risk-enhancing factor may change a patient’s 10-year risk
                  estimate quantitatively and therefore, clinician judgment is
                  also crucial to determine whether factors are significant
                  enough to reclassify an individual’s risk category.
                </li>
                <li>
                  - Adherence to healthy lifestyle recommendations. For all
                  patients, appropriate lifestyle modification should be
                  recommended. In patients at higher absolute predicted risk for
                  ASCVD (typically, a 10-year estimated risk) more intensive
                  lifestyle efforts are recommended.
                </li>
                <li>
                  - Potential for ASCVD risk-reduction benefits from statins and
                  antihypertensive drug therapy, and the potential for adverse
                  effects and drug–drug interactions. The Million Hearts
                  Longitudinal ASCVD Risk Assessment equations can also help to
                  quantify potential benefits of preventive therapies based on
                  high-quality evidence, and can be accessed in the Therapy
                  Impact tab at the top of this app.
                </li>
                <li>
                  - Patient preferences regarding the use of medications for
                  primary prevention. In addition, in patients at intermediate
                  10-year risk (7.5% to &lt;20%), and select patients at
                  borderline risk (5% to &lt;7.5%) for whom, after the
                  clinician-patient discussion, the benefits of statin
                  medication for the individual patient remain unclear, the
                  patient has important risk-modifying factors that suggest a
                  better or worse risk than the original estimate, or if the
                  patient is undecided regarding drug therapy, additional
                  testing to help with the decision making is reasonable. In
                  such cases, additional testing should only be used if it can
                  provide sufficient information to modify the decision.
                  Presently, the best additional test to help reclassify ASCVD
                  risk in these situations is measurement of a CAC score for
                  decision-making regarding statin therapy. Please see “Using A
                  CAC Score to Inform Decision Making” in the Resources section
                  at the bottom of this app for more information.
                </li>
              </ul>
            </div>
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">
                How to use this app for risk assessment:
              </h3>
            </div>
            <div class="medium-12 small-12 columns">
              <p>
                The ASCVD Risk Estimator Plus helps clinicians implement
                guideline-recommended risk equations to facilitate
                clinician-patient discussion and support decision making to
                optimize care and lower risk for atherosclerotic cardiovascular
                disease (ASCVD). Clinicians and patients should weigh and
                incorporate the information provided by this app in the context
                of other considerations, including recommended lifestyle
                interventions, patient preferences for taking medications,
                potential adverse drug reactions or interactions, and which
                treatment intervention approach might be most successful for a
                particular patient.
              </p>
              <p>
                <strong>Estimate Screen: </strong>Estimate and monitor patient’s
                10-year risk for atherosclerotic cardiovascular disease
              </p>
              <p>
                Users can choose to calculate a patient’s 10-year ASCVD in two
                ways:
              </p>
              <ul>
                <li>
                  Enter today’s data to calculate a patient’s current 10-year
                  ASCVD risk using the pooled cohort equation. This is most
                  appropriate if this is the first time you are seeing a patient
                  at an initial visit.
                </li>
                <li>
                  Enter data from both today and a previous visit. This allows
                  the app to calculate a patient’s previous risk for comparison,
                  and also more precisely adjust today’s ASCVD risk by factoring
                  in change in a patient’s risk factors over time using the
                  Million Hearts Longitudinal Assessment tool. This is most
                  appropriate if you have seen a patient before.
                </li>
              </ul>
              <p>
                <strong>Therapy Impact tab: </strong>Form a risk-lowering
                intervention plan with your patient at an initial visit
              </p>
              <ul>
                <li>
                  <strong>“Review Therapy Advice”:</strong> Review
                  evidence-based suggestions on an intervention strategy to help
                  discuss a risk-lowering treatment plan with your patient.
                </li>
                <li>
                  <strong>“Select Therapy(s)”: </strong>As part of the
                  discussion, enter different therapy combinations to view the
                  projected impact those therapies might have on a patient’s
                  ASCVD risk.
                </li>
              </ul>
              <p><strong>Advice Screen: </strong>Pull it all together</p>
              <ul>
                <li>
                  <strong>“Estimated 10-Year ASCVD Risk Profile”:</strong>
                  Visualize the change in risk over time the forecasted risk of
                  different treatment scenarios calculated on the previous
                  screens, and compare to the optimal risk that can be achieved
                  for this patient, in one summary graphic. To turn this graphic
                  into a handout for your patient, take a screen shot, save, and
                  print.
                </li>
                <li>
                  <strong>“Treatment Advice Summary”:</strong> Review an
                  expanded version of the evidence-based advice provided on the
                  Forecast screen, including treatment safety information and
                  supporting guideline recommendations.
                </li>
                <li>
                  <strong>“Inputs”:</strong> Capture a summary of the patient
                  parameters entered into the app.
                </li>
                <li>
                  <strong>“Email”: </strong>Email yourself a summary of the
                  calculated ASCVD risk, treatment suggestions, and patient
                  inputs to use as a patient handout or to include in your
                  records for this patient.
                </li>
              </ul>
              <p>
                <strong>Resources Screen: </strong>Visit this tab in the app for
              </p>
              <ul>
                <li>
                  A sample practice scenario for how to use this app with a
                  patient
                </li>
                <li>
                  Definitions of key terms, concepts, and calculations in the
                  app
                </li>
                <li>
                  Related tools and informational resources for both clinicians
                  and patients
                </li>
                <li>Links to reference documents</li>
              </ul>
            </div>

            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">
                What has changed and what remains the same in the new ASCVD Risk
                Estimator Plus:
              </h3>
              <div class="row">
                <div class="column small-12">
                  <p>
                    In addition to an upgrade to the app look and feel, the name
                    “ASCVD Risk Estimator Plus” refers to the fact that this new
                    version combines the original ASCVD Risk Estimator
                    functionality plus the 2016 Million Hearts Longitudinal
                    ASCVD Risk Assessment tool, published in 2016.
                  </p>
                  <p>
                    ASCVD Risk Estimator Plus maintains the same functionalities
                    as the original ASCVD Risk Estimator (e.g., 10-year risk via
                    the Pooled Cohort equation can be calculated under Initial
                    Visits on the Evaluate screen). However, the app now
                    includes additional capabilities to estimate and track
                    change in risk over time, and forecast potential benefit of
                    specific risk-lowering interventions. (See “Terms and
                    Concepts” in the “Resources” section of this app for more
                    information on how each individual value is calculated.) The
                    ASCVD Risk Estimator Plus has also expanded the guidance
                    provided by including expert advice regarding blood
                    pressure-lowering therapy, aspirin use, and smoking
                    cessation, along with the original statin initiation
                    recommendations.
                  </p>
                  <p>
                    Lastly, the ASCVD Risk Estimator Plus now allows the option
                    to calculate initial 10-year ASCVD risk for patients who
                    have already initiated a statin, “Initial 10-year ASCVD
                    risk" may be calculated for patients who have already
                    initiated statin therapy because recent evidence suggests a
                    patient’s cholesterol values have the same impact on ASCVD
                    risk regardless of whether current values were achieved with
                    or without the aid of statin therapy.
                  </p>
                </div>
              </div>
            </div>
            <div class="medium-12 small-12 columns">
              <h3 class="highlighted">How was this App developed?</h3>
            </div>
            <div class="medium-12 small-12 columns">
              <p>
                The App was designed and vetted through collaboration with the
                authors of the source documents listed above, as well as other
                ACC clinical members. It was further refined via user testing
                with physicians, nurse practitioners, and pharmacists.
              </p>
            </div>
            <div class="medium-12 small-12 columns">
              <p>
                <sup>*</sup>Adapted from Lloyd-Jones DM, Braun LT, Ndumele CE,
                Smith SC Jr, Sperling LS, Virani SS, Blumenthal RS. Use of risk
                assessment tools to guide decision-making in the primary
                prevention of atherosclerotic cardiovascular disease: a special
                report from the American Heart Association and American College
                of Cardiology; JACC Nov 2018, 25711;
                DOI:10.1016/j.jacc.2018.11.005
              </p>
            </div>
          </div>
        </div>
      </div>
      <!--        </div>-->
      <!--About App page ends here-->
      <!--News Section starts here -->
      <div
        data-bind="page: {id: 'news', name: 'news', afterShow:footertabchange}"
        class="page-wrapper fullscreen-spacer footer-tabs"
      >
        <div class="page-wrapper">
          <div class="row">
            <div class="medium-12 row collapse">
              <h1>News</h1>
            </div>
          </div>
          <div class="row group-section notification-cards">
            <div data-bind="foreach: notificationData()">
              <div class="row group-section">
                <div class="column">
                  <h4 class="with-underline" data-bind="text: Title"></h4>
                </div>
                <div class="column">
                  <p data-bind="htmlMarkup: Text" id="notification-text"></p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- News Section ends here-->
    </div>
    <div
      data-close-on-click="false"
      data-close-on-esc="false"
      class="reveal"
      id="critical_notification"
      data-reveal="true"
      style="padding: 0"
    >
      <div class="page with-group-sections">
        <div
          class="row collapse critical-text"
          data-bind="foreach: criticalNotification()"
        >
          <div class="columns large-12 medium-12 small-12 text-center">
            <h2
              class="highlighted colored-paper"
              style="color: white; padding: 1em; margin: 0"
            >
              <i class="fa fa-lock fa-2" aria-hidden="true"></i> Locked
            </h2>
          </div>
          <div class="columns large-12 medium-12 small-12 text-center">
            <h4 data-bind="text: Title">The system has been locked</h4>
            <p data-bind="text: Text">
              This version of the application has been <br />
              locked because of need to ugrade the science. <br />
              Please go to the store upgrade this application.
            </p>
            <br />
            <a
              class="button"
              data-bind="visible:(DisplayAppStoreUrl && notification.osType !== notification.osTypes.Web), attr: { href: notification.appStoreURL}"
              >Go to store</a
            >
          </div>
        </div>
      </div>
    </div>
    <footer class="page footer">
      <a href="#!/calculate/estimate" class="logo">
        <img
          style="border: none 0"
          src="assets/img/footer_image.png"
          alt="Risk Plus"
        />
      </a>
      <ul
        class="nav tabs tabs-primary reverse swappable small"
        style="margin: auto"
      >
        <li id="guideline-Tab" class="">
          <a href="#!/content/resources/">
            <span class="short-text btn-ga4">Resources</span>
            <span class="long-text btn-ga4">Resources</span>
          </a>
        </li>
        <li id="legal-Tab" class="">
          <a href="#!/content/terms/">
            <span class="short-text btn-ga4">Terms</span>
            <span class="long-text btn-ga4">Terms</span>
          </a>
        </li>
        <li id="about-Tab" class="">
          <a href="#!/content/about/">
            <span class="short-text btn-ga4">About</span>
            <span class="long-text btn-ga4">About the App</span>
          </a>
        </li>
        <li id="notifications-Tab" class="selected">
          <a href="#!/content/news/">
            <span class="short-text btn-ga4">News</span>
            <span class="long-text btn-ga4">News</span>
          </a>
        </li>
      </ul>
    </footer>

    <script type="text/html" id="clinician_resources_expand">
              <div data-bind="page: {id:'clinical_patient_scenario',afterShow: listchange}" class="group-section">
                                  <h1 class="with-underline">Patient Scenario</h1>
                                  <div>
                                      <p><strong>Initial visit:</strong> A 70-year-old black man presents for an initial visit to consider prevention of atherosclerotic cardiovascular disease (ASCVD). A friend recently had a stroke and he is concerned that he may be at risk as well. </p>
                                      <div class="row">
                                          <div class="column small-12">
                                              <ul class="patient-scenario">
                                                  <li><span class="with-underline">Past medical history:</span><span> Bleeding duodenal ulcer 10 years ago.</span></li>
                                                  <li><span class="with-underline">ASCVD risk factors:</span><span> Current smoker, ½ pack per day for 50 years; no history of diabetes mellitus.</span></li>
                                                  <li><span class="with-underline">Current medications:</span><span> None.</span></li>
                                                  <li><span class="with-underline">Physical examination:</span><span> Systolic blood pressure 160 mm Hg; no signs of ASCVD.</span></li>
                                                  <li><span class="with-underline">Lab data:</span><span> Total cholesterol 240 mg/dL, HDL-cholesterol 40 mg/dL, triglycerides 150 mg/dL, LDL-cholesterol 170 mg/dL.</span></li>
                                              </ul>
                                              <p>The clinician engages him in a discussion regarding his risks for ASCVD, and the potential for risk reduction. The clinician begins by estimating the patient’s 10-year risk for ASCVD based on his current risk profile. After entering the patient’s current data in the Estimate screen of the ASCVD Risk Estimator Plus app, the clinician and patient review the fact that the estimated 10-year risk is 30.8%. The clinician explains that this means that if we had 100 men like him, at the end of 10 years, about 31 of them will have had or died from a heart attack or stroke. This is considered to be a high-risk scenario by current clinical practice guidelines. The patient expresses a desire to lower his risk.
                                                  <br> The clinician provides important information to the patient about pursuing therapeutic lifestyle changes using the Lifestyle table on the Advice tab, including a heart healthy diet and regular physical activity. He agrees to focus on reducing calorie intake, limiting sodium intake, and to start a walking program for 20 minutes daily. Together, they review options for smoking cessation.
                                                  <br> Using the Therapy Impact tab in the ASCVD Risk Estimator Plus app, they review medications that may help reduce the patient’s risk. They note that, on average, starting a moderate intensity statin or blood pressure lowering therapy alone, or stopping smoking for 2 years, would each reduce his 10-year risk to about 23%, whereas aspirin alone would reduce the risk to about 28% (with possible risk of bleeding, in light of his history). Starting a statin and blood pressure lowering therapy plus smoking cessation could cut his 10-year risk to as little as 12%. The clinician and patient review the bar graph on the advice tab to visualize all these options together.
                                                  <br> The patient is uncertain about whether he is ready to adhere to all of these interventions concurrently. Given the patient’s particular interest in reducing stroke risk, and his current hypertension, the patient and clinician decide to pursue blood pressure lowering therapy with a calcium channel blocker, and to pursue smoking cessation with pharmacological assistance. They agree to discuss the use of aspirin or statins at a future visit, which is scheduled. </p>
                                          </div>
                                      </div>
                                  </div>
                                  <br>
                                  <div>
                                      <p><strong>Follow-up Visit:</strong> One year later, the patient returns for a follow-up visit, having had an interim visit at which his blood pressure regimen was adjusted with the addition of a thiazide diuretic. He successfully stopped smoking 8 months ago. His lipids are unchanged from baseline. His systolic blood pressure today is 140 mm Hg.
                                          <br> However, with his greater than expected blood pressure reduction and successful smoking cessation, the clinician calculates the patient’s updated risk by entering both the patient’s initial visit and follow up data into the app’s Estimate tab, and determines his risk is now 11.4%. The clinician congratulates the patient, and asks whether he would like to consider initiating moderate-intensity statin therapy. They consider the pros and cons and the patient’s preferences, and elect to pursue a moderate intensity statin, with plans to assess the patient’s LDL-cholesterol response in 3 months. The clinician emails themselves a summary of the visit and the patient’s progress to keep in their record, using the button on the Advice tab.</p>
                                  </div>
                              </div>
              <div data-bind="page: {id:'clinical_understanding',afterShow: listchange}" class="group-section">
                                  <h1 class="with-underline">Understanding Cardiovascular Risk</h1>
                                  <div data-bind="ui-accordion: {}" class="accordion">
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">10-Year ASCVD Risk</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <ul>
                                                      <li>The 10-year calculated ASCVD risk is a quantitative estimation of absolute risk based upon data from representative population samples. </li>
                                                      <li>The 10-year risk estimate for "optimal risk factors" is represented by the following specific risk factor numbers for an individual of the same age, sex and race: Total cholesterol of &le; 170 mg/dL, HDL-cholesterol of &ge; 50 mg/dL, untreated systolic blood pressure of &le; 110 mm Hg, no diabetes history, and not a current smoker.</li>
                                                      <li>While the risk estimate is applied to individuals, it is based on group averages. </li>
                                                      <li>Just because two individuals have the same estimated risk does not mean that they will or will not have the same event of interest. </li>
                                                      <li>Example: If the 10-year ASCVD risk estimate is 10%, this indicates that among 100 patients with the entered risk factor profile, 10 would be expected to have a heart attack or stroke in the next 10 years.</li>
                                                  </ul>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Lifetime ASCVD Risk</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <ul>
                                                      <li>The lifetime calculated ASCVD risk represents a quantitative estimation of absolute risk for a 50 year old man or woman with the same risk profile.</li>
                                                      <li>This estimation of risk is based on the grouping of risk factor levels into 5 strata.
                                                          <ul>
                                                              <li>All risk factors are optimal*</li>
                                                              <li>&ge;1 risk factors are not optimal&dagger;</li>
                                                              <li>&ge;1 risk factors are elevated&Dagger;</li>
                                                              <li>1 major risk factor&sect;</li>
                                                              <li>&ge;2 major risk factors&sect;</li>
                                                          </ul>
                                                      </li>
                                                      <li>The division of lifetime risk by these 5 strata leads to thresholds in the data with large apparent changes in lifetime risk estimates.</li>
                                                      <li>Example: An individual that has all optimal risk factors except for a systolic blood pressure of 119 mm Hg has a lifetime ASCVD risk of 5%. In contrast, a similar individual that has all optimal risk factors except for a systolic blood pressure of 120 mm Hg has a lifetime ASCVD risk of 36%. This substantial difference in lifetime risk is due to the fact that they are in different stratum.</li>
                                                  </ul>
                                                  <p class="quiet">*Optimal risk levels for lifetime risk are represented by the simultaneous presence of all of the following: Untreated total cholesterol &lt;180 mg/dL, untreated blood pressure &lt;120/&lt;80 mm Hg, no diabetes history, and not a current smoker</p>
                                                  <p class="quiet">&dagger;Nonoptimal risk levels for lifetime risk are represented by 1 or more of the following: Untreated total cholesterol of 180 to 199 mg/dL, untreated systolic blood pressure of 120 to 139 mm Hg or diastolic&nbsp;blood pressure of 80 to 89 mm Hg, and no diabetes history and not a current smoker</p>
                                                  <p class="quiet">&Dagger;Elevated risk levels for lifetime risk are represented by 1 or more of the following: Untreated total cholesterol of 200 to 239 mg/dL, untreated systolic blood pressure of 140 to 159 mm Hg or diastolic&nbsp;blood pressure of 90 to 99 mm Hg, and no diabetes history and not a current smoker</p>
                                                  <p class="quiet">&sect;Major risk levels for lifetime risk are represented by any of the following: Total cholesterol &ge;240 mg/dL or treated, systolic blood pressure &ge;160 mm Hg or diastolic&nbsp;blood pressure &ge;100 mm Hg or treated, or diabetes, or current smoker</p>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                  </div>
                              </div>
              <div data-bind="page: {id:'clinical_lifestyle',afterShow: listchange}" class="group-section">
                                  <h1 class="with-underline">Lifestyle Recommendations</h1>
                                  <div data-bind="ui-accordion: {}" class="accordion">
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Diet recommendations for LDL-C lowering</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <ul>
                                                      <li>To reduce ASCVD risk in all patients:
                                                          <ul class="list-type-none">
                                                              <li>- A diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, and fish is recommended (I, B-R). A diet containing reduced amounts of cholesterol and sodium can be beneficial (IIa, B-NR).</li>
                                                              <li>- Replacement of saturated fat with dietary mono- and poly-unsaturated fats can be beneficial (IIa, B-NR).</li>
                                                              <li>- Minimizing the intake of trans fats, processed meats, refined carbohydrates, and sweetened beverages as part of a heart healthy diet is reasonable (IIa, B-NR).</li>
                                                          </ul>
                                                      </li>
                                                      <li>For adults with type 2 diabetes mellitus:
                                                          <ul class="list-type-none">
                                                              <li>- A tailored nutrition plan focusing on a heart-healthy dietary pattern is recommended to improve glycemic control, achieve weight loss (if needed), and improve other ASCVD risk factors (I, A).</li>
                                                          </ul>
                                                      </li>
                                                  </ul>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Weight Management Recommendations</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">

                                                  <ul>
                                                      <li>In overweight and obese adults:
                                                          <ul class="list-type-none">
                                                              <li>- Weight loss is recommended to improve the ASCVD risk-factor profile (I, B-R).</li>
                                                              <li>- Counseling and comprehensive lifestyle interventions, including calorie restriction, are recommended for achieving and maintaining weight loss (I, B-R).</li>
                                                              <li>- Calculating body mass index is recommended annually or more frequently to identify overweight and obese adults for weight loss considerations (I, C-EO). </li>
                                                              <li>- It is reasonable to measure waist circumference to identify those at higher cardiometabolic risk (IIa, B-NR). </li>
                                                          </ul>
                                                      </li>
                                                  </ul>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Physical Activity Recommendations</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <ul>
                                                      <li>To reduce ASCVD risk, adults should:
                                                          <ul class="list-type-none">
                                                              <li>- Be routinely counseled to optimize a physically active lifestyle (I, B-R).</li>
                                                              <li>- Engage in at least 150 minutes per week of accumulated moderate intensity or 75 minutes per week of vigorous intensity aerobic physical activity (or an equivalent combination of moderate and vigorous activity) (I, B-NR). This includes adults with type 2 diabetes mellitus (I, A). </li>
                                                              <li>- Decrease sedentary behavior (IIb, C-LD).</li>
                                                          </ul>
                                                      </li>
                                                      <li>For adults unable to meet the minimum physical activity recommendations:
                                                          <ul class="list-type-none">
                                                              <li>- Engaging in some moderate or vigorous intensity physical activity, even if less than this recommended amount, can be beneficial to reduce ASCVD risk (IIa, B-NR). </li>
                                                              <table class="table">
                                                                  <thead>
                                                                      <tr>
                                                                          <th>Intensity</th>
                                                                          <th>METS</th>
                                                                          <th>Examples</th>
                                                                      </tr>
                                                                  </thead>
                                                                  <tbody>
                                                                      <tr>
                                                                          <td>Sedentary Behavior<sup>*</sup></td>
                                                                          <td>1-1.5</td>
                                                                          <td> Sitting, reclining, or lying; watching TV </td>
                                                                      </tr>
                                                                      <tr>
                                                                          <td>Light</td>
                                                                          <td>1.6-2.9</td>
                                                                          <td>Walking slowly, cooking, light house work</td>
                                                                      </tr>
                                                                      <tr>
                                                                          <td>Moderate</td>
                                                                          <td>3.0-5.9</td>
                                                                          <td>Brisk walking (2.4-4mph), biking 5-9mph, ballroom dancing, active yoga, recreational swimming</td>
                                                                      </tr>
                                                                      <tr>
                                                                          <td>Vigorous</td>
                                                                          <td>≥6</td>
                                                                          <td>Jogging/running, biking ≥10mph, singles tennis, swimming laps</td>
                                                                      </tr>
                                                                  </tbody>
                                                              </table>
                                                              <p><sup>*</sup>Sedentary behavior is defined as any waking behavior characterized by an 			energy expenditure &le;1.5 metabolic equivalents (METs), while in a sitting, 			reclining, or lying posture.  Standing is a sedentary activity in that it involves 			&le;1.5 METs, but is not considered a component of sedentary behavior; mph indicates miles per hour</p>
                                                          </ul>

                                                      </li>
                                                  </ul>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                  </div>
                              </div>
                              <div data-bind="page: {id:'clinical_diabetes',afterShow: listchange}"
                              class="group-section clinical-diabetes">
                              <h1 class="with-underline">Diabetes Management</h1>
                              <p>The data are incomplete for the use of SGLT2 inhibitors and GLP-1RAs in patients who do not have DKD
                                  or
                                  established ASCVD, although expert consensus recommends their use for patients with a high burden of
                                  1 risk factors for CV disease.</p>
                              <div data-bind="ui-accordion: {}" class="accordion">
                                  <div>
                                      <h2 class="toggle"><i class="fa fa-holder"></i><span class="text"> Doses, Indications, Dose
                                              Modifications, Contraindications, Cautions, and Adverse Effects of SGLT2 Inhibitors with
                                              Demonstrated CV Benefit</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content">
                                              <div class="table-wrapper">
                                                  <table class="table ">
                                                      <thead>
                                                          <tr>
                                                              <th>&nbsp;</th>
                                                              <th><strong>Canagliflozin</strong></th>
                                                              <th><strong>Dapagliflozin</strong></th>
                                                              <th><strong>Empagliflozin</strong></th>
                                                          </tr>
                                                      </thead>
                                                      <tbody>
                                                          <tr>
                                                              <td><strong>Recommended Doses for CV Benefit*</strong></td>
                                                              <td>
                                                                  <ul>
                                                                      <li>100 mg PO daily</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>100 mg PO daily</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>100 mg PO daily</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td><strong>Indications</strong></td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D as an adjunct to
                                                                          diet and exercise</li>
                                                                      <li>Reduce risk of MI, stroke, or CV death in adults with T2D
                                                                          and CV
                                                                          disease</li>
                                                                      <li>Reduce the risk of end-stage kidney disease, doubling of
                                                                          serum
                                                                          creatinine, CV death, and hospitalization for HF in patients
                                                                          with T2D and diabetic nephropathy with albuminuria</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>eGFR 2: use is not recommended for glycemic control</li>
                                                                      <li>Reduce the risk of hospitalization for HF in adults with T2D
                                                                          and
                                                                          established CV disease or multiple CV risk factors</li>
                                                                      <li>Reduce the risk of CV death and hospitalization for HF in
                                                                          adults
                                                                          with HFrEFa</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D as an adjunct to
                                                                          diet and exercise</li>
                                                                      <li>Reduce risk of CV death in adults with T2D and established
                                                                          CV
                                                                          disease</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td><strong>Dose Modifications</strong></td>
                                                              <td>
                                                                  <ul>
                                                                      <li>eGFR 30 to 59 ml/min/1.73m<sup>2</sup>: max dose 100 mg
                                                                          daily
                                                                      </li>
                                                                      <li>eGFR 2: use is not recommended for glycemic control</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>eGFR 2: use is not recommended for glycemic control</li>
                                                                      <li>eGFR 2: use is contraindicated</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>eGFR 2: use is not recommended</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td><strong>Contraindications</strong></td>
                                                              <td colspan="3">
                                                                  <ul>
                                                                      <li>History of serious hypersensitivity reaction to drug</li>
                                                                      <li>Pregnancy or breastfeeding</li>
                                                                      <li>On dialysis</li>
                                                                      <li>eGFR 2 (dapagliflozin)</li>
                                                                      <li>ESRD (dapagliflozin and empagliflozin)</li>
                                                                      <li>Severe renal impairment (empagliflozin)</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td><strong>Cautions</strong></td>
                                                              <td colspan="3">
                                                                  <ul>
                                                                      <li>If HbA1c well-controlled at baseline, or known history of
                                                                          frequent hypoglycemic events, wean or stop sulfonylurea or
                                                                          glinide and consider reducing total daily insulin dose by
                                                                          ~20%
                                                                          when starting therapy</li>
                                                                      <li>May contribute to intravascular volume contraction; consider
                                                                          stopping or reducing diuretic dose if applicable</li>
                                                                      <li>Use with caution in patients with prior amputation, severe
                                                                          peripheral neuropathy, severe peripheral vascular disease,
                                                                          or
                                                                          active diabetic foot ulcers or soft tissue infections</li>
                                                                      <li>Possible increased risk of bone fractures (canagliflozin)
                                                                      </li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td><strong>Adverse Effects to Monitor</strong></td>
                                                              <td colspan="3">
                                                                  <ul>
                                                                      <li>Genital fungal infections</li>
                                                                      <li>Urinary tract infections</li>
                                                                      <li>Euglycemic diabetic ketoacidosis</li>
                                                                      <li>Lower limb ulcerations and soft tissue infections</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                      </tbody>
                                                  </table>
                                              </div>
                                              <p><sup>*</sup>Because there is no evidence of a graded dose response regarding CV and
                                                  renal
                                                  effects, SGLT2 inhibitors with CV benefit should be initiated at the lowest dose
                                                  tested
                                                  in CV and renal outcomes trials. Those doses are listed here. No further dose
                                                  titration
                                                  is needed for CV or renal risk reduction. However, dose increases may provide
                                                  further
                                                  glucose reduction benefits if indicated</p>
                                              <p>CV = cardiovascular; eGFR = estimated glomerular filtration rate; ESRD= end stage
                                                  renal
                                                  disease; HbA1c = hemoglobin A1c; HF= heart failure; PO = “per os", by mouth; SGLT2 =
                                                  sodium-glucose cotransporter-2; T2D = type 2 diabetes</p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                                  <div>
                                      <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Doses, Indications, Dose
                                              Modifications, Contraindications, Cautions, and Adverse Effects of GLP-1RAs with
                                              Demonstrated CV Benefit</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content">
                                              <div class="table-wrapper">
                                                  <table class="table ">
                                                      <thead>
                                                          <th>&nbsp;</th>
                                                          <th><strong>Dulaglutide</strong></th>
                                                          <th><strong>Exenatide QW</strong></th>
                                                          <th><strong>Liraglutide</strong></th>
                                                          <th><strong>Lixisenatide</strong></th>
                                                          <th><strong>Semaglutide SC</strong></th>
                                                          <th><strong>Semaglutide PO</strong></th>
                                                      </thead>
                                                      <tbody>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Recommended Doses for CV Benefit</strong></p>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Initiate 0.75 mg SC per week</li>
                                                                      <li>Titrate slowly to 1.5 mg or maximally tolerated dose based
                                                                          on
                                                                          prescribing information</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>2 mg SC per week</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Initiate 0.6 mg SC daily.</li>
                                                                      <li>Titrate slowly to 1.8 mg or maximally tolerated dose based
                                                                          on
                                                                          prescribing information</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>10 mcg SC daily</li>
                                                                      <li>Titrate as tolerated to 20 mcg daily based on prescribing
                                                                          information.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Initiate 0.25 mg SC per week.</li>
                                                                      <li>Titrate slowly to 1 mg once weekly or maximally tolerated
                                                                          dose
                                                                          based on prescribing information.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Initiate 3 mg PO per day for the first 30 days.</li>
                                                                      <li>Titrate slowly to 14 mg daily or maximally tolerated dose
                                                                          based
                                                                          on prescribing information.</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Indications</strong></p>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D</li>
                                                                      <li>Reduce MACE for people with T2D with and without established
                                                                          CV
                                                                          disease</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D</li>
                                                                      <li>Reduce risk of MI, CVA, or CV death in adults with T2D and
                                                                          CV
                                                                          disease</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D.</li>
                                                                      <li>Reduce risk of MI, CVA, or CV death in adults with T2D and
                                                                          CV
                                                                          disease.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Improve glycemic control in adults with T2D.</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Dose Modifications</strong></p>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Up-titrate slowly to reduce nausea and vomiting</li>
                                                                      <li>Discontinue if pancreatitis is suspected and do not restart
                                                                          if
                                                                          pancreatitis is confirmed</li>
                                                                      <li>No dose adjustment necessary with renal or hepatic
                                                                          impairment;
                                                                          data in end-stage renal disease are limited</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Discontinue if pancreatitis is suspected and do not restart
                                                                          if
                                                                          pancreatitis is confirmed</li>
                                                                      <li>eGFR &lt;45 mL/min/1.73 m2: Use is not recommended</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Up-titrate slowly to reduce nausea and vomiting</li>
                                                                      <li>Discontinue if pancreatitis is suspected and do not restart
                                                                          if
                                                                          pancreatitis is confirmed</li>
                                                                      <li>No dose adjustment is necessary with renal or hepatic
                                                                          impairment
                                                                      </li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Up-titrate slowly to reduce nausea and vomiting.</li>
                                                                      <li>Discontinue if pancreatitis is suspected, and do not restart
                                                                          if
                                                                          pancreatitis is confirmed .</li>
                                                                      <li>eGFR &ge;30 mL/min: No dosage adjustment is required.</li>
                                                                      <li>eGFR 15 to 29 mL/min: Use caution and monitor renal
                                                                          function.
                                                                      </li>
                                                                      <li>eGFR &lt;15 mL/min: Use is not recommended.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Up-titrate slowly to reduce nausea and vomiting.</li>
                                                                      <li>Discontinue if pancreatitis is suspected and do not restart
                                                                          if
                                                                          pancreatitis is confirmed.</li>
                                                                      <li>No dose adjustment is necessary with renal or hepatic
                                                                          impairment.</li>
                                                                  </ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li>Up-titrate slowly to reduce nausea and vomiting.</li>
                                                                      <li>Discontinue if pancreatitis is suspected and do not restart
                                                                          if
                                                                          pancreatitis is confirmed.</li>
                                                                      <li>No dose adjustment is necessary with renal or hepatic
                                                                          impairment.</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Contraindications</strong></p>
                                                              </td>
                                                              <td colspan="6">
                                                                  <ul>
                                                                      <li>History of serious hypersensitivity reaction to drug</li>
                                                                      <li>Pregnancy or breast feeding</li>
                                                                      <li>Severe renal impairment or end-stage renal failure
                                                                          (exenatide,
                                                                          lixisenatide)</li>
                                                                      <li>Personal or family history of medullary thyroid cancer</li>
                                                                      <li>Personal or family history of MEN2</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Cautions</strong></p>
                                                              </td>
                                                              <td colspan="6">
                                                                  <ul>
                                                                      <li>Hypoglycemia risk increased with insulin, sulfonylureas, or
                                                                          glinides</li>
                                                                      <li>May delay gastric emptying; not recommended in patients with
                                                                          clinically meaningful gastroparesis. This effect is usually
                                                                          transient with longer-acting GLP-1RAs</li>
                                                                      <li>Care should be taken in patients with prior gastric surgery,
                                                                          including bariatric surgery</li>
                                                                      <li>Diabetic retinopathy complications were reported with
                                                                          semaglutide (injectable), although it is unclear if this is
                                                                          a
                                                                          direct effect of the drug or due to other factors such as
                                                                          rapid
                                                                          improvement in blood glucose control</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td>
                                                                  <p><strong>Adverse Effects to Monitor</strong></p>
                                                              </td>
                                                              <td colspan="6">
                                                                  <ul>
                                                                      <li>Nausea, vomiting, diarrhea, headache, weakness, or dizziness
                                                                      </li>
                                                                      <li>Hypoglycemia when given with insulin, sulfonylureas, or
                                                                          glinides
                                                                      </li>
                                                                      <li>Weight loss</li>
                                                                      <li>Injection site reactions</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                      </tbody>
                                                  </table>
                                              </div>
                                              <p>CV = cardiovascular; CVA = cerebrovascular accident; eGFR = estimated glomerular
                                                  filtration rate; GLP-1RA = glucagon-like peptide-1 receptor agonist; MACE = major
                                                  adverse cardiovascular events; MEN2 = multiple endocrine neoplasia, type 2; MI =
                                                  myocardial infarction; PO = "per os", by mouth; T2D = type 2 diabetes; SC =
                                                  subcutaneous; QW = once weekly</p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                                  <div>
                                      <h2 class="toggle"><i class="fa fa-holder"></i><span class="text"> Opportunities to Initiate an
                                              SGLT2 inhibitor or a GLP-1RA with Demonstrated CV or Renal Benefit in Patients with
                                              T2D*</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content considerations-for-drug">
                                              <table class="table ">
                                                  <tbody>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>In a patient with T2D and ASCVD (SGLT2 inhibitor or GLP-1RA)
                                                                  </li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>At the time of diagnosis of clinical ASCVD (SGLT2 inhibitor or
                                                                      GLP-1RA), DKD, and/or HF (SGLT2 inhibitor)<sup>&dagger; </sup>in
                                                                      a
                                                                      patient with T2D on a drug regimen that does not include a SGLT2
                                                                      inhibitor or GLP-1RA with CV benefit</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>At the time of diagnosis of T2D in a patient with clinical ASCVD
                                                                      (SGLT2 inhibitor or GLP-1RA), DKD and/or HF (SGLT2
                                                                      inhibitor)<sup>
                                                                          &dagger;</sup><sup>&Dagger;</sup></li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>At hospital discharge (with close outpatient follow-up) after
                                                                      admission for an ASCVD (SGLT2 inhibitor or GLP-1RA) or HF (SGLT2
                                                                      inhibitor) event<sup>&sect;</sup></li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>In a patient with T2D and diabetic kidney disease (SGLT2
                                                                      inhibitor,
                                                                      alternatively GLP-1RA for eGFR&lt;30 ml/min/1.73 m2)
                                                                      <sup>&Dagger;</sup></li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>In patients determined to be at high risk of ASCVD<sup>||</sup>
                                                                      (SGLT2 inhibitor or GLP-1RA) or HF (SGLT2 inhibitor)
                                                                      <sup>&dagger;&Dagger;</sup></li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                  </tbody>
                                              </table>
                                              <p>*At the time of hospital discharge or in the outpatient setting. Increased vigilance
                                                  regarding hypoglycemia surveillance is warranted, especially if on background
                                                  insulin,
                                                  sulfonylurea, or glinide therapy.</p>
                                              <p>&dagger;A minority of patients included in the CANVAS, LEADER, SUSTAIN-6, and EXSCEL
                                                  trials and a majority of patients in the REWIND trial could be characterized as
                                                  high-risk primary prevention patients. These patients did not have established ASCVD
                                                  but
                                                  did have prespecified ASCVD risk factors.</p>
                                              <p>&Dagger;Use clinical judgement when initiating an SGLT2 inhibitor in a patient who
                                                  will
                                                  be starting or uptitrating an ACE inhibitor or ARB if the patient&rsquo;s renal
                                                  function
                                                  is impaired.</p>
                                              <p>&sect;Hospitalized patients were not included in most of the CV outcome trials
                                                  discussed
                                                  here. There is a lack of practical and safety data regarding in-hospital addition of
                                                  SGLT2 inhibitors or GLP-1RAs to a patient&rsquo;s regimen.</p>
                                              <p><sup>||</sup>Consider for patients at very high risk of ASCVD to include patients
                                                  with
                                                  end-organ damage such as left ventricular hypertrophy or retinopathy or with
                                                  multiple CV
                                                  risk factors (e.g., age, hypertension, smoking, dyslipidemia, obesity).</p>
                                              <p>ACE = angiotensin converting enzyme; ARB = angiotensin reception blocker; ASCVD =
                                                  atherosclerotic cardiovascular disease; CANVAS = Canagliflozin Cardiovascular
                                                  Assessment
                                                  Study; CV = cardiovascular; DKD = diabetic kidney disease; eGFR = estimated
                                                  glomerular
                                                  filtration rate; EXSCEL = Exenatide Study of Cardiovascular Event Lowering Trial;
                                                  GLP-1RA = glucagon-like peptide-1 receptor agonist; HF = heart failure; LEADER =
                                                  Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome
                                                  Results;
                                                  REWIND = Researching CV Events With a Weekly Incretin in Diabetes; SGLT2 =
                                                  sodium-glucose cotransporter-2; SUSTAIN-6 = Trial to Evaluate CV and Other Long-term
                                                  Outcomes With Semaglutide in Subjects With T2D;T2D = type 2 diabetes</p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                                  <div>
                                      <h2 class="toggle"><i class="fa fa-holder"></i><span class="text"> Patient and Clinician
                                              Preferences
                                              and Priorities for Considering SGLT2 Inhibitors with Demonstrated CV Benefit Versus
                                              GLP-1RAs
                                              with Demonstrated CV Benefit</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content patient-and-clinician-preferences">
                                              <div class="table-wrapper">
                                                  <table class="table ">
                                                      <tbody>
                                                          <th><strong>Preference or Priority</strong></th>
                                                          <th><strong>Consider using an SGLT2 inhibitor first when patient and
                                                                  clinician
                                                                  priorities include:</strong></th>
                                                          <th><strong>Consider using a GLP-1RA first when patient and clinician
                                                                  priorities
                                                                  include:</strong></th>
                                                          <tr>
                                                              <td>MACE prevention</td>
                                                              <td>+++</td>
                                                              <td>+++</td>
                                                          </tr>
                                                          <tr>
                                                              <td>HF prevention</td>
                                                              <td>+++</td>
                                                              <td>&nbsp;</td>
                                                          </tr>
                                                          <tr>
                                                              <td>Weight loss</td>
                                                              <td>+</td>
                                                              <td>+++</td>
                                                          </tr>
                                                          <tr>
                                                              <td>Renal disease progression prevention</td>
                                                              <td>+++</td>
                                                              <td>+</td>
                                                          </tr>
                                                          <tr>
                                                              <td>Mode of administration</td>
                                                              <td>Oral</td>
                                                              <td>Subcutaneous</td>
                                                          </tr>
                                                          <tr>
                                                              <td>Considerations that may prompt use of an alternative class</td>
                                                              <td>
                                                                  <ul>
                                                                      <li> Severely reduced kidney function*&dagger;</li>
                                                                      <li> History of prior amputation, severe peripheral arterial
                                                                          disease, or active diabetic foot ulcers (caution with
                                                                          canagliflozin)</li>
                                                                      <li> History of recurrent genital candidiasis</li>
                                                                      <li> History of diabetic ketoacidosis</li>
                                                                      <li> History of fracture (caution with canagliflozin)</li>
                                                                      <li> The patient is considering pregnancy</li>
                                                                      <li> The patient is breast feeding</li>
                                                                      <ul>
                                                              </td>
                                                              <td>
                                                                  <ul>
                                                                      <li> Persistent nausea, despite appropriate dietary education
                                                                          and
                                                                          low doses</li>
                                                                      <li> History of gastroparesis</li>
                                                                      <li> Active gallbladder disease
                                                                      <li> History of MEN2 or medullary thyroid cancer</li>
                                                                      <li> History of proliferative retinopathy (caution with
                                                                          semaglutide
                                                                          or dulaglutide)</li>
                                                                      <li> The patient is considering pregnancy</li>
                                                                      <li> The patient is breast feeding</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                      </tbody>
                                                  </table>
                                              </div>
                                              <p>*eGFR &lt;45 ml/min/1.73 m<sup>2</sup> is currently a caution due to a decrease in
                                                  glycemic efficacy (not due to safety), but ongoing studies are testing whether SGLT2
                                                  inhibitors offer renal benefits in these patients. The FDA label for canagliflozin
                                                  allows use of canagliflozin to an eGFR of 30 ml/min/1.73m<sup>2 </sup>specifically
                                                  for
                                                  patients with DKD.</p>
                                              <p>&dagger;Use clinical judgement when initiating an SGLT2 inhibitor in a patient who
                                                  will
                                                  be starting or uptitrating an ACE inhibitor or ARB if the patient&rsquo;s renal
                                                  function
                                                  is impaired</p>
                                              <p>ACE = angiotensin converting enzyme; ARB = angiotensin reception blocker; CV =
                                                  cardiovascular; DKD = diabetic kidney disease; eGFR = estimated glomerular
                                                  filtration
                                                  rate; FDA = Food and Drug Administration; GLP-1RA = glucagon-like peptide-1 receptor
                                                  agonist; HF = heart failure; MACE = major adverse cardiovascular event; MEN2 =
                                                  multiple
                                                  endocrine neoplasia type 2; SGLT2 = sodium-glucose cotransporter-2</p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                                  <div>
                                      <h2 class="toggle"><i class="fa fa-holder"></i><span class="text"> Considerations for Drug
                                              Initiation and Monitoring in Patients Starting an SGLT2 Inhibitor with Demonstrated CV
                                              Benefit</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content considerations-for-drug">
                                              <table class="table ">
                                                  <tbody>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>If HbA1c is well-controlled at baseline or known history of
                                                                      frequent
                                                                      hypoglycemic events, wean or stop sulfonylurea and consider
                                                                      reducing
                                                                      total daily insulin dose by ~20% when starting therapy.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Educate patients regarding potential for genital mycotic
                                                                      infections
                                                                      and importance of genital hygiene.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Avoid hypovolemia. May need to reduce diuretic dose if the
                                                                      patient
                                                                      has symptoms of dehydration. Educate patients regarding symptoms
                                                                      of
                                                                      dehydration (lightheadedness, orthostasis, weakness) and to hold
                                                                      medication if low oral intake.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Instruct patients to more closely monitor glucose at home for
                                                                      the
                                                                      first 4 weeks of therapy (especially if on insulin,
                                                                      sulfonylurea,
                                                                      and/or glinides). Consider discontinuing any sulfonylurea or
                                                                      glinide. For patients taking insulin, consider modestly reducing
                                                                      total daily insulin dose (by up to 20%).</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Educate patients regarding symptoms of diabetic ketoacidosis
                                                                      (nausea, vomiting, abdominal pain, weakness) and that diabetic
                                                                      ketoacidosis can occur even if blood glucose readings are in the
                                                                      150&ndash;250 mg/dL range. If patient experiences diabetic
                                                                      ketoacidosis-like symptoms, he/she should be instructed to seek
                                                                      urgent medical attention.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Educate patients regarding foot care, especially in patients
                                                                      with
                                                                      diabetic neuropathy. Ask patients to report any foot wounds
                                                                      immediately.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                  </tbody>
                                              </table>
                                              <p>CV = cardiovascular; HbA1c = hemoglobin A1c; SGLT2 = sodium-glucose cotransporter-2.
                                              </p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                                  <div>
                                      <h2 class="toggle considerations-for-drug-header"><i class="fa fa-holder"></i><span
                                              class="text">
                                              Considerations for Drug Initiation and Monitoring in Patients Starting a GLP-1RA with
                                              Demonstrated CV Benefit</span></h2>
                                      <div class="collapsable-panel ">
                                          <div class="bar close">
                                              <a class="action-btn close" data-bind="click:panelHide"> <i
                                                      class="fa fa-holder"></i>close</a>
                                          </div>
                                          <div class="content considerations-for-drug">
                                              <table class="table ">
                                                  <tbody>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>If HbA1c is well-controlled at baseline or known history of
                                                                      frequent
                                                                      hypoglycemic events, wean or stop sulfonylurea and consider
                                                                      reducing
                                                                      total daily insulin dose by ~20% when starting therapy.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Instruct patients to more closely monitor glucose at home for
                                                                      the
                                                                      first 4 weeks of therapy. Consider discontinuing any
                                                                      sulfonylurea or
                                                                      glinide. For patients taking insulin, consider modestly reducing
                                                                      total daily insulin dose (by up to 20%).</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Discontinue DPP-4 inhibitor before starting.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>To mitigate nausea, recommend small portion sizes for meals,
                                                                      start
                                                                      at the lowest dose, and up-titrate as tolerated toward the goal
                                                                      doses used in CV outcome trials.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Advise patients to undergo appropriate, guideline-recommended
                                                                      eye
                                                                      examinations before starting therapy if not done within the last
                                                                      12
                                                                      months.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Discuss potential risk of diabetic retinopathy complications
                                                                      (for
                                                                      dulaglutide or injectable semaglutide).</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                      <tr>
                                                          <td>
                                                              <ul>
                                                                  <li>Avoid in patients with diabetic gastroparesis or active
                                                                      gallbladder
                                                                      disease.</li>
                                                              </ul>
                                                          </td>
                                                      </tr>
                                                  </tbody>
                                              </table>
                                              <p>CV = cardiovascular; DPP4 = dipeptidyl peptidase-4; GLP-1RA = glucagon-like peptide-1
                                                  receptor agonist; HbA1c = hemoglobin A1c.</p>
                                          </div>
                                          <div class="bar jumpToTop">
                                              <a class="action-btn top" data-bind="click:panelScrollTop"> <i
                                                      class="fa fa-holder"></i>top</a>
                                          </div>
                                      </div>
                                  </div>
                              </div>
                          </div>
              <div data-bind="page: {id:'clinical_tobacco',afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Tobacco Cessation</h1>
                  <div data-bind="ui-accordion: {}" class="accordion">
                      <div>
                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Guideline Recommendations for Tobacco Cessation</span></h2>
                          <div class="collapsable-panel ">
                              <div class="bar close tobacco-cessation">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                              <div class="content">
                                  <table class="recommendationTable  table">
                                      <thead>
                                          <tr class="recommendationLevel1">
                                              <th colspan="3" class="text-center">Recommendations for Tobacco Treatment</th>
                                          </tr>
                                      </thead>
                                      <tbody>
                                          <tr>
                                              <td><b>COR</b></td>
                                              <td><b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b></td>
                                              <td class="text-center"><b>Recommendations</b></td>
                                          </tr>
                                          <tr>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                              <td>1. All adults should be assessed at every visit for tobacco use and their tobacco use status recorded as a vital sign to facilitate tobacco cessation.</td>
                                          </tr>
                                          <tr>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                              <td>2.	All adults who use tobacco should be firmly advised to quit in order to achieve tobacco abstinence.</td>
                                          </tr>
                                          <tr>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                              <td>3.	In adults who use tobacco, a combination of behavioral interventions plus pharmacotherapy is recommended to maximize quit rates.</td>
                                          </tr>
                                          <tr>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-B"> B-NR </td>
                                              <td>4.	In adults who use tobacco, tobacco abstinence is recommended to reduce ASCVD risk.</td>
                                          </tr>
                                          <tr>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B-R </td>
                                              <td>5.	It is reasonable to dedicate trained staff to tobacco treatment in every health system to facilitate tobacco cessation.</td>
                                          </tr>
                                          <tr>
                                              <td class="No-Benifit text-center"> III: <br/> Harm </td>
                                              <td class="LOE-B"> B-NR </td>
                                              <td>6.	All adults and adolescents should avoid secondhand smoke exposure to reduce ASCVD risk.</td>
                                          </tr>
                                      </tbody>
                                  </table>
                              </div>
                              <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                              </div>
                          </div>
                      </div>
                      <div>
                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Clinician Pharmacotherapy Tool: Tobacco Cessation for Patients with Cardiovascular Disease</span></h2>
                          <div class="collapsable-panel ">
                              <div class="bar close">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                              <div class="content">
                                  <ul>
                                      <li>This tool was developed to complement the 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment, which provides clinicians with the framework and guidance in delivering effective smoking cessation therapy for adult patients with cardiovascular disease (CVD) in a clinical practice setting.</li>
                                      <li>Clinicians can use this tool once they’ve decided to combine pharmacotherapy with behavioral interventions, to review recommended 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> line interventions for outpatients with stable CVD and for inpatients with acute coronary syndrome. It provides specific information on medications, dosing, administration, side effects, and advantages/disadvantages of each therapy.</li>
                                  </ul>
                                  <p><a class="link" href="http://www.acc.org/tobaccocessation" target="_blank">View the Clinician Pharmacotherapy Tool</a></p>
                              </div>
                              <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                              </div>
                          </div>
                      </div>
                      <div>
                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Examples of Behavioral Interventions for Nicotine Dependence</span></h2>
                          <div class="collapsable-panel ">
                              <div class="bar close">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                              <div class="content">
                                  <p>The below table is from the 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.</p>
                                  <table class="table">
                                      <thead>
                                          <tr>
                                              <th colspan="2" class="text-center">Examples of Behavioral Interventions for Nicotine Dependence</th>
                                          </tr>
                                      </thead>
                                      <tbody>
                                          <tr>
                                              <td><b>Treatment</b></td>
                                              <td><b>Examples</b></td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Cognitive behavioral skills training </td>
                                              <td>
                                                  <p>Instructions, modeling, rehearsal, and feedback to teach smokers how to change their smoking behavior. Examples include: </p>
                                                  <ol>
                                                      <li>Self-monitoring to identify triggers for smoking. Smokers are asked to keep a real-time record of the times, places, and situations in which smoking occur. </li>
                                                      <li>Behavioral rehearsals such as practice quit attempts and practicing how to respond to a lapse back to smoking.</li>
                                                      <li>Practicing self-control over smoking triggers. Avoiding triggers (e.g., putting away ashtrays, abstaining from alcohol), altering trigger situations (e.g., taking work breaks in a place in which you cannot smoke), using substitutes in place of smoking (e.g., gum, candy, a stress ball, exercise), and refocusing thoughts when cravings arise (e.g., statements of self-determination such as “I can do this”; delay statements such as “wait a minute or 2 and the urge will pass”). </li>
                                                      <li>Assertiveness training to help smokers better handle social situations likely to trigger cues to smoking. </li>
                                                      <li>Instruction and training (e.g., deep breathing, yoga, mindfulness training) for handling stress and negative emotions that are often linked to smoking urges. </li>
                                                      <li>Instructions on how to use medications properly to increase medication adherence and quit rates.</li>
                                                      <li>Biofeedback to smokers using a simple breath test measuring expired carbon monoxide to educate patients about immediate health risks. from smoking and enhance motivation for cutting down and quitting</li>
                                                      <li>Facilitated discussion with a group of smokers to share effective behavior change experiences and challenges.</li>
                                                  </ol>
                                              </td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Motivational interviewing</td>
                                              <td>Motivational interviewing is a goal-oriented, client-centered counseling style that aims to elicit behavior change by helping smokers explore and resolve ambivalence about making changes in their behavior. The method relies on the counselor eliciting from the client their own motivations for change, rather than imposing a treatment plan on the smoker.   </td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Incentives</td>
                                              <td>Incentives, usually provided as cash or vouchers, can be used to motivate smokers to try to quit and to reward them for making changes in their smoking behaviors. </td>
                                          </tr>
                                      </tbody>
                                  </table>
                              </div>
                              <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                              </div>
                          </div>
                      </div>
                      <div>
                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Community-based Behavioral Support Resources to Help Smokers Quit</span></h2>
                          <div class="collapsable-panel ">
                              <div class="bar close">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                              <div class="content">
                                  <p>The below table is from the 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.</p>
                                  <table class="table">
                                      <thead>
                                          <tr>
                                              <th colspan="2" class="text-center">Community-based Behavioral Support Resources to Help Smokers Quit</th>
                                          </tr>
                                      </thead>
                                      <tbody>
                                          <tr>
                                              <td><b>Resource</b></td>
                                              <td class="text-center"><b>Services Provided</b></td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Telephone Quitline <br/>1-800-QUIT-NOW <br/>(1-800-784-8669)
                                              </td>
                                              <td>
                                                  <ul>
                                                      <li>Counseling by telephone from a trained tobacco coach who offers support via a series of scheduled telephone calls before and after a smoker’s quit date.</li>
                                                      <li>Many Quitlines also offer text messaging and web coaching support.  </li>
                                                      <li>Many Quitlines also offer a free sample of non-prescription nicotine replacement products.</li>
                                                      <li>Providers can directly refer to Quitlines using fax or web enrollments. Quitline then contacts smoker directly to offer services.</li>
                                                  </ul>
                                              </td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Smokefree.gov <br/>(National Cancer Institute website)</td>
                                              <td>
                                                  <ul>
                                                      <li>SmokefreeTXT (text messaging program)</li>
                                                      <li>QuitGuide (mobile phone app)</li>
                                                      <li>Web-based information about quitting resources</li>
                                                  </ul>
                                              </td>
                                          </tr>
                                          <tr>
                                              <td class="top-aligned">Becomeanex.org <br/>(Truth Initiative)</td>
                                              <td><ul><li>Web-based support program that includes support from experts and an online community to help smokers quit</li></ul></td>
                                          </tr>
                                      </tbody>
                                  </table>
                              </div>
                              <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                              </div>
                          </div>
                      </div>
                  </div>
              </div>
              <div data-bind="page: {id:'statin',afterShow: listchange}" class="group-section">
                                  <h1 class="with-underline">Groups that Benefit from Statin Therapy</h1>
                                  <div data-bind="ui-accordion: {}" class="accordion">
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">1. Secondary Prevention:</span> <span class="sub-line">Clinical ASCVD</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <p>Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin.</p>
                                                  <p>High-intensity statin therapy should be initiated or continued as first-line therapy in women and men &le;75 years of age who have clinical ASCVD, unless contraindicated (I, A).</p>
                                                  <p>In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated (I, A).</p>
                                                  <p>In individuals with clinical ASCVD &gt;75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it (IIa, B).</p>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">2. Primary Prevention: </span> <span class="sub-line">LDL-C &ge;190 mg/dL</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <p>Individuals with LDL-C &ge;190 mg/dL or triglycerides &ge;500 mg/dL should be evaluated for secondary causes of hyperlipidemia (I, B).</p>
                                                  <p>Adults &ge;21 years of age with primary LDL-C &ge;190 mg/dL should be treated with high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity (I, B). </p>
                                                  <p>For individuals &ge;21 years of age with an untreated primary LDL-C &ge;190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction (IIa, B). </p>
                                                  <p>For individuals &ge;21 years of age with an untreated primary LDL-C &ge;190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a nonstatin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences (IIb, C). </p>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">3. Primary Prevention:</span><span class="sub-line"> Diabetes and aged 40 to 75 years with LDL-C between 70 - 189 mg/dL</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <p>Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. (I A)</p>
                                                  <p>High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a &ge;7.5% estimated 10-year ASCVD risk unless contraindicated (IIa, B).</p>
                                                  <p>In adults with diabetes mellitus, who are &lt;40 or &gt;75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy (IIa, C).</p>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">4. Primary Prevention: </span><span class="sub-line">No diabetes and estimated 10-year ASCVD risk of &ge;7.5% who are between 40 to 75 years of age with LDL-C between 70 - 189 mg/dL</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <p> The Pooled Cohort Equations should be used to estimate 10-year ASCVD risk for individuals with LDL-C 70 to 189 mg/dL without clinical ASCVD to guide initiation of statin therapy for the primary prevention of ASCVD (I, B). </p>
                                                  <p> Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 - 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment (IIa, C). </p>
                                                  <p> Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk &ge;7.5% should be treated with moderate- to high-intensity statin therapy (I, A). </p>
                                                  <p> It is reasonable to offer treatment with a moderate-intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk of 5% to &lt;7.5% (IIa, B). </p>
                                                  <p> In adults with LDL-C &lt;190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk-based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preferences (IIb, C). </p>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Additional Factors</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <p><strong>These factors may include:</strong></p>
                                                  <p>Statin benefit may be less clear in other groups; additional factors may be considered to inform treatment decision making.</p>
                                                  <ol>
                                                      <li>5 to &lt;7.5% 10-year ASCVD risk</li>
                                                      <li>Primary LDL-C &ge;160 mg/dL or other evidence of genetic hyperlipidemias</li>
                                                      <li>Family history of premature ASCVD</li>
                                                      <li>High sensitivity C-reactive protein &ge;2 mg/L</li>
                                                      <li>Coronary artery calcium score &ge;300 Agatston units or &ge;75th percentile for age, sex, and ethnicity</li>
                                                      <li>Ankle-brachial index &lt;0.9</li>
                                                      <li>Lifetime risk of ASCVD</li>
                                                  </ol>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                  </div>
                              </div>
              <div data-bind="page: {id:'summary_recommendations',afterShow: listchange}" class="group-section">
                                  <h1>
      	Blood Cholesterol Recommendation Summary
      </h1>
                                  <table class="recommendationTable table">
                                      <thead>
                                          <tr class="recommendationTableHeaders swappable medium">
                                              <th>
                                                  <div class=""> <strong class="left long-text">
      						Recommendations
      					</strong> <strong class="left short-text">
      						REC
      					</strong> </div> <small class="left">
      					<a href="#!/content/clinician-split-layout/statin_dose" class="link">
      						Click here for Definitions of Statin Intensity
      					</a>
      				</small> </th>
                                              <th> <small class="short-text">
      					ACC/ AHA
      				</small> <small class="long-text">
      					ACC/AHA
      				</small> <strong>
      					COR
      				</strong> </th>
                                              <th> <small class="short-text">
      					ACC/ AHA
      				</small> <small class="long-text">
      					ACC/AHA
      				</small> <strong>
      					LOE
      				</strong> </th>
                                          </tr>
                                      </thead>
                                      <tbody>
                                          <tr>
                                              <td class="recommendationLevel1" colspan="3"> A. Heart-healthy lifestyle habits should be encouraged for all individuals. </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel1" colspan="3"> B <em>
      					.
      				</em> The appropriate intensity of statin therapy should be initiated or continued: <em></em> </td>
                                          </tr>
                                          <tr>
                                              <td colspan="3" class="recommendationLevel2"> 1. Clinical ASCVD* </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Age &le;75 y and no safety concerns: High-intensity statin </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> b. Age &gt;75 y or safety concerns: Moderate-intensity statin </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 2. Primary prevention &ndash; Primary LDL&ndash;C &ge;190 mg/dL </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Rule out secondary causes of hyperlipidemia </td>
                                              <td colspan="2"></td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> b. Age &ge;21y: High-intensity statin </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> c. Achieve at least a 50% reduction in LDL&ndash;C </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> d. LDL&ndash;C lowering nonstatin therapy may be considered to further reduce LDL&ndash;C </td>
                                              <td class="CORIIb"> IIb </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 3. Primary prevention &ndash; Diabetes 40-75 years of age and LDL&ndash;C 70-189 mg/dL </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Moderate-intensity statin </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> b. Consider high-intensity statin when &ge;7.5% 10-y ASCVD risk using the Pooled Cohort Equations&dagger; </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 4. Primary prevention &ndash; No diabetes 40-75 years of age and LDL&ndash;C 70-189 mg/dL </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equations&dagger; in those NOT receiving a statin; estimate risk every 4-6 y </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> b. To determine whether to initiate a statin, engage in a clinician-patient discussion of the potential for ASCVD risk reduction, adverse effects, drug-drug interactions, and patient preferences. </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> c. Re-emphasize heart-healthy lifestyle habits and address other risk factors. </td>
                                              <td colspan="2"></td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> i. &ge;7.5% 10-y ASCVD risk: Moderate- or high-intensity statin </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> ii. 5 to &lt;7.5% 10-y ASCVD risk: Consider moderate-intensity statin </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> iii. Other factors may be considered&Dagger;: LDL&ndash;C &ge;160 mg/dL, family history of premature cardiovascular disease, hs-CRP &ge;2.0 mg/L, CAC score &ge;300 Agaston units, ABI &lt;0.9 or lifetime ASCVD risk </td>
                                              <td class="CORIIb"> IIb </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 5. Primary prevention when LDL&ndash;C &lt;190 mg/dL and age &lt;40 or &gt;75 y, or &lt;5% 10-y ASCVD risk </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Statin therapy may be considered in selected individuals&Dagger; </td>
                                              <td class="CORIIb"> IIb </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 6. Statin therapy is not routinely recommended for individuals with NYHA class II-IV heart failure or who are receiving maintenance hemodialysis </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel1" colspan="3"> C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments. </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2"> 1. Assess adherence, response to therapy, and adverse effects within 4-12 wk following statin initiation or change in therapy. </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> a. Measure a fasting lipid panel </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> b. Do not routinely monitor ALT or CK unless symptomatic </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> c. Screen and treat type 2 diabetes according to current practice guidelines. Heart-healthy lifestyle habits should be encouraged to prevent progression to diabetes </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> d. Anticipated therapeutic response approximately &ge;50% reduction in LDL&ndash;C from baseline for high-intensity statin and 30% to &lt;50% for moderate-intensity statin </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> i. Insufficient evidence for LDL&ndash;C or non-HDL-C treatment targets from RCTs </td>
                                              <td colspan="2"></td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> ii. For those with unknown baseline LDL&ndash;C, an LDL&ndash;C &lt;100 mg/dL was observed in RCTs of high-intensity statin therapy </td>
                                              <td colspan="2"></td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> e. Less than anticipated therapeutic response: </td>
                                              <td colspan="2"></td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> i. Reinforce improved adherence to lifestyle and drug therapy </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> ii. Evaluate for secondary causes of hyperlipidemia if indicated </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel4"> iii. Increase statin intensity, or if on maximally-tolerated statin intensity, consider addition of nonstatin therapy in selected high-risk individuals&sect; </td>
                                              <td class="CORIIb"> IIb </td>
                                              <td class="LOE-C"> C </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel3"> f. Regularly monitor adherence to lifestyle and drug therapy every 3-12 mo once adherence has been established. Continued assessment of adherence for optimal ASCVD risk reduction and safety. </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-A"> A </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel1"> D. In individuals intolerant of the recommended intensity of statin therapy, use the maximally-tolerated intensity of statin. </td>
                                              <td class="CORI"> I </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2"> 1. If there are muscle or other symptoms, establish that they are related to the statin </td>
                                              <td class="CORIIa"> IIa </td>
                                              <td class="LOE-B"> B </td>
                                          </tr>
                                          <tr>
                                              <td class="recommendationLevel2" colspan="3"> 2. For specific recommendations on managing muscle symptoms <a href="#!/content/clinician-split-layout/clinical_reference_safety_recomendations" class="link">
      					(see Statin Safety Recommendations)
      				</a> </td>
                                          </tr>
                                      </tbody>
                                  </table>
                                  <div class="row">
                                      <p class="quiet"> <strong>
      			*
      		</strong> Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. </p>
                                      <p class="quiet"> <strong>
      			&dagger;
      		</strong> Estimated 10-year or &quot;hard&quot; ASCVD risk includes first occurrence of nonfatal MI, CHD death, and nonfatal and fatal stroke as used by the Risk Assessment Work Group in developing the Pooled Cohort Equations. </p>
                                      <p class="quiet"> <strong>
      			&Dagger;
      		</strong> These factors may include primary LDL&ndash;C &ge;160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset &lt;55 years of age in a first-degree male relative or &lt;65 years of age in a first-degree female relative; hs-CRP &ge;2 mg/L; CAC score &ge;300 Agatston units or &ge;75 <sup>
      			th
      		</sup> percentile for age, sex, and ethnicity; ABI &lt;0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment could be identified in the future. </p>
                                      <p class="quiet"> <strong>
      			&sect;
      		</strong> High-risk individuals include those with clinical ASCVD, an untreated LDL&ndash;C &ge;190 mg/dL suggesting genetic hypercholesterolemia, or diabetes. </p>
                                      <p class="quiet"> ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ALT, alanine aminotransferase, a test of hepatic function; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; CK, creatine kinase, a test of muscle injury; COR, Class of Recommendation; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL&ndash;C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, New York Heart Association; RCTs, randomized controlled trials; and TIA, transient ischemic attack. </p>
                                  </div>
                              </div>
              <div data-bind="page: {id:'guideline_flowchart',afterShow: listchange}" class="group-section flow-chart">
                                  <h1 class="with-underline">Primary Prevention of ASCVD - Summary </h1>
                                  <div class="holder primary-prevention-panzoom">
                                      <div class="parent panzoom" style="margin: 0;">
                                          <div class="panzoom-element"> <img
                                              src="assets/img/squared_metal_@2X.png" data-src="assets/graphics/new-primary-prevention.svg" alt="Primary Prevention" style="width:100%"> </div>
                                      </div>
                                  </div>
                                  <div class="row">
                                      <p class="text">apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery 	calcium; HIV, human immunodeficiency virus; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density 	lipoprotein cholesterol; and Lp(a), lipoprotein (a).</p>
                                  </div>
                              </div>
              <div data-bind="page: {id:'statin_dose',afterShow: listchange}" class="group-section">
                                  <div data-bind="template: {name: 'statin-intensity-table-resource-section'}" style="overflow: auto"></div>
                              </div>
              <div data-bind="page: {id:'monitor_flowchart',afterShow: listchange}" class="group-section flow-chart">
                      <h1>Recommendations to Monitor Response to LDL-C Lowering Therapy</h1>

                      <table class="recommendationTable table">
                          <thead>
                              <tr class="recommendationLevel1">
                                  <th colspan="3" class="text-center">Recommendations to Monitor Response to LDL-C Lowering Therapy</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr>
                                  <td> <b>COR</b> </td>
                                  <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                                  <td class="text-center"> <b>Recommendations</b> </td>
                              </tr>
                              <tr>
                                  <td class="CORI"> I </td>
                                  <td class="LOE-A"> A </td>
                                  <td> 1.	Adherence to changes in lifestyle and effects of LDL-C–lowering medication should be assessed by measurement of fasting lipids and appropriate safety indicators 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter based on need to assess adherence or safety.   </td>
                              </tr>
                              </tbody>
                      </table>

              </div>
              <div data-bind="page: {id:'clinical_reference_safety_recomendations',afterShow: listchange}" class="group-section">
                                  <h1 class="with-underline">Statin Safety Recommendations</h1>

                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Recommendations for Statin Safety and Statin-Associated Side Effects</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 1.	A clinician–patient risk discussion is recommended before initiation of statin therapy to review net clinical benefit, weighing the potential for ASCVD risk reduction against the potential for statin-associated side effects, statin–drug interactions, and safety, while emphasizing that side effects can be addressed successfully.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 2.	In patients with statin-associated muscle symptoms (SAMS), a thorough assessment of symptoms is recommended, in addition to an evaluation for nonstatin causes and predisposing factors.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 3.	In patients with indication for statin therapy, identification of potential predisposing factors for statin-associated side effects, including new-onset diabetes mellitus and SAMS, is recommended before initiation of treatment.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 4.	In patients with statin-associated side effects that are not severe, it is recommended to reassess and to rechallenge to achieve a maximal LDL-C lowering by modified dosing regimen, an alternate statin or in combination with nonstatin therapy.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 5.	In patients with increased diabetes mellitus risk or new-onset diabetes mellitus, it is recommended to continue statin therapy, with added emphasis on adherence, net clinical benefit, and the core principles of regular moderate-intensity physical activity, maintaining a healthy dietary pattern, and sustaining modest weight loss.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 6.	In patients treated with statins, it is recommended to measure creatine kinase levels in individuals with severe statin-associated muscle symptoms, objective muscle weakness, and to measure liver transaminases (aspartate aminotransferase, alanine aminotransferase) as well as total bilirubin and alkaline phosphatase (hepatic panel) if there are symptoms suggesting hepatotoxicity.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 7.	In patients at increased ASCVD risk with chronic, stable liver disease (including non-alcoholic fatty liver disease) when appropriately indicated, it is reasonable to use statins after obtaining baseline measurements and determining a schedule of monitoring and safety checks.  </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 8.	In patients at increased ASCVD risk with severe statin-associated muscle symptoms or recurrent statin-associated muscle symptoms despite appropriate statin rechallenge, it is reasonable to use RCT proven nonstatin therapy that is likely to provide net clinical benefit. </td>
                          </tr>
                          <tr>
                              <td class="No-Benifit"> III: No Benefit </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 9.	Coenzyme Q10 is not recommended for routine use in patients treated with statins or for the treatment of SAMS. </td>
                          </tr>
                          <tr>
                              <td class="No-Benifit"> III: No Benefit </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 10. In patients treated with statins, routine measurements of creatine kinase and transaminase levels are not useful. </td>
                          </tr>
                      </tbody>
                  </table>

                              </div>
              <div data-bind="page: {id:'oral_hypertensive_drug_dosing',afterShow: listchange}" class="group-section flow-chart">
                                  <h1>Oral Antihypertensive Drug Dosing and Usage</h1>
                                  <div class="holder oral-antihypertensive-panzoom">
                                      <div class="parent panzoom" style="margin: 0;">
                                          <div class="panzoom-element"> <img src="assets/img/squared_metal_@2X.png" data-src="assets/graphics/DrugTablev2.svg" alt="oral antihypertensive drug dosing and usage"> </div>
                                      </div>
                                  </div>

                              </div>
              <div data-bind="page: {id:'nonpharmacologic_blood_pressure_interventions',afterShow: listchange}" class="group-section flow-chart">
                                  <h1>Nonpharmacologic Hypertension Interventions</h1>
                                  <div class="holder nonpharmacologic-hypertension-panzoom">
                                      <div class="parent panzoom" style="margin: 0;">
                                          <div class="panzoom-element"> <img src="assets/img/squared_metal_@2X.png" data-src="assets/graphics/NonDrugTable.svg" alt="nonpharmacologic hypertension interventions"> </div>
                                      </div>
                                  </div>

                              </div>
              <div data-bind="page: {id:'prescribing_information',afterShow: listchange}" class="group-section">
                                  <h3>Statin</h3>
                                  <nav class="nav nav-list small" id="prescribing-information-links">
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020702s073lbl.pdf"> <span class="text">Atorvastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf"> <span class="text">Fluvastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf"> <span class="text">Fluvastatin XL</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022363s012lbl.pdf"> <span class="text">Pitavastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf"> <span class="text">Pravastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021366s031lbl.pdf"> <span class="text">Rosuvastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019766s093lbl.pdf"> <span class="text">Simvastatin</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>Beta blockers</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019982s016lbl.pdf"> <span class="text">Bisoprolol</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020297s037lbl.pdf"> <span class="text">Carvedilol </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019962s044lbl.pdf"> <span class="text">Metoprolol succinate </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>ACEs</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018343s084lbl.pdf"> <span class="text">Captopril</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208686s000lbl.pdf"> <span class="text">Enalapril (Epaned) </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018998s080lbl.pdf"> <span class="text">Enalapril (vasotec)</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf"> <span class="text">Fosinopril</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019777s074lbl.pdf"> <span class="text">Lisinopril  (Zestril)</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019558s060lbl.pdf"> <span class="text">Lisinopril  (Prinivil)</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208401s000lbl.pdf"> <span class="text">Lisinopril  (Qbrelis)</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020184s022lbl.pdf"> <span class="text">Perindopril</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019885s042lbl.pdf"> <span class="text">Quinapril</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019901s065lbl.pdf"> <span class="text">Ramipril</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>ARBs</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020838s039lbl.pdf"> <span class="text">Candesartan </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf"> <span class="text">Losartan </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf"> <span class="text">Valsartan </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>ARNIs</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf"> <span class="text">Sacubitril </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdf"> <span class="text">Valsartan  </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>Aldosterone antagonists </h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021437s013lbl.pdf"> <span class="text">Eplerenone </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012151s072lbl.pdf"> <span class="text">Spironolactone </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>Vasodilators</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf"> <span class="text">Hydralazine  </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdf"> <span class="text">Isosorbide dinitrate (Dilatrate-SR) </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/012093s052lbl.pdf"> <span class="text">Isosorbide dinitrate (Isordil) </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020727s005lbl.pdf"> <span class="text">Fixed dose combination isosorbide dinitrate/hydralazine </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                      <h3>Aspirin</h3>
                                      <ul>
                                          <li>
                                              <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203697Orig1s000lbl.pdf"> <span class="text">Aspirin (over-the-counter) </span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                  </nav>
                              </div>
              <div data-bind="page: {id:'terms_conditions',afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Terms and Concepts </h1>
                  <div>
                      <p><strong>ASCVD:</strong>atherosclerotic cardiovascular disease, defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke </p>
                      <p><strong>ABCS Therapies: </strong>Aspirin therapy in appropriate patients, Blood pressure control, Cholesterol management, and Smoking cessation </p>
                      <p><strong>Initial Visit: </strong> </p>
                      <div class="row">
                          <div class="column small-12">
                              <p> - First time a patient undergoes an ASCVD risk assessment with a particular clinician and initiates a discussion regarding the benefits of starting (or intensifying) therapy with aspirin, blood pressure lowering medication, cholesterol lowering medication, and/or smoking/tobacco cessation (ABCS) as part of a risk-reduction plan. The 10-year ASCVD risk determined at the initial visit should also be used as a benchmark with which to compare updated risk at follow-up visit.</p>
                              <p> - The patient may have already initiated any of the ABCS therapies prior to the initial visit, individually or in combination.</p>
                              <p><i>10-year ASCVD risk calculated at the initial visit, without comparison to a previous visit:</i></p>
                              <p> - The initial 10-year ASCVD Risk serves as a baseline or reference-point risk. The patient parameters used to calculate are also needed to calculate a representative follow-up risk, and the initial risk value itself serves as a comparison point for follow up risk.</p>
                          </div>
                      </div>
                      <p><strong>Follow Up Visit:</strong>Any visit after the established initial visit at which an updated 10-year ASCVD risk is calculated based on updated clinical and laboratory values. </p>
                      <p><strong>Optimal Risk:</strong>Predicted 10-year ASCVD risk for someone with the same age and race/ethnicity category who has an optimal risk factor profile (total cholesterol, 170 mg/dL; HDL-cholesterol, 60 mg/d; SBP, 110 mm Hg; nonsmoker; non-diabetic; and no blood pressure–lowering drugs). </p>
                      <p><strong>Smokers:</strong>For the purposed of this app, smokers are defined as cigarette smokers in accordance with the patient populations studied in the relevant clinical trials used to develop the tool. Clinical judgement should be exercised in the case of patient’s who use e-cigarettes and other nicotine and tobacco products. </p>
                      <p><strong>Lifestyle:</strong>AHA/ACC guidelines stress the importance of lifestyle modifications as the foundation to lowering cardiovascular disease risk. These include eating a heart-healthy diet, regular aerobic exercises, maintenance of desirable body weight and avoidance of tobacco products. The evidence base for this specific tool focused on average patient responses to the ABCS therapies (aspirin when appropriate, blood pressure control, cholesterol management, and smoking cessation). Evidence for quantification of benefit from individual therapeutic lifestyle interventions is currently lacking and was out of the scope for this tool. However, the tool is intended to guide decision-making around ABCS in the context of, and in addition to, recommended lifestyle interventions. Benefit from lifestyle intervention is reflected in the app’s updated 10-year risk calculation at a follow up visit through the “credit” given for improvement of patient’s LDL-C and/or systolic blood pressure, regardless of how that improvement was achieved. </p>
                      <h3>How are the different risk values in the app calculated?</h3>
                      <p><strong>Lifetime ASCVD Risk:</strong></p>
                      <p>Estimates of lifetime risk for ASCVD are provided for adults 20 through 59 years of age and are shown as the lifetime risk for ASCVD for a 50-year old without ASCVD who has the risk factor values entered at the initial visit. Because the primary use of these lifetime risk estimates is to facilitate the very important discussion regarding risk reduction through lifestyle change, the imprecision introduced is small enough to justify proceeding with lifestyle change counseling informed by these results.</p>
                      <strong>Estimated 10 Year ASCVD Risk</strong>
                      <div class="row">
                          <div class="column small-12">
                              <p><span class="text-highlight-color">At Initial Visit (without comparison to a previous visit): </span>Calculated using the ACC/AHA 2013 Pooled Cohort Equation, which predict the absolute 10-year risk for an ASCVD for a patient with the profile entered at initial visit. This is the same as the previous version of the ASCVD Risk Estimator app. </p>
                              <p><span class="text-highlight-color">At Follow-up visit (with comparison to a previous visit):</span> Updated 10-year risk for ASCVD is a function of the initial visit risk, the follow-up age, and the interim change in therapies and risk factor levels, which are themselves a function of response to therapy and adherence. The confidence of the updated on-treatment risk estimate is improved by scaling the risk reduction to the amount of change in SBP or LDL-cholesterol or duration of smoking cessation. The values for the actual updated 10-year ASCVD risk estimate also have floor and ceiling values applied. The floor value is calculated as the predicted 10-year ASCVD risk for someone with optimal risk factor levels at the follow-up age. A patient’s 10-year risk at follow up will not be calculated to a value below this floor value. The ceiling value is the predicted 10-year ASCVD risk calculated from the actual updated risk factor profile, including use of medications. </p>
                          </div>
                      </div>
                      <strong>Projected 10 Year ASCVD Risk on the Therapy Impact Tab</strong>
                      <div class="row">
                          <div class="column small-12"> Numbers on Therapy Impact mode represent the projected 10-year ASCVD risk that would be associated with institution of specific preventive therapies as designated for each row by the scenarios selected by the user. These estimates are a function of the initial visit predicted 10-year risk from for the patient and the expected average relative risk reduction associated with a given therapy experienced by participants in randomized clinical trials, using systematic review data described in the original Million Hearts Longitudinal ASCVD Risk Assessment Tool manuscript. In instances where a therapy is not advised or relevant for a given patient based on the profile entered (smoking cessation for a patient who has never smoked), the forecasted risk for this therapy will be displayed as “NA”. See below for more information about individual therapies. </div>
                      </div>
                      <br>
                      <h3>What effect do the different ABCS therapies and related risk factors have on the calculations in the app? </h3>
                      <div class="row">
                          <div class="column small-12">
                              <p><strong>Systolic Blood Pressure and Blood Pressure Medications</strong></p>
                              <ul>
                                  <li>Risk reduction estimates related to blood pressure medication come from randomized controlled trials that have tended to last for 3 to 5 years, so it is assumed that patients who would start a blood pressure medication would stay on it for at least that period of time, and adhere to the therapy similarly to participants in the trials.</li>
                                  <li>If follow up risk is estimated for a patient who has not yet initiated blood pressure medication, and then a forecasted risk is calculated with the initiation of BP meds, the user may see the patient’s risk actually increase. This is because the app is forecasting what the patient’s risk would be if they had achieved the same blood pressure reduction they’ve already achieved, but with the aid of medication, and the calculation gives more “credit” for blood pressure reduction without the aid of medication than with. This same principle applies to the initial visit 10-year risk calculation. </li>
                                  <li>In terms for forecasting, for patients already taking blood pressure–lowering drugs, one can estimate the expected effect of additional medication. However, if a patient has an initial visit SBP &lt;120 mm Hg, or &lt;130 mm Hg with diabetes mellitus, no additional benefit of SBP lowering is assumed.</li>
                              </ul>
                              <p><strong>LDL-C and Statin Therapy</strong></p>
                              <ul>
                                  <li>As an update to the original ASCVD Risk Estimator, “Initial 10 year ASCVD risk may be calculated for patients who have already initiated statin therapy because recent evidence suggests a patient’s cholesterol values have the same the impact on ASCVD risk regardless of whether current values were achieved with or without the aid of statin therapy. However, the specific LDL-C value and statin use status at initial visit does still does not affect the initial visit 10-year risk calculation itself. They are only collected at initial visit to provide context for the forecasted risk reduction and to provide baseline values for updating ASCVD risk at follow-up visits.</li>
                                  <li>Patients with LDL-cholesterol of at least 190 mg/dL may have familial hypercholesterolemia and should be evaluated and considered for statin therapy regardless of age and estimated 10-year ASCVD risk.</li>
                                  <li>Risk reduction estimates related to statin therapy come from randomized controlled trials that have tended to last for 3 to 5 years, so it is assumed that patients who would start satin therapy would stay on it for at least that period of time, and adhere to the therapy similarly to participants in the trials. </li>
                                  <li>For patients with estimated 10-year ASCVD risk below 5%, users will see “NA” appear in initial visit forecast scenarios where statin use or intensification would be added, given that the guidelines do not recommend consideration of statin therapy for this group. </li>
                              </ul>
                              <p><strong>Aspirin Use</strong></p>
                              <ul>
                                  <li>Aspirin use status does not affect the initial visit 10-year risk calculation itself, but is collected at initial visit to provide context for the forecasted risk reduction and to provide baseline values for updating ASCVD risk at follow-up visits.</li>
                                  <li>If the patient is taking aspirin therapy at initial visit, the expected risk reduction for continuing aspirin is assumed to be the same as starting aspirin de novo, because it is uncertain how to quantify any increase in risk associated with aspirin cessation.</li>
                                  <li>For initial visit forecasting, patients with estimated 10- year ASCVD risk below 10%, users will see “NA” appear in rows where aspirin would be started because guidelines do not typically recommend consideration of aspirin therapy for patients with 10-year risk &lt;10%.</li>
                              </ul>
                              <p><strong>Smokers and Smoking Cessation</strong></p>
                              <ul>
                                  <li>The app calculations are based on studies that estimated the time-dependent effects of successful smoking cessation on ASCVD risk reduction (See the original Million Hearts Longitudinal ASCVD Risk Assessment Tool manuscript). As a result, the combined estimates for risk reduction associated with smoking cessation are 15% at 1 year, 27% at 2 years, 38% at 3 years, and 47% at 4 years. Because the risk reduction estimates for aspirin, blood pressure–lowering, and statins were based on trials with typical follow-up exceeding 2 years, the app uses the 2-year estimate for smoking cessation as the basis for prospective risk reduction estimation.</li>
                                  <li>For the purposed of this app, smokers are defined as cigarette smokers in accordance with the patient populations studied in the relevant clinical trials used to develop the tool. Clinical judgement should be exercised in the case of patient’s who use e-cigarettes and other nicotine and tobacco products.</li>
                                  <li>Counseling and efforts aimed at smoking cessation should be considered for all current smokers.</li>
                              </ul>
                          </div>
                      </div>
                  </div>
              </div>
              <div data-bind="page: {id: 'recommendation_class_and_evidence_level', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Class of Recommendation and Level of Evidence Table </h1>

                  <b>
                      Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated August 2015)
                  </b>
                   <p class="text italic">
                      Recommendations are designated with both a class of recommendation (COR) and a level of evidence (LOE).  The class of recommendation indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The level of evidence rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources.
                  </p>

                  <div class="row collapse-small-only">
                      <section class="columns small-12 medium-6 collapse-left">
                          <article class="recommendation-card gray">
                              <div class="card-header">
                                  <h5>CLASS (STRENGTH) OF RECOMMENDATION</h5>
                              </div>
                          </article>
                          <article class="recommendation-card green">
                              <div class="card-header">
                                  <span>CLASS I (STRONG)</span>
                                  <span class="float-right">Benefit &gt;&gt;&gt;Risk</span>
                              </div>
                              <div class="card-body">
                                  Suggested phrases for writing recommendations:
                                  <ul class="list-type-square">
                                      <li>Is recommended</li>
                                      <li>Is indicated/useful/effective/beneficial</li>
                                      <li>Should be performed/administered/other</li>
                                      <li>
                                          Comparative-Effectiveness Phrases†:
                                          <ul class="list-type-circle">
                                              <li>Treatment/strategy A is recommended/indicated in preference to treatment B</li>
                                              <li>Treatment A should be chosen over treatment B</li>
                                          </ul>
                                      </li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card yellow">
                              <div class="card-header">
                                  <span>CLASS IIa (MODERATE)</span>
                                  <span class="float-right">Benefit &gt;&gt;Risk</span>
                              </div>
                              <div class="card-body">
                                  Suggested phrases for writing recommendations:
                                  <ul class="list-type-square">
                                      <li>Is reasonable</li>
                                      <li>Can be useful/effective/beneficial</li>
                                      <li>
                                          Comparative-Effectiveness Phrases†:
                                          <ul class="list-type-circle">
                                              <li>Treatment/strategy A is probably recommended/indicated in preference to treatment B</li>
                                              <li>It is reasonable to choose treatment A over treatment B</li>
                                          </ul>
                                      </li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card orange">
                              <div class="card-header">
                                  <span>CLASS IIb (WEAK)</span>
                                  <span class="float-right">Benefit &ge; Risk</span>
                              </div>
                              <div class="card-body">
                                  Suggested phrases for writing recommendations:
                                  <ul class="list-type-square">
                                      <li>May/might be reasonable</li>
                                      <li>May/might be considered</li>
                                      <li>Usefulness/effectiveness is unknown/unclear/uncertain or not well established</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card pink">
                              <div class="card-header">
                                  <span>CLASS III: No Benefit (MODERATE)</span>
                                  <span class="float-right">Benefit = Risk</span><br/>
                                  <small class="italics">(Generally, LOE A or B use only)</small>
                              </div>
                              <div class="card-body">
                                  Suggested phrases for writing recommendations:
                                  <ul class="list-type-square">
                                      <li>Is not recommended</li>
                                      <li>Is not indicated/useful/effective/beneficial</li>
                                      <li>Should not be performed/administered/other</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card red">
                              <div class="card-header">
                                  <span>CLASS III: Harm (STRONG)</span>
                                  <span class="float-right">Risk &gt;Benefit</span>
                              </div>
                              <div class="card-body">
                                  Suggested phrases for writing recommendations:
                                  <ul class="list-type-square">
                                      <li>Potentially harmful</li>
                                      <li>Causes harm</li>
                                      <li>Assosciated with excess morbidity/mortality</li>
                                      <li>Should not be performed/administered/other</li>
                                  </ul>
                              </div>
                          </article>
                      </section>
                      <section class="columns small-12 medium-6 collapse-right">
                          <article class="recommendation-card gray">
                              <div class="card-header">
                                  <h5>LEVEL (QUALITY) OF EVIDENCEǂ</h5>
                              </div>
                          </article>
                          <article class="recommendation-card darkblue">
                              <div class="card-header">
                                  <span>LEVEL A</span>
                              </div>
                              <div class="card-body">
                                  <ul class="list-type-square">
                                      <li>High-quality evidenceǂ from more than 1 RCT</li>
                                      <li>Meta-analyses of high-quality RCTs</li>
                                      <li>One or more RCTs corroborated by high-quality registry studies</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card lightblue">
                              <div class="card-header">
                                  <span>LEVEL B-R</span>
                                  <span class="float-right">(Randomized)</span>
                              </div>
                              <div class="card-body">
                                  <ul class="list-type-square">
                                      <li>Moderate-quality evidenceǂ from 1 or more RCTs</li>
                                      <li>Meta-analyses of moderate-quality RCTs</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card lightblue">
                              <div class="card-header">
                                  <span>LEVEL B-NR</span>
                                  <span class="float-right">(Nonrandomized)</span>
                              </div>
                              <div class="card-body">
                                  <ul class="list-type-square">
                                      <li>Moderate-quality evidenceǂ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</li>
                                      <li>Meta-analyses of such studies</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card lighterblue">
                              <div class="card-header">
                                  <span>LEVEL C-LD</span>
                                  <span class="float-right">(Limited Data)</span>
                              </div>
                              <div class="card-body">
                                  <ul class="list-type-square">
                                      <li>Randomized or nonrandomized observational or registry studies with limitations of design or execution</li>
                                      <li>Meta-analyses of such studies</li>
                                      <li>Physiological or mechanistic studies in human subjects</li>
                                  </ul>
                              </div>
                          </article>
                          <article class="recommendation-card lighterblue">
                              <div class="card-header">
                                  <span>LEVEL C-EO</span>
                                  <span class="float-right">(Expert Opinion)</span>
                              </div>
                              <div class="card-body">
                                  <ul class="list-type-none">
                                      <li>Consensus of expert opinion based on clinical experience</li>
                                  </ul>
                              </div>
                          </article>
                          <small>
                              <p class="text">
                                  COR and LOE are determined independently (any COR may be paired with any LOE).
                              </p>
                              <p class="text">
                                  A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
                              </p>
                              <p class="text">
                                  <sup>*</sup>The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).
                              </p>
                              <p class="text">
                                  <sup>†</sup> For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
                              </p>
                              <p class="text">
                                  <sup>‡</sup> The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.
                              </p>
                              <p class="text">COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.</p>
                          </small>
                      </section>
                  </div>
              </div>
              <div data-bind="page: {id:'reference_external_links',afterShow: listchange}" class="group-section">
                                  <h1>External Links &amp; References</h1>
                                  <nav class="nav nav-list small" id="resources-external-links">
                                      <ul>
                                          <li>
                                              <a target="_blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S102.full.pdf"> <span class="text">2013  AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="http://circ.ahajournals.org/content/129/25_suppl_2/S76.full.pdf"> <span class="text">2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK63952/"> <span class="text">2008 AHRQ Guideline on Treating Tobacco Use and Dependence</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="http://www.acc.org/clinical-topics/dyslipidemia#sort=%40fwhatstrendingscore86069%20descending"> <span class="text">ACC Dyslipidemia Clinical Community</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                          <li>
                                              <a target="_blank" href="http://www.acc.org/education-and-meetings/education-catalog#f:TopicSearchFacet=[Dyslipidemia]"> <span class="text">Clinical  Vignettes</span><i class="fa fa-holder-dynamic"></i> </a>
                                          </li>
                                      </ul>
                                  </nav>
                              </div>
              <div data-bind="page: {id: 'accurate_bp_measurement', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Accurate BP Measurement</h1>
                  <table class="table">
                      <thead>
                          <tr class="row">
                              <th class="small-6 medium-4 top-aligned">Key Steps for Proper BP Measurements</th>
                              <th class="small-6 medium-8 top-aligned">Specific Instructions</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr class="row">
                              <td class="top-aligned">Step 1: Properly prepare the patient</td>
                              <td>
                                  <ol>
                                      <li>Have the patient relax, sitting in a chair (feet on floor, back supported) for >5 min.</li>
                                      <li>The patient should avoid caffeine, exercise, and smoking for at least 30 min before measurement.</li>
                                      <li>Ensure patient has emptied his/her bladder.</li>
                                      <li>Neither the patient nor the observer should talk during the rest period or during the measurement.</li>
                                      <li>Remove all clothing covering the location of cuff placement.</li>
                                      <li>Measurements made while the patient is sitting or lying on an examining table do not fulfill these criteria.</li>
                                  </ol>
                              </td>
                          </tr>
                          <tr class="row">
                              <td class="top-aligned">Step 2: Use proper technique for BP measurements</td>
                              <td>
                                  <ol>
                                      <li>Use a BP measurement device that has been validated, and ensure that the device is calibrated periodically.*</li>
                                      <li>Support the patient’s arm (e.g., resting on a desk).</li>
                                      <li>Position the middle of the cuff on the patient’s upper arm at the level of the right atrium (the midpoint of the sternum).</li>
                                      <li>Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or smaller-than-normal cuff size is used.</li>
                                      <li>Either the stethoscope diaphragm or bell may be used for auscultatory readings.</li>
                                  </ol>
                              </td>
                          </tr>
                          <tr class="row">
                              <td class="top-aligned">Step 3: Take the proper measurements needed for diagnosis and treatment of elevated BP/hypertension</td>
                              <td>
                                  <ol>
                                      <li>At the first visit, record BP in both arms. Use the arm that gives the higher reading for subsequent readings.</li>
                                      <li>Separate repeated measurements by 1–2 min.</li>
                                      <li>For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP. Inflate the cuff 20–30 mm Hg above this level for an auscultatory determination of the BP level.</li>
                                      <li>For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.</li>
                                  </ol>
                              </td>
                          </tr>
                          <tr class="row">
                              <td class="top-aligned">Step 4: Properly document accurate BP readings</td>
                              <td>
                                  <ol>
                                      <li>Record SBP and DBP. If using the auscultatory technique, record SBP and DBP as onset of the first Korotkoff sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.</li>
                                      <li>Note the time of most recent BP medication taken before measurements.</li>
                                  </ol>
                              </td>
                          </tr>
                          <tr class="row">
                              <td class="top-aligned">Step 5: Average the readings</td>
                              <td>Use an average of ≥2 readings obtained on ≥2 occasions to estimate the individual’s level of BP.</td>
                          </tr>
                          <tr class="row">
                              <td class="top-aligned">Step 6: Provide BP readings to patient</td>
                              <td>Provide patients the SBP/DBP readings both verbally and in writing.</td>
                          </tr>
                      </tbody>
                  </table>
              </div>
              <div data-bind="page: {id: 'substances_that_can_elevate_bp', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Substances that Can Elevate BP</h1>
                      <table class="table">
                          <thead>
                              <tr class="row">
                                  <th class="small-6 medium-4 top-aligned">Agent</th>
                                  <th class="small-6 medium-8 top-aligned">Possible Management Strategy</th>
                              </tr>
                          </thead>
                          <tbody>
                              <tr class="row">
                                  <td class="top-aligned">Alcohol</td>
                                  <td>
                                      <ul>
                                          <li>Limit alcohol to ≤1 drink daily for women and ≤2 drinks for men</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Amphetamines (e.g., amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine)</td>
                                  <td>
                                      <ul>
                                          <li>Discontinue or decrease dose </li>
                                          <li>Consider behavioral therapies for ADHD </li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Antidepressants (e.g., MAOIs, SNRIs, TCAs)</td>
                                  <td>
                                      <ul>
                                          <li>Consider alternative agents (e.g., SSRIs) depending on indication</li>
                                          <li>Avoid tyramine-containing foods with MAOIs</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Atypical antipsychotics (e.g., clozapine, olanzapine)</td>
                                  <td>
                                      <ul>
                                          <li>Discontinue or limit use when possible</li>
                                          <li>Consider behavior therapy where appropriate</li>
                                          <li>Recommend lifestyle modification (see Section 6.2)</li>
                                          <li>Consider alternative agents associated with lower risk of weight gain, diabetes mellitus, and dyslipidemia (e.g., aripiprazole, ziprasidone) </li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Caffeine</td>
                                  <td>
                                      <ul>
                                          <li>Generally limit caffeine intake to &lt;300 mg/d </li>
                                          <li>Avoid use in patients with uncontrolled hypertension</li>
                                          <li>Coffee use in patients with hypertension is associated with acute increases in BP; long-term use is not associated with increased BP or CVD </li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Decongestants (e.g., phenylephrine, pseudoephedrine)</td>
                                  <td>
                                      <ul>
                                          <li>Use for shortest duration possible, and avoid in severe or uncontrolled hypertension</li>
                                          <li>Consider alternative therapies (e.g., nasal saline, intranasal corticosteroids, antihistamines) as appropriate</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Herbal supplements (e.g., Ma Huang [ephedra], St. John’s wort [with MAO inhibitors, yohimbine])</td>
                                  <td class="top-aligned">
                                      <ul>
                                          <li>Avoid use</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Immunosuppressants (e.g., cyclosporine)</td>
                                  <td>
                                      <ul>
                                          <li>Consider converting to tacrolimus, which may be associated with fewer effects on BP </li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Oral contraceptives</td>
                                  <td>
                                      <ul>
                                          <li>Use low-dose (e.g., 20–30 mcg ethinyl estradiol) agents  or a progestin-only form of contraception, or consider alternative forms of birth control where appropriate (e.g., barrier, abstinence, IUD)</li>
                                          <li>Avoid use in women with uncontrolled hypertension </li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">NSAIDs</td>
                                  <td>
                                      <ul>
                                          <li>Avoid systemic NSAIDs when possible </li>
                                          <li>Consider alternative analgesics (e.g., acetaminophen, tramadol, topical NSAIDs), depending on indication and risk</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Recreational drugs (e.g., “bath salts” [MDPV], cocaine, methamphetamine, etc.)</td>
                                  <td  class="top-aligned">
                                      <ul>
                                          <li>Discontinue or avoid use</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td style="vertical-align: top">Systemic corticosteroids (e.g., dexamethasone, fludrocortisone, methylprednisolone, prednisone, prednisolone)</td>
                                  <td class="top-aligned">
                                      <ul>
                                          <li>Avoid or limit use when possible</li>
                                          <li>Consider alternative modes of administration (e.g., inhaled, topical) when feasible</li>
                                      </ul>
                                  </td>
                              </tr>
                              <tr class="row">
                                  <td class="top-aligned">Angiogenesis inhibitor (e.g., bevacizumab) and tyrosine kinase inhibitors (e.g., sunitinib, sorafenif)</td>
                                  <td class="top-aligned">
                                      <ul>
                                          <li>Initiate or intensify antihypertensive therapy</li>
                                      </ul>
                                  </td>
                              </tr>
                          </tbody>
                      </table>
                  </div>

              <div data-bind="page: {id: 'bp_categories_and_treatement_strategies', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">BP Categories and Treatment Strategies</h1>
                  <div data-bind="ui-accordion: {}" class="accordion">
                  <div>
                       <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">For Patients with 10-Year ASCVD Risk: ≥ 10%</span></h2>
                       <div class="collapsable-panel ">
                            <div class="bar close">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                               <div class="content">
                                       <p class="italic">Individuals with SBP and DBP in 2 categories should be designated to the higher BP category.</p>

                                      <table class="table table-data-top banded">
                                              <colgroup>
                                                  <col style="width:20%">
                                                  <col style="width:20%">
                                                  <col style="width:25%">
                                                  <col style="width:25%">
                                              </colgroup>
                                              <thead>
                                                  <tr>
                                                      <th>SBP <br>(mm Hg)</th>
                                                      <th>&nbsp;</th>
                                                      <th>DBP <br>(mm Hg)</th>
                                                      <th>BP Category</th>
                                                  </tr>
                                              </thead>
                                      </table>
                                      <table class="table table-data-top banded">
                                                  <colgroup>
                                                      <col style="width:20%">
                                                      <col style="width:20%">
                                                      <col style="width:25%">
                                                      <col style="width:25%">
                                                  </colgroup>
                                                  <tbody><tr>
                                                      <td>&lt; 120</td>
                                                      <td>And</td>
                                                      <td>&lt; 80</td>
                                                      <td>Normal</td>
                                                  </tr>
                                                  <tr>
                                                      <td colspan="4">
                                                          <b>Treatment Strategy:</b>
                                                          <ul>
                                                              <li>Promote optimal lifestyle habits
                                                              </li>
                                                              <li>
                                                                  Reassess in 1 year (Class IIa)
                                                              </li>
                                                          </ul>
                                                      </td>
                                                  </tr>
                                      </tbody></table>
                                      <table class="table table-data-top banded">
                                                  <colgroup>
                                                      <col style="width:20%">
                                                      <col style="width:20%">
                                                      <col style="width:25%">
                                                      <col style="width:25%">
                                                  </colgroup>
                                                  <tbody><tr>
                                                      <td>120 - 129</td>
                                                      <td>And</td>
                                                      <td>&lt; 80</td>
                                                      <td>Elevated</td>
                                                  </tr>
                                                  <tr>
                                                      <td colspan="4">
                                                          <b>Treatment Strategy: </b>
                                                          <p>Manage with nonpharmacologic therapy<sup>*</sup> and reassess in 3 to 6 months (Class I).</p>
                                                      </td>
                                                  </tr>
                                      </tbody></table>
                                      <table class="table table-data-top banded">
                                                  <colgroup>
                                                      <col style="width:20%">
                                                      <col style="width:20%">
                                                      <col style="width:25%">
                                                      <col style="width:25%">
                                                  </colgroup>
                                                  <tbody><tr>
                                                      <td>130 - 139</td>
                                                      <td>Or</td>
                                                      <td>80 - 89</td>
                                                      <td>Stage 1 HTN</td>
                                                  </tr>
                                                  <tr>
                                                      <td colspan="4">
                                                          <b>Treatment Strategy: </b>
                                                          <ul>
                                                              <li>Initiate combination of nonpharmacologic<sup>*</sup> and antihypertensive drug therapy (Class I)<sup>**</sup>.</li>
                                                              <li>Reassess in 1 month (Class I).</li>
                                                              <li>If BP goal<sup>†</sup> not met, assess and optimize therapy adherence, reassess in 1 month, and consider intensification of the therapy </li>
                                                              <li>If BP goal<sup>†</sup> met, reassess in 3-6 months (Class IIb). </li>
                                                          </ul>
                                                      </td>
                                                  </tr>
                                      </tbody></table>
                                      <table class="table table-data-top banded">
                                                  <colgroup>
                                                      <col style="width:20%">
                                                      <col style="width:20%">
                                                      <col style="width:25%">
                                                      <col style="width:25%">
                                                  </colgroup>
                                                  <tbody><tr>
                                                      <td>≥ 140</td>
                                                      <td>Or</td>
                                                      <td>≥ 90</td>
                                                      <td>Stage 2 HTN</td>
                                                  </tr>
                                                  <tr>
                                                      <td colspan="4">
                                                          <b>Treatment Strategy: </b>
                                                           <ul>
                                                              <li>Initiate combination of nonpharmacologic<sup>*</sup> and antihypertensive drug therapy (Class I)<sup>**</sup>.</li>
                                                              <li>Reassess in 1 month (Class I).</li>
                                                              <li>If BP goal<sup>†</sup> not met, assess and optimize therapy adherence, reassess in 1 month, and consider intensification of the therapy </li>
                                                              <li>If BP goal<sup>†</sup> met, reassess in 3-6 months (Class IIb). </li>
                                                          </ul>
                                                      </td>
                                                  </tr>
                                      </tbody></table>
                                      <br>
                                      <p><sup>*</sup>Nonpharmacologic therapy interventions include weight loss; a heart healthy diet such as DASH; sodium reduction; potassium supplementation; increased physical activity; and moderation in alcohol consumption
                                      </p>
                                      <br>
                                      <b><sup>**</sup>Drug Therapy Considerations:</b>
                                      <ul>
                                          <li>For initiation of antihypertensive drug therapy, first line agents should include thiazide diuretics, CCBs, and ACE inhibitors or ARBs (Class I). <br>
                                                               - Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes.
                                          </li>
                                          <li>Adults initiating a new or adjusted drug regimen for hypertension should have a follow-up evaluation on adherence and response to treatment at monthly intervals until control is achieved (Class I).<br>
                                                               - For initiation of renin-angiotensin system inhibitor or diuretic therapy, assess blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy.
                                          </li>
                                          <li>
                                              See “Oral Antihypertensive Drugs” table in the Resources section of this document for common drug, drug dosage, and other usage information.
                                          </li>
                                      </ul>
                                      <br>
                                      <p>
                                          <sup>†</sup>For adults with confirmed hypertension and known CVD or greater than or equal to 10%  10-year ASCVD event risk, a BP target of less than 130/80 mm Hg is recommended. (Class I)
                                      </p>

                             </div>
                             <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                             </div>
                      </div>
                      </div>
                      <div>
                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">For Patients with 10-Year ASCVD Risk: &lt; 10%</span></h2>
                          <div class="collapsable-panel ">
                              <div class="bar close">
                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                              </div>
                              <div class="content">
                                   <p class="italic">Individuals with SBP and DBP in 2 categories should be designated to the higher BP category.</p>

                                  <table class="table table-data-top banded">
                                      <colgroup>
                                          <col style="width:20%">
                                          <col style="width:20%">
                                          <col style="width:25%">
                                          <col style="width:25%">
                                      </colgroup>
                                      <thead>
                                              <tr>
                                                  <th>SBP <br>(mm Hg)</th>
                                                  <th>&nbsp;</th>
                                                  <th>DBP <br>(mm Hg)</th>
                                                  <th>BP Category</th>
                                              </tr>
                                      </thead>
                                  </table>
                                  <table class="table table-data-top banded">
                                      <colgroup>
                                          <col style="width:20%">
                                          <col style="width:20%">
                                          <col style="width:25%">
                                          <col style="width:25%">
                                      </colgroup>
                                      <tbody>
                                              <tr>
                                                  <td>&lt; 120</td>
                                                  <td>And</td>
                                                  <td>&lt; 80</td>
                                                  <td>Normal</td>
                                              </tr>
                                              <tr>
                                                  <td colspan="4">
                                                      <b>Treatment Strategy:</b>
                                                      <ul>
                                                          <li>Promote optimal lifestyle habits
                                                          </li>
                                                          <li>
                                                              Reassess in 1 year (Class IIa)
                                                          </li>
                                                      </ul>
                                                  </td>
                                              </tr>
                                      </tbody>
                                  </table>
                                  <table class="table table-data-top banded">
                                      <colgroup>
                                          <col style="width:20%">
                                          <col style="width:20%">
                                          <col style="width:25%">
                                          <col style="width:25%">
                                      </colgroup>
                                      <tbody>
                                              <tr>
                                                  <td>120 - 129</td>
                                                  <td>And</td>
                                                  <td>&lt; 80</td>
                                                  <td>Elevated</td>
                                              </tr>
                                              <tr>
                                                  <td colspan="4">
                                                      <b>Treatment Strategy: </b>
                                                      <p>Manage with nonpharmacologic therapy<sup>*</sup> and reassess in 3 to 6 months (Class I).</p>
                                                  </td>
                                              </tr>
                                      </tbody>
                                  </table>
                                  <table class="table table-data-top banded">
                                      <colgroup>
                                          <col style="width:20%">
                                          <col style="width:20%">
                                          <col style="width:25%">
                                          <col style="width:25%">
                                      </colgroup>
                                      <tbody>
                                              <tr>
                                                  <td>130 - 139</td>
                                                  <td>Or</td>
                                                  <td>80 - 89</td>
                                                  <td>Stage 1 HTN</td>
                                              </tr>
                                              <tr>
                                                  <td colspan="4">
                                                      <b>Treatment Strategy: </b>
                                                      <p>Manage with nonpharmacologic therapy<sup>*</sup> and reassess in 3 to 6 months (Class I).</p>
                                                  </td>
                                              </tr>
                                      </tbody>
                                  </table>
                                  <table class="table table-data-top banded">
                                      <colgroup>
                                          <col style="width:20%">
                                          <col style="width:20%">
                                          <col style="width:25%">
                                          <col style="width:25%">
                                      </colgroup>
                                      <tbody>
                                              <tr>
                                                  <td>≥ 140</td>
                                                  <td>Or</td>
                                                  <td>≥ 90</td>
                                                  <td>Stage 2 HTN</td>
                                              </tr>
                                              <tr>
                                                  <td colspan="4">
                                                      <b>Treatment Strategy: </b>
                                                      <ul>
                                                          <li>Initiate combination of nonpharmacologic<sup>*</sup> and antihypertensive drug therapy<sup>**</sup> (Class I).</li>
                                                          <li>Reassess in 1 month (Class I).</li>
                                                          <li>If BP goal<sup>†</sup> not met, assess and optimize therapy adherence, reassess in 1 month, and consider intensification of the therapy </li>
                                                          <li>If BP goal<sup>†</sup> met, reassess in 3-6 months (Class IIb). </li>
                                                      </ul>
                                                  </td>
                                              </tr>
                                      </tbody>
                                  </table>
                                  <br>
                                  <p><sup>*</sup>Nonpharmacologic therapy interventions include weight loss; a heart healthy diet such as DASH; sodium reduction; potassium supplementation; increased physical activity; and moderation in alcohol consumption
                                  </p>
                                  <br>
                                  <b><sup>**</sup>Drug Therapy Considerations:</b>
                                  <ul>
                                      <li>For initiation of antihypertensive drug therapy, first line agents should include thiazide diuretics, CCBs, and ACE inhibitors or ARBs (Class I). <br>
                                                           - Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes.
                                      </li>
                                      <li>Adults initiating a new or adjusted drug regimen for hypertension should have a follow-up evaluation on adherence and response to treatment at monthly intervals until control is achieved (Class I).<br>
                                                           - For initiation of renin-angiotensin system inhibitor or diuretic therapy, assess blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy.
                                      </li>
                                      <li>
                                          See “Oral Antihypertensive Drugs” table in the Resources section of this document for common drug, drug dosage, and other usage information.
                                      </li>
                                  </ul>
                                  <br>
                                  <p>
                                      <sup>†</sup>For adults with confirmed hypertension, without additional markers of increased CVD risk, a BP target of less than 130/80 mm Hg may be reasonable (Class IIb).
                                  </p>
                              </div>
                              <div class="bar jumpToTop">
                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                              </div>
                          </div>
                      </div>

                  </div>
              </div>
              <div data-bind="page: {id: 'key_points', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Key Points from 2018 Cholesterol Guideline</h1>
                  <div class="row">
                      <ol>
                          <li><b>In all individuals, emphasize a heart-healthy lifestyle across the life course.</b>A healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In younger individuals, healthy lifestyle can reduce development of risk factors and is the foundation of ASCVD risk reduction. In young adults 20 to 39 years of age, an assessment of lifetime risk facilitates the clinician–patient risk discussion (see No. 6) and emphasizes intensive lifestyle efforts. In all age groups, lifestyle therapy is the primary intervention for metabolic syndrome. </li>
                          <li><b>In patients with clinical ASCVD, reduce low-density lipoprotein cholesterol (LDL-C) with high-intensity statin therapy or maximally tolerated statin therapy. </b>The more LDL-C is reduced on statin therapy, the greater will be subsequent risk reduction.  Use a maximally tolerated statin to lower LDL-C levels by ≥50%. </li>
                          <li><b>In very high-risk ASCVD, use a LDL-C threshold of 70 mg/dL (1.8 mmol/L) to consider addition of nonstatins to statin therapy. </b> Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions. In very high-risk ASCVD patients, it is reasonable to add ezetimibe to maximally tolerated statin therapy when the LDL-C level remains ≥70 mg/dL (≥1.8 mmol/L). In patients at very high risk whose LDL-C level remains ≥70 mg/dL (≥1.8 mmol/L) on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable, although the long-term safety (>3 years) is uncertain and cost effectiveness is low at mid-2018 list prices.</li>
                          <li><b>In patients with severe primary hypercholesterolemia (LDL-C level ≥190 mg/dL [≥4.9 mmol/L]), without calculating 10-year ASCVD risk, begin high-intensity statin therapy without calculating 10-year ASCVD risk. </b> If the LDL-C level remains ≥100 mg/dL (≥2.6 mmol/L), adding ezetimibe is reasonable. If the LDL-C level on statin plus ezetimibe remains ≥100 mg/dL (≥2.6 mmol/L) and the patient has multiple factors that increase subsequent risk of ASCVD events, a PCSK9 inhibitor may be considered, although the long-term safety (>3 years) is uncertain and economic value is low at mid-2018 list prices.</li>
                          <li><b>In patients 40 to 75 years of age with diabetes mellitus and LDL-C ≥70 mg/dL (≥1.8 mmol/L), start moderate-intensity statin therapy without calculating 10-year ASCVD risk. </b>In patients with diabetes mellitus at higher risk, especially those with multiple risk factors or those 50 to 75 years of age, it is reasonable to use a high-intensity statin to reduce the LDL-C level by ≥50%. </li>
                          <li><b>In adults 40 to 75 years of age evaluated for primary ASCVD prevention, have a clinician–patient risk discussion before starting statin therapy. </b>Risk discussion should include a review of major risk factors (e.g., cigarette smoking, elevated blood pressure, LDL-C, hemoglobin A1C [if indicated], and calculated 10-year risk of ASCVD); the presence of risk-enhancing factors (see No. 8); the potential benefits of lifestyle and statin therapies; the potential for adverse effects and drug–drug interactions; consideration of costs of statin therapy; and patient preferences and values in shared decision-making. </li>
                          <li><b>In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels ≥70 mg/dL (≥1.8 mmol/L), at a 10-year ASCVD risk of ≥7.5%, start a moderate-intensity statin if a discussion of treatment options favors statin therapy. </b> Risk-enhancing factors favor statin therapy (see No. 8). If risk status is uncertain, consider using coronary artery calcium (CAC) to improve specificity (see No. 9). If statins are indicated, reduce LDL-C levels by ≥30%, and if 10-year risk is ≥20%, reduce LDL-C levels by ≥50%. </li>
                          <li><b>In adults 40 to 75 years of age without diabetes mellitus and 10-year risk of 7.5% to 19.9% (intermediate risk), risk-enhancing factors favor initiation of statin therapy (see No. 7). </b>Risk-enhancing factors include family history of premature ASCVD; persistently elevated LDL-C levels ≥160 mg/dL (≥4.1 mmol/L); metabolic syndrome; chronic kidney disease; history of preeclampsia or premature menopause (age &lt;40 years); chronic inflammatory disorders (e.g., rheumatoid arthritis, psoriasis, or chronic HIV); high-risk ethnic groups (e.g., South Asian); persistent elevations of triglycerides ≥175 mg/dL (≥1.97 mmol/L); and, if measured in selected individuals, apolipoprotein B ≥130 mg/dL,  high-sensitivity C-reactive protein ≥2.0 mg/L, ankle-brachial index &lt;0.9 and lipoprotein (a) ≥50 mg/dL or 125 nmol/L, especially at higher values of lipoprotein (a). Risk-enhancing factors may favor statin therapy in patients at 10-year risk of 5-7.5% (borderline risk).</li>
                          <li><b>In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels ≥70 mg/dL- 189 mg/dL (≥1.8-4.9 mmol/L), at a 10-year ASCVD risk of ≥7.5% to 19.9%, if a decision about statin therapy is uncertain, consider measuring CAC. </b>If CAC is zero, treatment with statin therapy may be withheld or delayed, except in cigarette smokers, those with diabetes mellitus, and those with a strong family history of premature ASCVD. A CAC score of 1 to 99 favors statin therapy, especially in those ≥55 years of age. For any patient, if the CAC score is ≥100 Agatston units or ≥75th percentile, statin therapy is indicated unless otherwise deferred by the outcome of clinician–patient risk discussion. </li>
                          <li><b>Assess adherence and percentage response to LDL-C–lowering medications and lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed. </b>Define responses to lifestyle and statin therapy by percentage reductions in LDL-C levels compared with baseline. In ASCVD patients at very high-risk, triggers for adding nonstatin drug therapy are defined by threshold LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) on maximal statin therapy (see No. 3).</li>
                      </ol>
                  </div>
              </div>
              <div data-bind="page: {id: 'risk_enhancing_factors', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">ASCVD Risk Enhancing Factors</h1>
                  <table class="table">
                      <thead>
                          <th>ASCVD Risk Enhancing Factors</th>
                      </thead>
                      <tbody>
                          <td>
                  <div class="row">
                          <ul>
                              <li><b>Family history of premature ASCVD</b><br>
                                      - Males, age &lt;55 years <br>
                                      - Females, age &lt;65 years</li>
                              <li><b>Primary hypercholesterolemia </b><br>
                                  - LDL-C 160-189 mg/dL [4.1- 4.8 mmol/L] <br>
                                  - Non-HDL-C 190-219 mg/dL [4.9-5.6 mmol/L]<sup>*</sup> </li>
                              <li><b>Metabolic syndrome </b><br>
                                  Factors: (tally of 3 makes the diagnosis)<br>
                                  - Increased waist circumference<br>
                                  - Elevated triglycerides (&ge;150 mg/dL)<br>
                                  - Elevated blood pressure<br>
                                  - Elevated glucose<br>
                                  -  Low HDL-C (&lt; 40 mg/dL in men; &lt; 50 mg/dL in women) </li>
                              <li><b>Chronic kidney disease</b> <br>
                                  - eGFR 15-59 ml/min per1.73 m<sup>2</sup> with or without albuminuria; not treated with dialysis or kidney transplantation</li>
                              <li><b>Chronic inflammatory conditions </b><br>
                                  - Conditions such as psoriasis, rheumatoid arthritis, or HIV/AIDS</li>
                              <li><b>History of premature menopause (before age 40) and history of pregnancy-associated conditions that increase later ASCVD risk such as pre-eclampsia</b></li>
                              <li><b>High-risk race/ ethnicities </b>(e.g.    South Asian ancestry)</li>
                              <li><b>Lipid/biomarkers: </b>Associated with increased ASCVD risk<br>
                                  - Persistently* elevated, primary hypertriglyceridemia ( ≥ 175 mg/dL) <br>
                                  - If measured: <ul class="list-type-circle"><li><b>Elevated high-sensitivity C-reactive protein  </b>(≥ 2.0 mg/L) </li>
                                  <li><b>Elevated Lp(a) </b> ≥ 50 mg/dl or ≥ 125 nmol/L constitutes a risk-enhancing factor especially at higher Lp(a) </li>
                                  <li><b>Elevated apoB </b>≥ 130 mg/dl corresponds to an LDL-C > 160 mg/dL and constitutes a risk-enhancing factor</li>
                                  <li><b>ABI</b> (ankle-branchial index) &lt; 0.9</li>
                                  </ul></li>
                          </ul>
                  </div>
                              </td>
                          </tbody>
                      </table>
                  <p class="text"><sup>*</sup>Optimally, three determinations</p>
              </div>

              <div data-bind="page: {id: 'ethnicity_issues', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Ethnicity Issues in Risk Evaluation</h1>
                  <div data-bind="ui-accordion: {}" class="accordion">
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">EVALUATION</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <div data-bind="" class="nested-accordion">
                                                      <div class="ascvd-issues">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.ascvd-issues')"><i class="fa fa-holder"></i><span class="text">       ASCVD Issues informed by ethnicity </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> South Asian and East Asian ASCVD risk varies by country of origin; Individuals 	from South Asia have increased ASCVD risk. </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> Race and country of origin together with socio-economic status 	and acculturation level may explain risk factor burden more precisely. e.g. ASCVD risk is higher 	among individuals from Puerto Rico than from Mexico.</p>
                                                                      <p class="text"><b>African-Americans:</b> ASCVD risk assessment in African American women shows increased ASCVD 	risk compared to their otherwise similar white counterparts.</p>
                                                                      <p class="text"><b>Comments: </b>Heterogeneity in risk according to ethnic groups and within ethnic groups.  </p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                      <div class="lipid-issues">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.lipid-issues')"><i class="fa fa-holder"></i><span class="text">       Lipid issues informed by ethnicity </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> Lower levels of HDL-C     compared to whites. Higher prevalence of
                                                                          LDL-C among Asian Indians, Filipinos, Japanese, and Vietnamese compared to whites. An 	increased prevalence of high TGs was seen in all Asian American subgroups.
                                                                      </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> Hispanic/Latino women have higher prevalence of low HDL-C 	compared to Hispanic/Latino men.</p>
                                                                      <p class="text"><b>African-Americans:</b> Higher levels of HDL-C and lower levels of triglycerides (TG) than in Non-Hispanic 	whites or Mexican-Americans.</p>
                                                                      <p class="text"><b>Comments: </b>All ethnic groups appear to be at greater risk for dyslipidemia, but important to identify those with more sedentary behavior and less favorable diet. Cultural and racial differences between Asians and Hispanic/Latinos subgroups make generalizations unreliable.</p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                      <div class="metabolic-issues">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.metabolic-issues')"><i class="fa fa-holder"></i><span class="text">       Metabolic issues informed by ethnicity </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> Increased Metabolic Syndrome (MetS) seen with lower waist circumference 	than in whites. Type 2 diabetes (DM) develops at a lower lean body mass and at earlier age (17-	19).  Majority of risk in South Asians explained by known risk factors, especially those related to 	insulin resistance.
                                                                      </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> DM disproportionately present compared to whites and blacks. 	Increased prevalence MetS, DM in Mexican Americans compared to whites & Puerto Ricans.</p>
                                                                      <p class="text"><b>African-Americans:</b> Increased DM and hypertension.</p>
                                                                      <p class="text"><b>Comments: </b>Increased prevalence of DM. Features of MetS vary by ethnicity. Waist 	circumference, not weight, should be used to determine abdominal adiposity when possible.</p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                  </div>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">RISK DECISIONS</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <div data-bind="" class="nested-accordion">
                                                      <div class="pooled-cohort">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.pooled-cohort')"><i class="fa fa-holder"></i><span class="text">       Pooled Cohort Equations (PCE) </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> No separate PCE available; use PCE for whites. PCE may underestimate ASCVD 	risk in South Asians.  PCE may overestimate risk in East Asians.</p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> No separate PCE available; use PCE for non-Hispanic whites. If 	African American ancestry also, then use PCE for African Americans.</p>
                                                                      <p class="text"><b>African-Americans:</b> Use PCE for African Americans.</p>
                                                                      <p class="text"><b>Comments: </b>Country specific ethnicity, along with socio-economic status, may affect estimation 	of risk of PCE. </p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                      <div class="coronary-artery">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.coronary-artery')"><i class="fa fa-holder"></i><span class="text">       Coronary Artery Calcium (CAC) Score </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> In terms of CAC burden, South Asian men were similar to non-Hispanic white 	men, but higher CAC when compared to African Americans, Latinos and Chinese Americans. 	South Asian women had similar CAC to whites and other ethnic women, although CAC burden 	higher in older age.
                                                                      </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> CAC predicts similarly in whites and those who identify as 	Hispanic/Latino.</p>
                                                                      <p class="text"><b>African-Americans:</b> In MESA (Multi-Ethnic Study of Atherosclerosis), CAC score was highest in 	Caucasian and Hispanic men, with African-Americans having significantly lower prevalence and 	severity of CAC.  </p>
                                                                      <p class="text"><b>Comments: </b>Risk factor differences in MESA between ethnicities didn’t fully explain variability in CAC However, CAC predicted ASCVD events over and above traditional risk factors in all 	ethnicities.</p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                  </div>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">TREATMENT </span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <div data-bind="" class="nested-accordion">
                                                      <div class="lifestyle-counseling">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.lifestyle-counseling')"><i class="fa fa-holder"></i><span class="text">       Lifestyle counseling</span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b>  Utilize lifestyle counseling to recommend a heart healthy diet consistent with 	ethnic preferences to avoid weight gain, address BP and lipids.</p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> Utilize lifestyle counseling to recommend a heart healthy diet 	consistent with ethnic preferences to avoid weight gain, address BP and lipids.</p>
                                                                      <p class="text"><b>African-Americans:</b> Utilize lifestyle counseling to recommend a heart healthy diet consistent 	with ethnic preferences to avoid weight gain, address BP and lipids.</p>
                                                                      <p class="text"><b>Comments: </b> Need to disaggregate Asian and Hispanic/Latino groups due to regional differences 	in lifestyle preferences. Challenge is to avoid increased sodium, sugar and calories as groups 	acculturate. </p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                      <div class="intensity-of-statin-therapy">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.intensity-of-statin-therapy')"><i class="fa fa-holder"></i><span class="text">       Intensity of statin therapy and response to LDL-C lowering </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> Japanese patients may be sensitive to statin dosing. In an open-label, 	randomized primary prevention trial, Japanese participants had a reduction in CVD events with 	low-intensity doses of pravastatin as compared to placebo. In a secondary prevention trial, 	Japanese participants with CAD benefitted from a moderate-intensity doses of pitavastatin.
                                                                      </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> No sensitivity to statin dosage compared to non-Hispanic white or 	black individuals.</p>
                                                                      <p class="text"><b>African-Americans:</b> No sensitivity to statin dosage compared to non-Hispanic white individuals.</p>
                                                                      <p class="text"><b>Comments: </b>Using a lower statin intensity in Japanese patients may give results similar to those 	seen with higher intensities in non-Japanese patients. </p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                      <div class="safety">
                                                          <h2 class="nested-toggle with-underline" onclick="nestedPanelVisibleToggle('.safety')"><i class="fa fa-holder"></i><span class="text">       Safety </span></h2>
                                                          <div class="nested-collapsable-panel " style="display:none;">
                                                              <div class="content">
                                                                  <div class="row">
                                                                      <p class="text"><b>Asian-Americans:</b> Higher rosuvastatin plasma levels in Japanese, Chinese, Malay, and Asian-	Indians compared to white. FDA recommends a lower starting dose (5 mg of rosuvastatin in 	Asians vs. 10 mg in whites). Caution urged as dose uptitrated.
                                                                      </p>
                                                                      <p class="text"><b>Hispanic/Latino-Americans:</b> No specific safety issues with statins related to Hispanic/Latino 	status.</p>
                                                                      <p class="text"><b>African-Americans:</b> Baseline serum CK values are higher in AA than in whites. The 95th 	percentile race/ethnic specific and sex-specific serum CK normal levels are available for 	assessing changes in serum CK.</p>
                                                                      <p class="text"><b>Comments: </b>Clinicians should take Asian ethnicity into account when prescribing dose of 	rosuvastatin (see package insert). In adults of East Asian descent, other statins should be used 	preferentially over simvastatin.</p>
                                                                  </div>
                                                              </div>
                                                          </div>
                                                      </div>
                                                  </div>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                  </div>
                  <div class="row">
                      <p class="text"><sup>*</sup>The term Asian characterizes a diverse population group. Individuals from Bangladesh, India, Nepal, Pakistan and Sri Lanka make up the majority of the South Asian group. Individuals from Japan, Korea, and China make up the majority of the East Asian group. </p>
                      <p class="text"><sup>†</sup>The term Hispanics/Latinos in the United States characterizes a diverse population group. This includes white, black, and Native American races. Their ancestry goes from Europe to America, including among these, individuals from the Caribbean, Mexico, Central and South America</p>
                  </div>
              </div>

              <div data-bind="page: {id: 'general_population', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">General Populations Recommendation Summary</h1>
                  <p><b><u>Treatment Initiation Summary</u></b></p>
                  <ul>
                      <li><b>In all individuals: </b>Emphasize a heart-healthy lifestyle across the life course.</li>
                      <li><b>In patients with clinical ASCVD: </b>Reduce low-density lipoprotein cholesterol (LDL-C) with high intensity statin therapy or maximally tolerated statin therapy. In very high-risk ASCVD, use an LDL-C threshold of 70 mg/dL (1.8 mmol/L) to consider addition of nonstatins to statin therapy.</li>
                      <li><b>In patients with severe primary hypercholesterolemia (LDL-C level ≥190 mg/dL [≥4.9 mmol/L]): </b>Begin high-intensity statin therapy without calculating 10- year ASCVD risk.</li>
                      <li><b>In adults 40 to 75 years of age with diabetes mellitus and LDL-C ≥70 mg/dL- 189 mg/dL (≥1.8-4.9 mmol/L): </b>Start moderate-intensity statin therapy without calculating 10-year ASCVD risk.</li>
                      <li><b>In adults 40 to 75 years of age without diabetes mellitus and with LDL-C levels ≥70 mg/dL- 189 mg/dL (≥1.8-4.9 mmol/L) evaluated for primary ASCVD prevention: </b>
                          <ul class="list-type-none">
                              <li>-	Have a clinician–patient risk discussion before starting statin therapy.</li>
                              <li>-	With 10-year ASCVD risk of ≥7.5%, start a moderate-intensity statin if a discussion of treatment options favors statin therapy. </li>
                              <li>-	With 10-year risk of 7.5% to 19.9% (intermediate risk), risk-enhancing factors favor initiation of statin therapy, and, if a decision about statin therapy is uncertain, consider measuring CAC.</li>
                          </ul>
                      </li>
                  </ul>
                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Primary Prevention Recommendations for Adults 40 to 75 Years of Age with LDL Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L)</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 1. In adults at intermediate-risk, statin therapy reduces risk of ASCVD, and in the context of a risk discussion, if a decision is made for statin therapy, a moderate- intensity statin should be recommended.  </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 2.	In intermediate-risk patients, LDL-C levels should be reduced by 30% or more, and for optimal ASCVD risk reduction, especially in high-risk patients, levels should be reduced by 50% or more. </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 3.	For the primary prevention of clinical ASCVD* in adults 40 to 75 years of age without diabetes mellitus and with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), the 10-year ASCVD risk of a first “hard” ASCVD event (fatal and nonfatal MI or stroke) should be estimated by using the race- and sex-specific PCE, and adults should be categorized as being at low risk (&lt;5%), borderline risk (5% to &lt;7.5%), intermediate-risk (≥7.5% to &lt;20%), and high-risk (≥20%). </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 4. Clinicians and patients should engage in a risk discussion that considers risk factors, adherence to healthy lifestyle, the potential for ASCVD risk-reduction benefits, and the potential for adverse effects and drug–drug interactions, as well as patient preferences, for an individualized treatment decision. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 5. In intermediate-risk adults, risk-enhancing factors favor initiation or intensification of statin therapy. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 6. In intermediate-risk or selected borderline-risk adults,  if the decision about statin use remains uncertain, it is reasonable to use a CAC score in the decision to withhold, postpone or initiate statin therapy. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 7. In intermediate-risk adults or selected borderline-risk adults in whom a CAC score is measured for the purpose of making a treatment decision, AND
                              <ul><li>If the coronary calcium score is zero, it is reasonable to withhold statin therapy and reassess in 5 to 10 years, as long as higher risk conditions are absent (diabetes mellitus, family history of premature CHD, cigarette smoking);</li><li>If CAC score is 1 to 99, it is reasonable to initiate statin therapy for patients ≥55 years of age; </li><li>If CAC score is 100 or higher or in the 75th percentile or higher, it is reasonable to initiate statin therapy.</li></ul></td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 8. In intermediate-risk adults who would benefit from more aggressive LDL-C lowering and in whom high-intensity statins are advisable but not acceptable or tolerated, it may be reasonable to add a nonstatin drug (ezetimibe or bile acid sequestrant) to a moderate-intensity statin. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 9. In patients at borderline risk, in risk discussion, the presence of risk-enhancing factors may justify initiation of moderate-intensity statin therapy. </td>
                          </tr>
                      </tbody>
                  </table>
                  <p>*Definition of clinical ASCVD includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin.</p>
                  <br>
                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Recommendations for Older Adults</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 1.	In adults 75 years of age or older with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), initiating a moderate-intensity statin may be reasonable. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 2.	In adults 75 years of age or older, it may be reasonable to stop statin therapy when functional decline (physical or cognitive), multimorbidity, frailty, or reduced life-expectancy limits the potential benefits of statin therapy.  </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 3.	In adults 76 to 80 years of age with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), it may be reasonable to measure CAC to reclassify those with a CAC score of zero to avoid statin therapy. </td>
                          </tr>
                      </tbody>
                  </table>
                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Recommendations for Patients with Diabetes Mellitus</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 1.	In adults 40 to 75 years of age with diabetes mellitus, regardless of estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 2.	In adults 40 to 75 years of age with diabetes mellitus and an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), it is reasonable to assess the 10-year risk of a first ASCVD event by using the race and sex-specific PCE to help stratify ASCVD risk. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 3. In adults with diabetes mellitus who have multiple ASCVD risk factors, it is reasonable to prescribe high-intensity statin therapy with the aim to reduce LDL-C levels by 50% or more. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 4. In adults older than 75 years of age with diabetes mellitus and who are already on statin therapy, it is reasonable to continue statin therapy.</td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 5. In adults with diabetes mellitus and 10-year ASCVD risk of 20% or higher, it may be reasonable to add ezetimibe to maximally tolerated statin therapy to reduce LDL-C levels by 50% or more.</td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 6. In adults older than 75 years with diabetes mellitus, it may be reasonable to initiate statin therapy after a clinician–patient discussion of potential benefits and risks.</td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 7. In adults 20 to 39 years of age with diabetes mellitus that is either of long duration (≥10 years of type 2 diabetes mellitus, ≥20 years of type 1 diabetes mellitus), albuminuria (≥30 mcg of albumin/mg creatinine), estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m<sup>2</sup>, retinopathy, neuropathy, or ankle-brachial index (ABI; &lt;0.9), it may be reasonable to initiate statin therapy.</td>
                          </tr>
                  </table>
                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Recommendations for Primary Severe Hypercholesterolemia (LDL-C ≥ 190 mg/dL (≥ 4.9 mmol/L))</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 1.	In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL (≥4.9 mmol/L) or higher, maximally tolerated statin therapy is recommended. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 2. In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL (≥4.9 mmol/L) or higher who achieve less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C level of 100 mg/dL (≥2.6 mmol/L) or higher, ezetimibe therapy is reasonable. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 3.	In patients 20 to 75 years of age with a baseline LDL-C level ≥190 mg/dL (≥4.9 mmol/L), who achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides ≤300 mg/dL (≤3.4 mmol/L). while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant may be considered. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 4. In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL (≥2.6 mmol/L) or higher while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered.</td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 5.	In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL (≥5.7 mmol/L) or higher and who achieve an on-treatment LDL-C level of 130 mg/dL (≥3.4 mmol/L) or higher while receiving maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. </td>
                          </tr>
                          <tr>
                              <td colspan="2" class="text-center"> Value Statement: Uncertain Value (B-NR) </td>
                              <td> 6.	Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors provide uncertain value at mid-2018 U.S. list prices. </td>
                          </tr>
                      </tbody>
                  </table>
                  <table class="recommendationTable table">
                      <thead>
                          <tr class="recommendationLevel1">
                              <th colspan="3" class="text-center">Recommendations for Statin Therapy Use in Patients with ASCVD</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td> <b>COR</b> </td>
                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                              <td class="text-center"> <b>Recommendations</b> </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 1.	In patients who are 75 years of age or younger with clinical ASCVD,* high-intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels. </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-A"> A </td>
                              <td> 2.	In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim of achieving a 30% to 49% reduction in LDL-C levels. </td>
                          </tr>
                          <tr>
                              <td class="CORI"> I </td>
                              <td class="LOE-B"> B-NR </td>
                              <td> 3.	In patients with clinical ASCVD who are  judged to be very high risk and <i>considered for PCSK9 inhibitor therapy</i>, maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and ezetimibe. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> A <sup>SR</sup></td>
                              <td> 4.	In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated LDL-C lowering therapy with LDL-C 70 mg/dL (≥1.8 mmol/L) or higher or a non–HDL-C level of 100 mg/dL (≥2.6 mmol/L) or higher, it is reasonable to add a PCSK9 inhibitor following a clinician–patient discussion about the net benefit, safety, and cost. </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 5.	In patients with clinical ASCVD who are on maximally tolerated statin therapy and are judged to be at very high risk and have an LDL-C level of 70 mg/dL (≥1.8 mmol/L) or higher, it is reasonable to add ezetimibe therapy. </td>
                          </tr>
                          <tr>
                              <td colspan="2" class="text-center">Value Statement: Low Value (LOE: B-NR)</td>
                              <td> 6.	At mid-2018 list prices, PCSK9 inhibitors have a low cost value (>$150,000 per QALY) compared to good cost value (&lt;$50,000 per QALY) </td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 7.	In patients older than 75 years of age with clinical ASCVD, it is reasonable to initiate moderate- or high-intensity statin therapy after evaluation of the potential for ASCVD risk reduction, adverse effects, and drug–drug interactions, as well as patient frailty and patient preferences.</td>
                          </tr>
                          <tr>
                              <td class="CORIIa"> IIa </td>
                              <td class="LOE-C"> C-LD </td>
                              <td> 8.	In patients older than 75 years of age who are tolerating high-intensity statin therapy, it is reasonable to continue high-intensity statin therapy after evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 9.	In patients with clinical ASCVD who are receiving maximally tolerated statin therapy and whose LDL-C level remains 70 mg/dL (≥1.8 mmol/L) or higher, it may be reasonable to add ezetimibe. </td>
                          </tr>
                          <tr>
                              <td class="CORIIb"> IIb </td>
                              <td class="LOE-B"> B-R </td>
                              <td> 10. In patients with heart failure (HF) with reduced ejection fraction attributable to ischemic heart disease who have a reasonable life expectancy (3 to 5 years) and are not already on a statin because of ASCVD, clinicians may consider initiation of moderate-intensity statin therapy to reduce the occurrence of ASCVD events. </td>
                          </tr>
                  </table>
                  <p>*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin.</p>
              </div>

              <div data-bind="page: {id: 'secondary_prevention', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Secondary Prevention - Patients with Clinical ASCVD</h1>
                  <div class="holder secondary_prevention_panzoom">
                            <div class="parent panzoom" style="margin: 0;">
                          <div class="panzoom-element">
                              <img data-src="assets/graphics/new-secondary-prevention.png" src="assets/img/squared_metal_@2X.png"  alt="secondary prevention">
                          </div>
                      </div>
                  </div>
                  <div class="row">
                      <p>Clinical ASCVD consists of ACS, those with history of MI, stable or unstable angina or coronary other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin.</p>
                      <p>ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction; and PCSK9-I, PCSK9 inhibitor.</p>
                      <p><sup>*</sup>Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions.</p>
                  </div>
              </div>

              <div data-bind="page: {id: 'ldlc_treatment_younger_patients', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline"> LDL-C Treatment Suggestions for Younger Patients</h1>
                  <p>The following is a summary of some of the key suggestions for primary prevention in patients age 20-39 provided by the 2018 ACC/AHA Cholesterol Guideline.</p>
                  <ul>
                      <li>
                          In patients without phenotypically severe hypercholesterolemia:<br>
                          -	Expert consensus discussion suggests beginning risk assessment by estimating lifetime risk. Multiple risk factors indicate lifestyle intervention.
                      </li>
                      <li>
                          In patients with persistent, moderate hypercholesterolemia (LDL-C 160-189 mg/dL (4.1-4.8 mmol/L)):<br>
                          -	Expert consensus discussion suggests that lifestyle intervention is indicated, and long-term statin therapy would be beneficial, especially for those with other risk enhancing factors.
                      </li>
                      <li>
                          In patients with severe hypercholesterolemia (LDL-C >190 mg/dL (≥4.9 mmol/L)):<br>
                          -	Expert consensus discussion suggests lifestyle intervention is indicated.<br>
                          -	Guideline also recommends maximally tolerated therapy statin therapy.  (I, B)<br>
                          -	If recommended LDL-C reduction of > 50% is not achieved, then possible addition of non-statin therapies is also recommended.
                      </li>
                      <li>
                          In patients with diabetes either of long duration (≥10 years of T2D, ≥20 years of T1D), and/or albuminuria (≥30 mcg albumin/mg creatinine), eGFR &lt;60 ml/min/m2, retinopathy, neuropathy:<br>
                          -	Expert consensus discussion suggests lifestyle intervention is indicated.<br>
                          -	Guideline recommends that it may be reasonable to initiate statin therapy. (IIb, C)
                      </li>
                  </ul>
              </div>

              <div data-bind="page: {id: 'discussion_checklist', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Discussion Checklist for Therapy Initiation</h1>
                  <table class="table checklist-therapy">
                      <thead>
                          <tr>
                              <th class="small-4">Checklist Item</th>
                              <th class="small-8">Recommendation</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td>ASCVD Risk Assessment</td>
                              <td>
                                  <ul>
                                      <li>Assign to statin treatment group; use ASCVD risk estimator plus <ul><li>In lower risk primary prevention adults 40-75 years with LDL-C ≥70 mg/dL(≥1.8 mmol/L) . Not needed in secondary prevention, LDL-C ≥190 mg/dL (≥4.9 mmol/L) and those 40-75 years with diabetes. </li></ul></li>
                                      <li>Assess other patient characteristics which influence risk. See Risk Enhancing Factors</li>
                                      <li>Assess calcium artery calcium if risk decision uncertain and additional information is needed to clarify ASCVD risk<ul><li>Use decision tools to explain risk (such as this app, Mayo Clinic Statin Choice Decision Aid)</li></ul></li>
                                  </ul>
                              </td>
                          </tr>
                          <tr>
                              <td>Lifestyle Modifications</td>
                              <td>
                                  <ul>
                                      <li>Review lifestyle habits (diet, physical activity, weight/BMI, tobacco use)</li>
                                      <li>Endorse a healthy lifestyle and provide relevant advice/materials/referrals (CardioSmart, AHA Life's Simple 7, NLA Patient Tear Sheets, PCNA Clinicians' Lifestyle Modification Toolbox, cardiac rehab, dietitian, smoking cessation program)</li>
                                  </ul>
                              </td>
                          </tr>
                          <tr>
                              <td>Potential Net-Clinical Benefit of Pharmacotherapy</td>
                              <td>
                                  <ul>
                                      <li>Recommend statins as first-line therapy </li>
                                      <li>Consider the combination of statin and non-statin therapy in select patients </li>
                                      <li>Discuss potential risk reduction from lipid-lowering therapy</li>
                                      <li>Discuss the potential for adverse effects/drug-drug interactions</li>
                                  </ul>
                              </td>
                          </tr>
                          <tr>
                              <td>Cost Considerations</td>
                              <td>
                                  <ul>
                                      <li>Discuss potential out-of-pocket cost of therapy to the patient (e.g., insurance plan coverage, tier level, copayment)</li>
                                  </ul>
                              </td>
                          </tr>
                          <tr>
                              <td>Shared Decision Making</td>
                              <td>
                                  <ul>
                                      <li>Encourage patient to verbalize what was heard (personal ASCVD risk, available options and their risk/benefit)</li>
                                      <li>Invite the patient to ask questions, express values/preferences, state ability to adhere to lifestyle changes and medications</li>
                                      <li>Collaborate with the patient to determine therapy and follow-up plan</li>
                                  </ul>
                              </td>
                          </tr>
                      </tbody>
                  </table>
              </div>

              <div data-bind="page: {id: 'cac_score_inform_decisions', afterShow: listchange}" class="group-section">
                  <h1 class="with-underline">Using CAC Score to Inform Decisions</h1>
                  <div data-bind="ui-accordion: {}" class="accordion">
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Specific CAC Guideline Recommendations</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <table class="recommendationTable table">
                                                      <tbody>
                                                          <tr>
                                                              <td> <b>COR</b> </td>
                                                              <td> <b>&nbsp;&nbsp;LOE&nbsp;&nbsp;</b> </td>
                                                              <td class="text-center"> <b>Recommendations</b> </td>
                                                          </tr>
                                                          <tr>
                                                              <td class="CORIIa"> IIa </td>
                                                              <td class="LOE-B"> B-NR </td>
                                                              <td> In intermediate-risk or selected borderline-risk adults, if the decision about statin use remains uncertain, it is reasonable to use a CAC score in the decision to withhold, postpone or initiate statin therapy.  </td>
                                                          </tr>
                                                          <tr>
                                                              <td class="CORIIa"> IIa </td>
                                                              <td class="LOE-B"> B-NR </td>
                                                              <td> In intermediate-risk adults or selected borderline-risk adults in whom a CAC score is measured for the purpose of making a treatment decision, AND
                                                                  <ul>
                                                                      <li>If the coronary calcium score is zero, it is reasonable to withhold statin therapy and reassess in 5 to 10 years, as long as higher risk conditions are absent (diabetes mellitus, family history of premature CHD, cigarette smoking);</li>
                                                                      <li>If CAC score is 1 to 99, it is reasonable to initiate statin therapy for patients ≥55 years of age; </li>
                                                                      <li>If CAC score is 100 or higher or the 75<sup>th</sup> percentile or higher, it is reasonable to initiate statin therapy.</li>
                                                                  </ul>
                                                              </td>
                                                          </tr>
                                                          <tr>
                                                              <td class="CORIIb"> IIb </td>
                                                              <td class="LOE-B"> B-R </td>
                                                              <td> In adults 76 to 80 years of age with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), it may be reasonable to measure CAC to reclassify those with a CAC score of zero to avoid statin therapy. </td>
                                                          </tr>
                                                      </tbody>
                                                  </table>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                      <div>
                                          <h2 class="toggle"><i class="fa fa-holder"></i><span class="text">Specific CAC Score Ethnicity Considerations</span></h2>
                                          <div class="collapsable-panel ">
                                              <div class="bar close">
                                                  <a class="action-btn close" data-bind="click:panelHide"> <i class="fa fa-holder"></i>close</a>
                                              </div>
                                              <div class="content">
                                                  <div class="table-scroll">
                                                      <table class="table">
                                                          <thead>
                                                              <tr>
                                                                  <th>&nbsp;</th>
                                                                  <th colspan="4" class="text-center">Ethnic/racial groupings</th>
                                                              </tr>
                                                          </thead>
                                                          <tbody>
                                                              <tr>
                                                                  <td>&nbsp;</td>
                                                                  <td><b>Asian-Americans<sup>*</sup></b></td>
                                                                  <td><b>Hispanic/Latino-Americans<sup>†</sup></b></td>
                                                                  <td><b>African-Americans </b></td>
                                                                  <td><b>Comments:</b></td>
                                                              </tr>
                                                              <tr>
                                                                  <td><b>Coronary Artery Calcium (CAC) Score </b></td>
                                                                  <td>In terms of CAC burden, South Asian men were similar to non-Hispanic white men, but higher CAC when compared to African Americans, Latinos and Chinese Americans. South Asian women had similar CAC to whites and other ethnic women, although CAC burden higher in older age.</td>
                                                                  <td>CAC predicts similarly in whites and those who identify as Hispanic/Latino.</td>
                                                                  <td>In MESA (Multi-Ethnic Study of Atherosclerosis), CAC score was highest in Caucasian and Hispanic men, with African-Americans having significantly lower prevalence and severity of CAC.  </td>
                                                                  <td>Risk factor differences in MESA between ethnicities didn’t fully explain variability in CAC However, CAC predicted ASCVD events over and above traditional risk factors in all ethnicities.</td>
                                                              </tr>
                                                          </tbody>
                                                      </table>
                                                  </div>
                                                  <div class="row">
                                                      <p class="text"><sup>*</sup>The term Asian characterizes a diverse population group. Individuals from Bangladesh, India, Nepal, Pakistan and Sri Lanka make up the majority of the South Asian group. Individuals from Japan, Korea, and China make up the majority of the East Asian group. </p>
                                                      <p class="text"><sup>†</sup> The term Hispanics/Latinos in the United States characterizes a diverse population group. This includes white, black, and Native American races. Their ancestry goes from Europe to America, including among these, individuals from the Caribbean, Mexico, Central and South America</p>
                                                  </div>
                                              </div>
                                              <div class="bar jumpToTop">
                                                  <a class="action-btn top" data-bind="click:panelScrollTop"> <i class="fa fa-holder"></i>top</a>
                                              </div>
                                          </div>
                                      </div>
                                  </div>
              </div>
    </script>
    <script type="text/html" id="statin-intensity-table-resource-section">
      <h1 class="with-underline">Intensities of Statin Therapy</h1>
      <div class="row">
        <p><b>High-, Moderate-, and Low-Intensity Statin Therapy</b></p>
        <table class="table ">
          <thead>
            <tr>
              <th>&nbsp;</th>
              <th><b>High-Intensity</b></th>
              <th><b>Moderate-Intensity</b></th>
              <th><b>Low-Intensity</b></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><b>LDL-C </b> <br /><b>Lowering </b>§</td>
              <td>≥ 50%</td>
              <td>30% to 49%</td>
              <td>< 30%</td>
            </tr>
            <tr>
              <td><b>Primary </b> <br /><b>Statins</b></td>
              <td>
                <b>Atorvastatin (40†)-80 mg</b> <br /><b>Rosuvastatin 20 </b
                ><i>(40)</i><b> mg</b>
              </td>
              <td>
                <b>Atorvastatin 10 </b><i>(20)</i><b> mg</b><br /><b
                  >Rosuvastatin</b
                >
                <i>(5)</i><b> 10 mg</b> <br /><b>Simvastatin 20-40 mg‡</b>
              </td>
              <td><i>Simvastatin 10 mg</i></td>
            </tr>
            <tr>
              <td><b>Other</b><br /><b>Statins</b></td>
              <td>-</td>
              <td>
                <b>Pravastatin 40 </b><i>(80)</i><b> mg</b><br /><b
                  >Lovastatin 40 </b
                ><i>(80)</i><b> mg</b><br /><i>Fluvastatin XL 80 mg</i><br /><b
                  >Fluvastatin 40 mg BID</b
                ><br /><i>Pitavastatin 1-4 mg</i>
              </td>
              <td>
                <b>Pravastatin 10-20 mg</b><br /><b>Lovastatin 20 mg</b><br /><i
                  >Fluvastatin 20-40 mg</i
                >
              </td>
            </tr>
          </tbody>
        </table>
      </div>
      <div class="row">
        <p class="text">
          Percent LDL-C reductions with the primary statin medications used in
          clinical practice (atorvastatin, rosuvastatin, simvastatin) were
          estimated using the median reduction in LDL-C from the VOYAGER
          database. Reductions in LDL-C for other statin medications
          (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified
          according to FDA approved product labeling in adults with
          hyperlipidemia, primary hypercholesterolemia and mixed dyslipidemia.
        </p>
      </div>
      <div class="row">
        <p class="text">
          <b>Boldface</b> type indicates specific statins and doses that were
          evaluated in RCTs, and the Cholesterol Treatment Trialists 2010
          meta-analysis. All these RCTs demonstrated a reduction in major
          cardiovascular events.
        </p>
      </div>
      <div class="row">
        <p class="text">
          <i>Italic</i> type indicates statins and doses that have been approved
          by the FDA but were not tested in the RCTs reviewed.
        </p>
        <p class="text">
          § LDL-C lowering that should occur with the dosage listed below each
          intensity
        </p>
        <p class="text">
          ‡ Although simvastatin 80 mg was evaluated in RCTs, initiation of
          simvastatin 80 mg or titration to 80 mg is not recommended by the FDA
          because of the increased risk of myopathy, including rhabdomyolysis
        </p>
        <p class="text">
          * Percent reductions are estimates from data across large populations.
          Individual responses to statin therapy varied in the RCTs and should
          be expected to vary in clinical practice.
        </p>
        <p class="text">
          † Evidence from 1 RCT only: down-titration if unable to tolerate
          atorvastatin 80 mg in the IDEAL (Incremental Decrease through
          Aggressive Lipid Lowering) study.
        </p>
        <p class="text">
          BID indicates twice daily; FDA, Food and Drug Administration; LDL-C,
          low-density lipoprotein cholesterol; and RCTs, randomized controlled
          trials.
        </p>
      </div>
    </script>
    <script type="text/html" id="statin-intensity-table">
      <h1 class="with-underline">Intensities of Statin Therapy</h1>
      <div class="row">
        <div class="column large-4">
          <h3>Low-Intensity</h3>
          <p>Daily dose lowers LDL-C, on average by approximately &lt;30%</p>
          <table class="table ">
            <thead>
              <tr>
                <th></th>
                <th><small> dose </small></th>
              </tr>
            </thead>
            <tbody>
              <!-- ko foreach: Statins() -->
              <tr>
                <!-- ko foreach: dose -->
                <!-- ko if: type == 'doselow' -->
                <!-- ko if: htmlText != '--' -->
                <td data-bind="html:$parent.name"></td>
                <td data-bind="html: htmlText" class="text-right"></td>
                <!-- /ko -->
                <!-- /ko -->
                <!-- /ko -->
              </tr>
              <!-- /ko -->
            </tbody>
          </table>
        </div>
        <div class="column large-4">
          <h3>Moderate-Intensity</h3>
          <p>
            Daily dose lowers LDL-C, on average by approximately 30% to &lt;50%
          </p>
          <table class="table ">
            <thead>
              <tr>
                <th></th>
                <th><small> dose </small></th>
              </tr>
            </thead>
            <tbody>
              <!-- ko foreach: Statins() -->
              <tr>
                <!-- ko foreach: dose -->
                <!-- ko if: type == 'dosemedium' -->
                <!-- ko if: htmlText != '--' -->
                <td data-bind="html:$parent.name"></td>
                <td data-bind="html: htmlText" class="text-right"></td>
                <!-- /ko -->
                <!-- /ko -->
                <!-- /ko -->
              </tr>
              <!-- /ko -->
            </tbody>
          </table>
        </div>
        <div class="column large-4">
          <h3>High-Intensity</h3>
          <p>Daily dose lowers LDL-C, on average by approximately &ge;50%</p>
          <table class="table ">
            <thead>
              <tr>
                <th></th>
                <th><small> dose </small></th>
              </tr>
            </thead>
            <tbody>
              <!-- ko foreach: Statins() -->
              <tr>
                <!-- ko foreach: dose -->
                <!-- ko if: type == 'dosehigh' -->
                <!-- ko if: htmlText != '--' -->
                <td data-bind="html:$parent.name"></td>
                <td data-bind="html: htmlText" class="text-right"></td>
                <!-- /ko -->
                <!-- /ko -->
                <!-- /ko -->
              </tr>
              <!-- /ko -->
            </tbody>
          </table>
        </div>
      </div>
      <div class="row">
        <p class="quiet">
          Statins and doses that are approved by the U.S. FDA but were not
          tested in the RCTs reviewed are listed in parentheses
        </p>
        <p class="quiet">
          <strong> * </strong> Evidence from 1 RCT (down-titration if unable to
          tolerate atorvastatin 80 mg)
        </p>
        <p class="quiet">
          <strong> ** </strong> Initiation of or titration to simvastatin 80 mg
          is not recommended by the FDA due to increased risk of myopathy,
          including rhabdomyolysis
        </p>
      </div>
    </script>
    <script type="text/html" id="statin-intensity-table-modified">
      <!--        <h1 class="with-underline">Intensities of Statin Therapy</h1>-->
      <div class="row">
        <p>
          <b
            >Table 3. High-, Moderate-, and Low-Intensity Statin Therapy<sup
              >*</sup
            ></b
          >
        </p>
        <table class="table ">
          <thead>
            <tr>
              <th>&nbsp;</th>
              <th><b>High-Intensity</b></th>
              <th><b>Moderate-Intensity</b></th>
              <th><b>Low-Intensity</b></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><b>LDL-C </b> <br /><b>Lowering§ </b></td>
              <td>≥ 50%</td>
              <td>30% to 49%</td>
              <td>< 30%</td>
            </tr>
            <tr>
              <td><b>Primary </b> <br /><b>Statins</b></td>
              <td>
                <b>Atorvastatin (40†)-80 mg</b> <br /><b>Rosuvastatin 20 </b
                ><i>(40)</i><b> mg</b>
              </td>
              <td>
                <b>Atorvastatin 10 </b><i>(20)</i><b> mg</b><br /><b
                  >Rosuvastatin</b
                >
                <i>(5)</i><b> 10 mg</b> <br /><b>Simvastatin 20-40 mg‡</b>
              </td>
              <td><i>Simvastatin 10 mg</i></td>
            </tr>
            <tr>
              <td><b>Other</b><br /><b>Statins</b></td>
              <td>-</td>
              <td>
                <b>Pravastatin 40 </b><i>(80)</i><b> mg</b><br /><b
                  >Lovastatin 40 </b
                ><i>(80)</i><b> mg</b><br /><i>Fluvastatin XL 80 mg</i><br /><b
                  >Fluvastatin 40 mg BID</b
                ><br /><i>Pitavastatin 1-4 mg</i>
              </td>
              <td>
                <b>Pravastatin 10-20 mg</b><br /><b>Lovastatin 20 mg</b><br /><i
                  >Fluvastatin 20-40 mg</i
                >
              </td>
            </tr>
          </tbody>
        </table>
      </div>
      <div class="row">
        <h5 class="italic">
          Racial/Ethnic Specific Considerations in Prescribing Statins
        </h5>
        <br />
        <p><b>Asian Americans</b></p>
        <ul>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b>Japanese patients
            may be sensitive to statin dosing, using a lower intensity dose may
            give results similar to those seen with higher intensities in
            non-Japanese patients. In an open-label, randomized
            primary-prevention trial, Japanese participants had a reduction in
            CVD events with low-intensity doses of pravastatin as compared with
            placebo. In a secondary-prevention trial, Japanese participants with
            CAD benefitted from a moderate-intensity dose of pitavastatin.
          </li>
          <li>
            <b>Safety: </b>Higher rosuvastatin plasma levels are seen in
            Japanese, Chinese, Malay, and Asian Indians as compared with whites.
            FDA recommends a lower starting dose (5 mg of rosuvastatin in Asians
            versus 10 mg in whites). Caution is urged as dose is uptitrated. In
            adults of East Asian descent, other statins should be used
            preferentially over simvastatin.
          </li>
        </ul>
        <p><b>Black and Hispanic/Latino Americans</b></p>
        <ul>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b>No sensitivity to
            statin dosage is seen, as compared with non-Hispanic white
            individuals.
          </li>
          <li>
            <b>Safety: </b>Baseline serum CK values are higher in blacks than in
            whites. The 95th percentile race/ethnicity- specific and
            sex-specific serum CK normal levels are available for assessing
            changes in serum CK. There are no specific safety issues with
            statins related to Hispanic/Latino ethnicity.
          </li>
        </ul>
      </div>
      <div class="row">
        <p class="text">
          Percent LDL-C reductions with the primary statin medications used in
          clinical practice (atorvastatin, rosuvastatin, simvastatin) were
          estimated using the median reduction in LDL-C from the VOYAGER
          database (12). Reductions in LDL-C for other statin medications
          (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified
          according to FDA approved product labeling in adults with
          hyperlipidemia, primary hypercholesterolemia and mixed dyslipidemia
          (16).
        </p>
      </div>
      <div class="row">
        <p class="text">
          <b>Boldface</b> type indicates specific statins and doses that were
          evaluated in RCTs(17-29), and the Cholesterol Treatment Trialists 2010
          meta-analysis (30). All these RCTs demonstrated a reduction in major
          cardiovascular events.
        </p>
      </div>
      <div class="row">
        <p class="text">
          <i>Italic</i> type indicates statins and doses that have been approved
          by the FDA but were not tested in the RCTs reviewed.
        </p>
        <p class="text">
          § LDL-C lowering that should occur with the dosage listed below each
          intensity
        </p>
        <p class="text">
          ‡ Although simvastatin 80 mg was evaluated in RCTs, initiation of
          simvastatin 80 mg or titration to 80 mg is not recommended by the FDA
          because of the increased risk of myopathy, including rhabdomyolysis
        </p>
        <p class="text">
          * Percent reductions are estimates from data across large populations.
          Individual responses to statin therapy varied in the RCTs and should
          be expected to vary in clinical practice (12).
        </p>
        <p class="text">
          † Evidence from 1 RCT only: down-titration if unable to tolerate
          atorvastatin 80 mg in the IDEAL (Incremental Decrease through
          Aggressive Lipid Lowering) study (28).
        </p>
        <p class="text">
          BID indicates twice daily; FDA, Food and Drug Administration; LDL-C,
          low-density lipoprotein cholesterol; and RCTs, randomized controlled
          trials.
        </p>
      </div>
    </script>
    <div class="reveal large" id="risk-enhancing-factors" data-reveal>
      <p>
        <b
          >Table 6. Risk-Enhancing Factors for Clinician–Patient Risk
          Discussion</b
        >
      </p>
      <table class="table">
        <thead>
          <th>Risk-Enhancing Factors</th>
        </thead>
        <tbody>
          <tr>
            <td>
              <ul>
                <li>
                  <b>Family history of premature ASCVD </b>(males, age &lt;55 y;
                  females, age &lt;65 y)
                </li>
                <li>
                  <b>Primary hypercholesterolemia </b> (LDL-C, 160–189 mg/dL
                  [4.1–4.8 mmol/L); non–HDL-C 190–219 mg/dL [4.9–5.6
                  mmol/L])<sup>*</sup>
                </li>
                <li>
                  <b>Metabolic syndrome </b> (increased waist circumference,
                  elevated triglycerides [&ge;150 mg/dL], elevated blood
                  pressure, elevated glucose, and low HDL-C [&lt;40 mg/dL in
                  men; &lt;50 in women mg/dL] are factors; tally of 3 makes the
                  diagnosis)
                </li>
                <li>
                  <b>Chronic kidney disease </b> (eGFR 15–59 mL/min/1.73 m<sup
                    >2</sup
                  >
                  with or without albuminuria; not treated with dialysis or
                  kidney transplantation)
                </li>
                <li>
                  <b>Chronic inflammatory conditions </b>such as psoriasis, RA,
                  or HIV/AIDS
                </li>
                <li>
                  <b
                    >History of premature menopause (before age 40 y) and
                    history of pregnancy-associated conditions that increase
                    later ASCVD risk such as preeclampsia</b
                  >
                </li>
                <li>
                  <b>High-risk race/ethnicities </b>(e.g., South Asian ancestry)
                </li>
                <li>
                  <b>Lipid/biomarkers: </b>Associated with increased ASCVD risk
                  <ul class="list-type-circle">
                    <li>
                      Persistently<sup>*</sup> elevated, primary
                      hypertriglyceridemia (≥175 mg/dL);
                    </li>
                    <li>
                      If measured:
                      <ul class="list-type-square">
                        <li>
                          <b>Elevated high-sensitivity C-reactive protein </b
                          >(≥2.0 mg/L)
                        </li>
                        <li>
                          <b>Elevated Lp(a): </b>A relative indication for its
                          measurement is family history of premature ASCVD. An
                          Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a
                          risk-enhancing factor especially at higher levels of
                          Lp(a).
                        </li>
                        <li>
                          <b>Elevated apoB </b>≥130 mg/dL: A relative indication
                          for its measurement would be triglyceride ≥200 mg/dL.
                          A level ≥130 mg/dL corresponds to an LDL-C >160 mg/dL
                          and constitutes a risk-enhancing factor
                        </li>
                        <li><b>ABI</b> &lt;0.9</li>
                      </ul>
                    </li>
                  </ul>
                </li>
              </ul>
            </td>
          </tr>
        </tbody>
      </table>
      <p><sup>*</sup>Optimally, 3 determinations.</p>
      <p>
        AIDS indicates acquired immunodeficiency syndrome; ABI, ankle-brachial
        index; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular
        disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density
        lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-C,
        low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); and RA,
        rheumatoid arthritis.
      </p>
      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <div class="reveal large" id="diabetes-specific-risk" data-reveal>
      <p>
        <b
          >Table 5. Diabetes-Specific Risk Enhancers Independent of Other Risk
          Factors in Diabetes Mellitus</b
        >
      </p>
      <table class="table">
        <thead>
          <th>Risk Enhancers</th>
        </thead>
        <tbody>
          <tr>
            <td>
              <ul>
                <li>
                  Long duration (≥10 years for type 2 diabetes mellitus or ≥20
                  years for type 1 diabetes mellitus)
                </li>
                <li>Albuminuria ≥30 mcg of albumin/mg creatinine</li>
                <li>eGFR &lt;60 mL/min/1.73 m<sup>2</sup></li>
                <li>Retinopathy</li>
                <li>Neuropathy</li>
                <li>ABI<sup>*</sup> &lt;0.9</li>
              </ul>
            </td>
          </tr>
        </tbody>
      </table>
      <p>
        <sup>*</sup>ABI indicates ankle-brachial index; and eGFR, estimated
        glomerular filtration rate.
      </p>
      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <script type="text/html" id="small-forecast-template">
      <div
        id="t1-score-banner"
        class="colored-paper shrinked-score-bar small-padding hide"
        data-bind="css:{info:Form().isTreatmentOne() && Form().TreatmentOneScore() == '~%', warning:Form().TreatmentOneScore()=='NA'}, visible:$root.Form().isTreatmentOne()"
      >
        <span data-bind="visible:$root.Form().isTreatmentOne()">
          <span
            class="text-bold small-fs-2x large-fs-3x"
            data-bind="text:Form().TreatmentOneScore() == 'NA' ?'NA*' :Form().TreatmentOneScore() "
            >T1 15.3 %</span
          >&nbsp;
          <span
            class="small-fs-2x large-fs-3x"
            data-bind="text:Form().TratmentOneCaption"
            >Stop Smoking, Add Statin Treatments</span
          >
        </span>
      </div>
      <div
        id="t2-score-banner"
        class="colored-paper shrinked-score-bar small-padding hide"
        data-bind="css:{info:Form().isTreatmentTwo() && Form().TreatmentTwoScore() == '~%', warning:Form().TreatmentTwoScore()=='NA'}, visible:$root.Form().isTreatmentTwo()"
      >
        <span data-bind="visible:$root.Form().isTreatmentTwo()">
          <span
            class="text-bold small-fs-2x large-fs-3x"
            data-bind="text:Form().TreatmentTwoScore() == 'NA' ?'NA*' :Form().TreatmentTwoScore() "
            >T1 15.3 %</span
          >&nbsp;
          <span
            class="small-fs-2x large-fs-3x"
            class=""
            data-bind="text:Form().TratmentTwoCaption"
            >Stop Smoking, Add Statin Treatments</span
          >
        </span>
      </div>
      <div
        id="t3-score-banner"
        class="colored-paper shrinked-score-bar small-padding hide"
        data-bind="css:{info:Form().isTreatmentThree() && Form().TreatmentThreeScore() == '~%', warning:Form().TreatmentThreeScore()=='NA'}, visible:$root.Form().isTreatmentThree()"
      >
        <span data-bind="visible:$root.Form().isTreatmentThree()">
          <span
            class="text-bold small-fs-2x large-fs-3x"
            data-bind="text:Form().TreatmentThreeScore() == 'NA' ?'NA*' :Form().TreatmentThreeScore() "
            >T1 15.3 %</span
          >&nbsp;
          <span
            class="small-fs-2x large-fs-3x"
            data-bind="text:Form().TratmentThreeCaption"
            >Stop Smoking, Add Statin Treatments</span
          >
        </span>
      </div>
    </script>
    <script type="text/html" id="young-patient-recommendation">
      <h1 class="with-underline">Key Suggestions for Patients age 20-39</h1>
      <div class="row">
        <h6>LDL-C Management</h6>
        <ul>
          <li>
            In patients without phenotypically severe hypercholesterolemia:<br />
            - Begin risk assessment by estimating lifetime risk. Multiple risk
            factors indicate lifestyle intervention.
          </li>
          <li>
            In patients with persistent, moderate hypercholesterolemia (LDL-C
            160-189 mg/dL (4.1-4.8 mmol/L)):<br />
            - Lifestyle intervention is indicated, and long-term statin therapy
            would be beneficial, especially for those with other risk enhancing
            factors.
          </li>
          <li>
            In patients with severe hypercholesterolemia (LDL-C >190 mg/dL (≥4.9
            mmol/L)):<br />
            - Lifestyle intervention is indicated.<br />
            - Maximally tolerated therapy statin therapy is recommended. (I,
            B-R)<br />
            - If recommended LDL-C reduction of > 50% is not achieved, then
            possible addition of non-statin therapies is also recommended.
          </li>
          <li>
            In patients with diabetes either of long duration (≥10 years of T2D,
            ≥20 years of T1D), and/or albuminuria (≥30 mcg albumin/mg
            creatinine), eGFR &lt;60 ml/min/m2, retinopathy, neuropathy:<br />
            - Lifestyle intervention is indicated.<br />
            - It may be reasonable to initiate statin therapy. (IIb, C-LD)
          </li>
        </ul>
      </div>
      <div class="row">
        <h6>Blood Pressure Management</h6>
        <p>
          Lifetime risk may be calculated for these patients. Because the
          ACC/AHA pooled cohort equations are currently validated for patients
          aged 40-79, a default age of 40 may be used for younger adult patients
          in order to view certain advice from the 2017 ACC/AHA High Blood
          Pressure Guideline, with the awareness that the specific calculated
          10-year risk and related advice tied to a risk threshold is more
          approximate for these patients.
        </p>
      </div>
      <div class="row columns large-4 text-center">
        <a
          class="button btn-ga4"
          data-rel="external"
          onclick="emailYoungPatients()"
          >Email Advice</a
        >
      </div>
    </script>
    <script type="text/html" id="discussion-checklist-list">
      <div class="row">
        <p>
          <b
            >Table 7. Checklist for Clinician–Patient Shared Decision-Making for
            Initiating Therapy</b
          >
        </p>
        <table class="table">
          <thead>
            <th>Checklist Item</th>
            <th>Recommendations</th>
          </thead>
          <tbody>
            <tr>
              <td>ASCVD risk assessment</td>
              <td>
                <ul>
                  <li>
                    Assign to statin treatment group; use ASCVD Risk Estimator
                    Plus.<sup>*</sup>
                    <ul class="list-type-circle">
                      <li>
                        In lower-risk primary-prevention adults 40-75 y of age
                        with LDL-C ≥70 mg/dL (≥1.8 mmol/L).
                      </li>
                      <li>
                        Not needed in secondary prevention, in those with LDL-C
                        ≥190 mg/dL (≥4.9 mmol/L), or in those 40-75 y of age
                        with diabetes mellitus.
                      </li>
                    </ul>
                  </li>
                  <li>
                    Assess other patient characteristics that influence risk.
                    See Risk-Enhancing Factors (Section 4.4.1.3. and Table 6)
                  </li>
                  <li>
                    Assess CAC (Section 4.4.1.4.) if risk decision is uncertain
                    and additional information is needed to clarify ASCVD risk.
                    <ul class="list-type-circle">
                      <li>
                        Use decision tools to explain risk (e.g., ASCVD Risk
                        Estimator Plus,* Mayo Clinic Statin Choice Decision
                        Aid).
                      </li>
                    </ul>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>Lifestyle modifications</td>
              <td>
                <ul>
                  <li>
                    Review lifestyle habits (e.g., diet, physical activity,
                    weight or body mass index, and tobacco use).
                  </li>
                  <li>
                    Endorse a healthy lifestyle and provide relevant advice,
                    materials, or referrals. (e.g., CardioSmart, AHA Life’s
                    Simple 7, NLA Patient Tear Sheets, PCNA Clinicians’
                    Lifestyle Modification Toolbox, cardiac rehabilitation,
                    dietitian, smoking cessation program).
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>Potential net clinical benefit of pharmacotherapy</td>
              <td>
                <ul>
                  <li>Recommend statins as first-line therapy.</li>
                  <li>
                    Consider the combination of statin and nonstatin therapy in
                    selected patients.
                  </li>
                  <li>
                    Discuss potential risk reduction from lipid-lowering
                    therapy.
                  </li>
                  <li>
                    Discuss the potential for adverse effects or drug–drug
                    interactions.
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>Cost considerations</td>
              <td>
                <ul>
                  <li>
                    Discuss potential out-of-pocket cost of therapy to the
                    patient (e.g., insurance plan coverage, tier level,
                    copayment).
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>Shared decision-making</td>
              <td>
                <ul>
                  <li>
                    Encourage the patient to verbalize what was heard (e.g.,
                    patient’s personal ASCVD risk, available options, and
                    risks/benefits).
                  </li>
                  <li>
                    Invite the patient to ask questions, express values and
                    preferences, and state ability to adhere to lifestyle
                    changes and medications.
                  </li>
                  <li>
                    Refer patients to trustworthy materials to aid in their
                    understanding of issues regarding risk decisions.
                  </li>
                  <li>
                    Collaborate with the patient to determine therapy and
                    follow-up plan.
                  </li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </div>
    </script>
    <div class="reveal large" id="discussion-checklist" data-reveal>
      <div
        data-bind="template: {name: 'discussion-checklist-list'}"
        style="overflow: auto"
      ></div>
      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <script type="text/html" id="race-ethnicity">
      <h1 class="with-underline">Racial/Ethnic Issues in ASCVD Risk</h1>
      <div class="row">
        <h4>Blacks</h4>
        <ul>
          <li>
            <b>ASCVD Issues: </b>ASCVD risk assessment in black women shows
            increased ASCVD risk compared with their otherwise similar white
            counterparts.
          </li>
          <li>
            <b>Lipid issues: </b>Blacks have higher levels of HDL-C and lower
            levels of triglycerides than non-Hispanic whites or Mexican
            Americans.
          </li>
          <li>
            <b>Metabolic Issues: </b>There is increased DM and hypertension.
          </li>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b>No sensitivity to
            statin dosage is seen, as compared with non-Hispanic white
            individuals.
          </li>
          <li>
            <b>Safety: </b>Baseline serum CK values are higher in blacks than in
            whites. The 95th percentile race/ethnicity- specific and
            sex-specific serum CK normal levels are available for assessing
            changes in serum CK.
          </li>
        </ul>
      </div>
      <div class="row">
        <h4>Hispanic/Latino Americans<sup>†</sup></h4>
        <ul>
          <li>
            <b>ASCVD Issues: </b>Race/ethnicity and country of origin, together
            with socioeconomic status and acculturation level, may explain risk
            factor burden more precisely (e.g., ASCVD risk is higher among
            individuals from Puerto Rico than those from Mexico).
          </li>
          <li>
            <b>Lipid issues: </b>Hispanic/Latino women have higher prevalence of
            low HDL-C compared with Hispanic/Latino men.
          </li>
          <li>
            <b>Metabolic Issues: </b>DM is disproportionately present compared
            with whites and blacks. There is increased prevalence of MetS and DM
            in Mexican Americans compared with whites and Puerto Ricans.
          </li>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b> No sensitivity to
            statin dosage is seen, as compared with non-Hispanic white or black
            individuals.
          </li>
          <li>
            <b>Safety: </b> There are no specific safety issues with statins
            related to Hispanic/Latino ethnicity.
          </li>
        </ul>
        <p>
          <sup>†</sup>The term “Hispanics/Latinos” in the United States
          characterizes a diverse population group. This includes white, black,
          and Native American races. Their ancestry goes from Europe to America,
          including among these, individuals from the Caribbean, Mexico, and
          Central and South America.
        </p>
      </div>
      <div class="row">
        <h4>Asian Americans<sup>*</sup></h4>
        <ul>
          <li>
            <b>ASCVD Issues: </b>ASCVD risk in people of South Asian and East
            Asian origin varies by country of origin; individuals from South
            Asia (see below) have increased ASCVD risk.
          </li>
          <li>
            <b>Lipid issues: </b>Asian Americans have lower levels of HDL-C than
            whites. There is higher prevalence of LDL-C among Asian Indians,
            Filipinos, Japanese, and Vietnamese than among whites. An increased
            prevalence of high TG was seen in all Asian American subgroups.
          </li>
          <li>
            <b>Metabolic Issues: </b> Increased MetS is seen with lower waist
            circumference than in whites. DM develops at a lower lean body mass
            and at earlier ages. Majority of risk in South Asians is explained
            by known risk factors, especially those related to insulin
            resistance.
          </li>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b>Japanese patients
            may be sensitive to statin dosing. In an open-label, randomized
            primary-prevention trial, Japanese participants had a reduction in
            CVD events with low-intensity doses of pravastatin as compared with
            placebo. In a secondary-prevention trial, Japanese participants with
            CAD benefitted from a moderate-intensity dose of pitavastatin.
          </li>
          <li>
            <b>Safety: </b>Higher rosuvastatin plasma levels are seen in
            Japanese, Chinese, Malay, and Asian Indians as compared with whites.
            FDA recommends a lower starting dose (5 mg of rosuvastatin in Asians
            versus 10 mg in whites). Caution is urged as dose is uptitrated.
          </li>
        </ul>
        <p>
          <sup>*</sup>The term “Asian” characterizes a diverse portion of the
          world’s population. Individuals from Bangladesh, India, Nepal,
          Pakistan, and Sri Lanka make up most of the South Asian group.
          Individuals from Japan, Korea, and China make up most of the East
          Asian group.
        </p>
      </div>
      <div class="row">
        <h4>General Comments</h4>
        <ul>
          <li>
            <b>ASCVD Issues: </b>There is heterogeneity in risk according to
            racial/ethnic group and within racial/ethnic groups. Native
            American/Alaskan populations have high rates of risk factors for
            ASCVD compared to non-Hispanic whites.
          </li>
          <li>
            <b>Lipid issues: </b>All ethnic groups appear to be at greater risk
            for dyslipidemia, but important to identify those with more
            sedentary behavior and less favorable diet.
          </li>
          <li>
            <b>Metabolic Issues: </b>There is increased prevalence of DM.
            Features of MetS vary by race/ethnicity. Waist circumference, not
            weight, should be used to determine abdominal adiposity when
            possible.
          </li>
          <li>
            <b>Statin therapy and LDL-Lowering Response: </b>Using a lower
            statin intensity in Japanese patients may give results similar to
            those seen with higher intensities in non-Japanese patients.
          </li>
          <li>
            <b>Safety: </b>Clinicians should take Asian race into account when
            prescribing dose of rosuvastatin (See package insert). In adults of
            East Asian descent, other statins should be used preferentially over
            simvastatin.
          </li>
        </ul>
      </div>
    </script>
    <div class="reveal large" id="race-ethnicity-issues" data-reveal>
      <div
        data-bind="template: {name: 'race-ethnicity'}"
        style="overflow: auto"
      ></div>
      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <script type="text/html" id="cac-modal">
      <h1 class="with-underline">
        General Guidance for Implementing CAC Scores in Decision Making
      </h1>
      <div class="row">
        <p>
          <b>In intermediate-risk adults or selected borderline-risk adults:</b>
        </p>
        <ul>
          <li>
            If the decision about statin use remains uncertain, it is reasonable
            to use a CAC score in the decision to withhold, postpone or initiate
            statin therapy. (IIa, B)
          </li>
          <li>
            If CAC score is measured for the purpose of making a treatment
            decision, AND:
          </li>
        </ul>
      </div>
      <table class="table">
        <thead>
          <th>CAC Score</th>
          <th>Recommendation</th>
        </thead>
        <tbody>
          <tr>
            <td>0<sup>*</sup></td>
            <td>
              It is reasonable to withhold statin therapy and reassess in 5 to
              10 years, as long as higher risk conditions are absent (diabetes
              mellitus, family history of premature CHD, cigarette smoking)
              (IIa, B)
            </td>
          </tr>
          <tr>
            <td>1 to 99</td>
            <td>
              It is reasonable to initiate statin therapy for patients ≥ 55
              years of age (IIa, B)
            </td>
          </tr>
          <tr>
            <td>≥ 100 or higher or ≥ 75th percentile</td>
            <td>It is reasonable to initiate statin therapy (IIa, B)</td>
          </tr>
        </tbody>
      </table>
      <p>
        If CAC is recommended, it should be performed in facilities that have
        current technology that delivers the lowest radiation possible.
      </p>
      <p>
        <sup>*</sup>Selected Examples of Candidates for CAC Measurement Who
        Might Benefit From Knowing Their CAC Score Is Zero
      </p>
      <ul>
        <li class="list-type-none">
          - Patients reluctant to initiate statin therapy who wish to understand
          their risk and potential for benefit more precisely
        </li>
        <li class="list-type-none">
          - Patients concerned about need to reinstitute statin therapy after
          discontinuation for statin-associated symptoms
        </li>
        <li class="list-type-none">
          - Older patients (men, 55-80 y of age; women, 60-80 y of age) with low
          burden of risk factors who question whether they would benefit from
          statin therapy
        </li>
        <li class="list-type-none">
          - Middle-aged adults (40-55 y of age) with PCE-calculated 10-year risk
          of ASCVD 5% to < 7.5% with factors that increase their ASCVD risk,
          although they are in a borderline risk group
        </li>
      </ul>
      <p><b>Racial/Ethnic Considerations in using a CAC score</b></p>
      <ul>
        <li>
          CAC burden: South Asian men were similar to nonHispanic white men, but
          higher CAC than blacks, Latinos, and Chinese Americans. South Asian
          women had similar CAC scores to whites and other racial/ethnic women,
          although CAC burden higher in older age
        </li>
        <li>
          CAC predicts similarly in whites and in those who identify as
          Hispanic/Latino.
        </li>
        <li>
          In MESA, CAC score was highest in white and Hispanic men, with blacks
          having significantly lower prevalence and severity of CAC.
        </li>
        <li>
          Risk factor differences in MESA between ethnicities did not fully
          explain variability in CAC. However, CAC predicted ASCVD events over
          and above traditional risk factors in all ethnicities
        </li>
      </ul>
    </script>
    <div class="reveal large" id="cac-score" data-reveal>
      <div
        data-bind="template: {name: 'cac-modal'}"
        style="overflow: auto"
      ></div>
      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <div class="reveal" id="heaviness-of-smoking" data-reveal>
      <h1 class="with-underline">Heaviness of Smoking Index:</h1>
      <p>
        Use to assess degree of nicotine dependence to help guide intensity of
        treatment.
      </p>
      <table class="table">
        <tr class="seperator disabled">
          <th colspan="2"><b>How many cigarettes do you smoke?</b></th>
        </tr>
        <tr>
          <td><b>Answer</b></td>
          <td><b>Score</b></td>
        </tr>
        <tr>
          <td>10 or fewer</td>
          <td>0</td>
        </tr>
        <tr>
          <td>11-20</td>
          <td>1</td>
        </tr>
        <tr>
          <td>21-30</td>
          <td>2</td>
        </tr>
        <tr>
          <td>&ge; 31</td>
          <td>3</td>
        </tr>
        <tr class="seperator disabled">
          <th colspan="2">
            How soon after waking up do you smoke your first cigarette of the
            day?
          </th>
        </tr>
        <tr>
          <td><b>Answer</b></td>
          <td><b>Score</b></td>
        </tr>
        <tr>
          <td>After 60 minutes</td>
          <td>0</td>
        </tr>
        <tr>
          <td>31-60 minutes</td>
          <td>1</td>
        </tr>
        <tr>
          <td>6-30 minutes</td>
          <td>2</td>
        </tr>
        <tr>
          <td>Within 5 minutes</td>
          <td>3</td>
        </tr>
        <tr class="seperator">
          <th colspan="2">
            Level of nicotine dependence is computed by adding the scores
            together
          </th>
        </tr>
        <tr>
          <td><b>Score</b></td>
          <td><b>Level of Nicotine Dependence</b></td>
        </tr>
        <tr>
          <td>0-2</td>
          <td>Low</td>
        </tr>
        <tr>
          <td>3-4</td>
          <td>Moderate</td>
        </tr>
        <tr>
          <td>5-6</td>
          <td>High</td>
        </tr>
      </table>

      <button
        class="close-button"
        data-close=""
        aria-label="Close reveal"
        type="button"
      >
        <span aria-hidden="true">×</span>
      </button>
    </div>
    <script type="text/javascript">
      if (
        document.URL.indexOf("http://") === -1 &&
        document.URL.indexOf("https://") === -1
      ) {
        //if mobile device detected
        //Load mobile-app.js dynamically
        var mobileScript = document.createElement("script");
        mobileScript.setAttribute("src", "assets/js/mobile-app.js");
        document.body.appendChild(mobileScript);
        var cordovaScript = document.createElement("script");
        cordovaScript.setAttribute("src", "cordova.js");
        document.head.appendChild(cordovaScript);
        //$('body').addClass('noselect');
        document.getElementsByTagName("body").className = "noselect";
      }
    </script>
    <script src="assets/js/styledown.js"></script>
    <script type="text/javascript" src="assets/js/jquery.js"></script>
    <script type="text/javascript" src="assets/js/jquery-ui.js"></script>
    <script
      type="text/javascript"
      src="assets/js/chosen/chosen.jquery.js"
    ></script>
    <script type="text/javascript" src="assets/js/selectonic.js"></script>
    <script type="text/javascript" src="assets/js/knockout.js"></script>
    <script type="text/javascript" src="assets/js/highcharts.js"></script>
    <script type="text/javascript" src="assets/js/underscore.js"></script>
    <script type="text/javascript" src="assets/js/foundation.min.js"></script>
    <script type="text/javascript" src="assets/js/koui.js"></script>
    <script type="text/javascript" src="assets/js/jquery.waypoints.js"></script>
    <script
      type="text/javascript"
      src="assets/js/waypoint/shortcuts/sticky.js"
    ></script>
    <script type="text/javascript" src="assets/js/pager.min.js"></script>
    <script type="text/javascript" src="assets/js/app.js"></script>
    <script type="text/javascript" src="assets/js/notification.js"></script>
    <script type="text/javascript" src="assets/js/formdata.js"></script>
    <script type="text/javascript" src="assets/js/appdata.js"></script>
    <script type="text/javascript" src="assets/js/riskformulas.js"></script>
    <script type="text/javascript" src="assets/js/appviewmodel.js"></script>
    <script type="text/javascript" src="assets/js/email.js"></script>
    <script
      type="text/javascript"
      src="assets/js/email-young-patients.js"
    ></script>
    <script type="text/javascript" src="assets/js/query-string.js"></script>
    <script type="text/javascript" src="assets/js/printer.js"></script>
    <script type="text/javascript">
      getCookieBanner("https://www.acc.org");
    </script>
    <script>
      $(document).foundation();
      function init() {
        var imgDefer = document.getElementsByTagName("img");
        for (var i = 0; i < imgDefer.length; i++) {
          if (imgDefer[i].getAttribute("data-src")) {
            imgDefer[i].setAttribute(
              "src",
              imgDefer[i].getAttribute("data-src")
            );
          }
        }
      }
      window.onload = init;
      if (appmodel.Form().Age() >= 20 && appmodel.Form().Age() <= 39)
        $("#young-recommendation-modal").foundation("open");
    </script>
  </body>
</html>
